id,type,description,contributions,reportedIn,direction,indication.id,indication.indication,indication.initial_approval_date,indication.initial_approval_url,indication.description,indication.raw_biomarkers,indication.raw_cancer_type,indication.raw_therapeutics,indication.icd10,indication.regimen_code,indication.reimbursement_category,indication.reimbursement_date,indication.reimbursement_details,indication.date_regular_approval,indication.date_accelerated_approval,indication.document.id,indication.document.type,indication.document.subtype,indication.document.name,indication.document.citation,indication.document.company,indication.document.drug_name_brand,indication.document.drug_name_generic,indication.document.first_published,indication.document.access_date,indication.document.publication_date,indication.document.url,indication.document.url_drug,indication.document.application_number,indication.document.organization.id,indication.document.organization.name,indication.document.organization.description,indication.document.organization.url,indication.document.organization.last_updated,proposition.id,proposition.type,proposition.predicate,proposition.biomarkers,proposition.conditionQualifier.id,proposition.conditionQualifier.conceptType,proposition.conditionQualifier.name,proposition.conditionQualifier.primaryCoding.id,proposition.conditionQualifier.primaryCoding.code,proposition.conditionQualifier.primaryCoding.name,proposition.conditionQualifier.primaryCoding.system,proposition.conditionQualifier.primaryCoding.systemVersion,proposition.conditionQualifier.primaryCoding.iris,proposition.conditionQualifier.mappings,proposition.objectTherapeutic.id,proposition.objectTherapeutic.membership_operator,proposition.objectTherapeutic.therapies,proposition.objectTherapeutic.conceptType,proposition.objectTherapeutic.name,proposition.objectTherapeutic.primaryCoding.id,proposition.objectTherapeutic.primaryCoding.code,proposition.objectTherapeutic.primaryCoding.name,proposition.objectTherapeutic.primaryCoding.system,proposition.objectTherapeutic.primaryCoding.systemVersion,proposition.objectTherapeutic.primaryCoding.iris,proposition.objectTherapeutic.mappings,proposition.objectTherapeutic.extensions,agency
0,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,0,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],0,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 119, 'conceptType': 'Drug', 'name': 'Tamoxifen', 'primaryCoding': {'id': 'ncit:C62078', 'code': 'C62078', 'name': 'Tamoxifen', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
1,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,1,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],0,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 119, 'conceptType': 'Drug', 'name': 'Tamoxifen', 'primaryCoding': {'id': 'ncit:C62078', 'code': 'C62078', 'name': 'Tamoxifen', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
2,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,2,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],0,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 119, 'conceptType': 'Drug', 'name': 'Tamoxifen', 'primaryCoding': {'id': 'ncit:C62078', 'code': 'C62078', 'name': 'Tamoxifen', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62078']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
3,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:1,"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",2018-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,3,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],1,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
4,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:1,"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",2018-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,4,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],1,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
5,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:1,"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",2018-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,5,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],1,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
6,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:1,"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",2018-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,6,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],2,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
7,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:1,"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",2018-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,7,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],2,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
8,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:1,"Verzenio is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.",2018-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208716s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on the MONARCH 3 (NCT02246621) clinical trial, which was a randomized (2:1), double-blinded, placebo-controlled, multicenter study. A total of 493 patients were randomized to receive 150 mg abemaciclib or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20%).","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,8,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],2,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
9,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:2,"Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",2017-09-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with fulvestrant,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,9,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],3,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
10,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:2,"Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",2017-09-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with fulvestrant,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,10,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],3,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
11,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:2,"Verzenio is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.",2017-09-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib) in combination with fulvestrant,,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,11,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],3,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
12,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:3,"Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",2017-09-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,12,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],99,,,Drug,Abemaciclib,ncit:C97660,C97660,Abemaciclib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660'],[],"[{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
13,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:3,"Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",2017-09-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,13,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],99,,,Drug,Abemaciclib,ncit:C97660,C97660,Abemaciclib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660'],[],"[{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
14,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:3,"Verzenio is a kinase inhibitor indicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",2017-09-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716Orig1s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","HR+, HER2-negative",advanced or metastatic breast cancer,Verzenio (abemaciclib),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,14,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],99,,,Drug,Abemaciclib,ncit:C97660,C97660,Abemaciclib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660'],[],"[{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
15,Statement,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.akeega', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Akeega (abiraterone acetate and niraparib) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Akeega', 'drug_name_generic': 'abiraterone acetate and niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-08-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793', 'application_number': 216793, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.akeega:0,"AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",2018-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,deleterious or suspected deleterious BRCA-mutated (BRCAm),metastatic castration-resistant prostate cancer,Akeega (abiraterone acetate and niraparib) in combination with prednisone,,,,,,,,doc:fda.akeega,Document,Regulatory approval,Akeega (abiraterone acetate and niraparib) [package insert]. FDA.,"Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.","Janssen Biotech, Inc.",Akeega,abiraterone acetate and niraparib,,2024-10-30,2023-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793,216793.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,15,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 4, 'name': 'BARD1 oncogenic variants', 'genes': [{'id': 5, 'name': 'BARD1', 'primaryCoding': {'id': 'hgnc:952', 'code': 'HGNC:952', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:952']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000465.4', 'code': 'NM_000465.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000465.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138376', 'code': 'ENSG00000138376', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138376']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:580', 'code': '580', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/580']}}], 'extensions': [{'name': 'location', 'value': '2q35'}, {'name': 'location_sortable', 'value': '02q35'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],4,AND,"[{'id': 6, 'conceptType': 'Drug', 'name': 'Niraparib', 'primaryCoding': {'id': 'ncit:C80059', 'code': 'C80059', 'name': 'Niraparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
16,Statement,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.akeega', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Akeega (abiraterone acetate and niraparib) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Akeega', 'drug_name_generic': 'abiraterone acetate and niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-08-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793', 'application_number': 216793, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.akeega:0,"AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",2018-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,deleterious or suspected deleterious BRCA-mutated (BRCAm),metastatic castration-resistant prostate cancer,Akeega (abiraterone acetate and niraparib) in combination with prednisone,,,,,,,,doc:fda.akeega,Document,Regulatory approval,Akeega (abiraterone acetate and niraparib) [package insert]. FDA.,"Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.","Janssen Biotech, Inc.",Akeega,abiraterone acetate and niraparib,,2024-10-30,2023-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793,216793.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,16,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 5, 'name': 'BRIP1 oncogenic variants', 'genes': [{'id': 11, 'name': 'BRIP1', 'primaryCoding': {'id': 'hgnc:20473', 'code': 'HGNC:20473', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20473']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_032043.3', 'code': 'NM_032043.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_032043.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000136492', 'code': 'ENSG00000136492', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000136492']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:83990', 'code': '83990', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/83990']}}], 'extensions': [{'name': 'location', 'value': '17q23.2'}, {'name': 'location_sortable', 'value': '17q23.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],4,AND,"[{'id': 6, 'conceptType': 'Drug', 'name': 'Niraparib', 'primaryCoding': {'id': 'ncit:C80059', 'code': 'C80059', 'name': 'Niraparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
17,Statement,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.akeega', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Akeega (abiraterone acetate and niraparib) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Akeega', 'drug_name_generic': 'abiraterone acetate and niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-08-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793', 'application_number': 216793, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.akeega:0,"AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",2018-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,deleterious or suspected deleterious BRCA-mutated (BRCAm),metastatic castration-resistant prostate cancer,Akeega (abiraterone acetate and niraparib) in combination with prednisone,,,,,,,,doc:fda.akeega,Document,Regulatory approval,Akeega (abiraterone acetate and niraparib) [package insert]. FDA.,"Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.","Janssen Biotech, Inc.",Akeega,abiraterone acetate and niraparib,,2024-10-30,2023-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793,216793.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,17,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 6, 'name': 'BRIP1 pathogenic variants', 'genes': [{'id': 11, 'name': 'BRIP1', 'primaryCoding': {'id': 'hgnc:20473', 'code': 'HGNC:20473', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20473']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_032043.3', 'code': 'NM_032043.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_032043.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000136492', 'code': 'ENSG00000136492', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000136492']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:83990', 'code': '83990', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/83990']}}], 'extensions': [{'name': 'location', 'value': '17q23.2'}, {'name': 'location_sortable', 'value': '17q23.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],4,AND,"[{'id': 6, 'conceptType': 'Drug', 'name': 'Niraparib', 'primaryCoding': {'id': 'ncit:C80059', 'code': 'C80059', 'name': 'Niraparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
18,Statement,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.akeega', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Akeega (abiraterone acetate and niraparib) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Akeega', 'drug_name_generic': 'abiraterone acetate and niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-08-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793', 'application_number': 216793, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.akeega:0,"AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA.",2018-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to Akeega (abiraterone acetate with niraparib) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Patients should be selected for therapy based on an FDA-approved test for Akeega.,deleterious or suspected deleterious BRCA-mutated (BRCAm),metastatic castration-resistant prostate cancer,Akeega (abiraterone acetate and niraparib) in combination with prednisone,,,,,,,,doc:fda.akeega,Document,Regulatory approval,Akeega (abiraterone acetate and niraparib) [package insert]. FDA.,"Janssen Biotech, Inc. Akeega (abiraterone acetate and niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed October 30, 2024.","Janssen Biotech, Inc.",Akeega,abiraterone acetate and niraparib,,2024-10-30,2023-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216793,216793.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,18,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 7, 'name': 'CDK12 pathogenic variants', 'genes': [{'id': 14, 'name': 'CDK12', 'primaryCoding': {'id': 'hgnc:24224', 'code': 'HGNC:24224', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000167258', 'code': 'ENSG00000167258', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000167258']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:51755', 'code': '51755', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/51755']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_016507.4', 'code': 'NM_016507.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],4,AND,"[{'id': 6, 'conceptType': 'Drug', 'name': 'Niraparib', 'primaryCoding': {'id': 'ncit:C80059', 'code': 'C80059', 'name': 'Niraparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
19,Statement,"The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.krazati', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Krazati (adagrasib) [package insert]. FDA.', 'citation': 'Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Mirati Therapeutics, Inc.', 'drug_name_brand': 'Krazati', 'drug_name_generic': 'adagrasib', 'first_published': '2022-12-12', 'access_date': '2024-10-30', 'publication_date': '2022-12-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340', 'application_number': 216340, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.krazati:0,"KRAZATI is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",2022-12-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to adagrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR), and that continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",KRAS G12C,locally advanced or metastatic non-small cell lung cancer,Krazati (adagrasib),,,,,,,2022-12-20,doc:fda.krazati,Document,Regulatory approval,Krazati (adagrasib) [package insert]. FDA.,"Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Mirati Therapeutics, Inc.",Krazati,adagrasib,2022-12-12,2024-10-30,2022-12-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340,216340.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,19,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 45, 'name': 'KRAS p.G12C', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '2'}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],54,,,Drug,Adagrasib,ncit:C157493,C157493,Adagrasib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C157493'],[],"[{'name': 'therapy_strategy', 'value': ['RAS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
20,Statement,The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [package insert]. FDA.', 'citation': 'Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-02', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427', 'application_number': 125427, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kadcyla:0,"KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease; or developed disease recurrence during or within six months of completing adjuvant therapy. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA.",2013-02-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf,The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine.,HER2-positive,metastatic breast cancer,Kadcyla (ado-trastuzumab emtansine),,,,,,,,doc:fda.kadcyla,Document,Regulatory approval,Kadcyla (ado-trastuzumab emtansine) [package insert]. FDA.,"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Genentech, Inc.",Kadcyla,ado-trastuzumab emtansine,,2024-10-30,2022-02-02,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427,125427.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,20,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],52,,,Drug,Trastuzumab emtansine,ncit:C82492,C82492,Trastuzumab Emtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
21,Statement,The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kadcyla', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kadcyla (ado-trastuzumab emtansine) [package insert]. FDA.', 'citation': 'Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Kadcyla', 'drug_name_generic': 'ado-trastuzumab emtansine', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-02', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427', 'application_number': 125427, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kadcyla:1,"KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA.",2019-05-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125427s105lbl.pdf,The U.S. Food and Drug Administration granted approval to ado-trastuzumab emtansine for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for ado-trastuzumab emtansine.,HER2-positive,early breast cancer,Kadcyla (ado-trastuzumab emtansine),,,,,,,,doc:fda.kadcyla,Document,Regulatory approval,Kadcyla (ado-trastuzumab emtansine) [package insert]. FDA.,"Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Genentech, Inc.",Kadcyla,ado-trastuzumab emtansine,,2024-10-30,2022-02-02,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125427s111lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125427,125427.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,20,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],52,,,Drug,Trastuzumab emtansine,ncit:C82492,C82492,Trastuzumab Emtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82492'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
22,Statement,"The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gilotrif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gilotrif (afatinib) [package insert]. FDA.', 'citation': 'Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf. Revised April 2022. Accessed October 30, 2024.', 'company': 'Boehringer Ingelheim Pharmaceuticals, Inc.', 'drug_name_brand': 'Gilotrif', 'drug_name_generic': 'afatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-04-07', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292', 'application_number': 201292, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gilotrif:0,GILOTRIF is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test (1.1) Limitations of Use: Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations.,2018-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf,"The U.S. Food and Drug Administration granted approval to afatinib for the first-line treatment of patients with metastatic non-small lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as detected by an FDA-approved test.",non-resistant EGFR mutations,metastatic non-small cell lung cancer,Gilotrif (afatinib),,,,,,,,doc:fda.gilotrif,Document,Regulatory approval,Gilotrif (afatinib) [package insert]. FDA.,"Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf. Revised April 2022. Accessed October 30, 2024.","Boehringer Ingelheim Pharmaceuticals, Inc.",Gilotrif,afatinib,,2024-10-30,2022-04-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201292,201292.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,21,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 72, 'name': 'EGFR somatic variants', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],34,,,Drug,Afatinib,ncit:C66940,C66940,Afatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66940'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
23,Statement,"The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.alecensa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alecensa (alectinib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Alecensa', 'drug_name_generic': 'alectinib', 'first_published': '2015-12-11', 'access_date': '2024-10-30', 'publication_date': '2024-04-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434', 'application_number': 208434, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.alecensa:0,ALECENSA is a kinase inhibitor indicated for the adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive) as detected by an FDA-approved test.,2024-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf,"The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.",ALK-positive,non-small cell lung cancer,Alecensa (alectinib),,,,,,,,doc:fda.alecensa,Document,Regulatory approval,Alecensa (alectinib) [package insert]. FDA.,"Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf. Revised February 2023. Accessed October 30, 2024.","Genentech, Inc.",Alecensa,alectinib,2015-12-11,2024-10-30,2024-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434,208434.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,22,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],9,,,Drug,Alectinib,ncit:C101790,C101790,Alectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
24,Statement,"The U.S. Food and Drug Administration granted approval to alectinib for the adjuvant treatment of adult patients, following tumor resection, with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors >= 4 cm or node positive), as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.alecensa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alecensa (alectinib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Alecensa', 'drug_name_generic': 'alectinib', 'first_published': '2015-12-11', 'access_date': '2024-10-30', 'publication_date': '2024-04-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434', 'application_number': 208434, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.alecensa:1,ALECENSA is a kinase inhibitor indicated for the treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.,2017-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to alectinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",ALK-positive,metastatic non-small cell lung cancer,Alecensa (alectinib),,,,,,2017-11-06,2015-12-11,doc:fda.alecensa,Document,Regulatory approval,Alecensa (alectinib) [package insert]. FDA.,"Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf. Revised February 2023. Accessed October 30, 2024.","Genentech, Inc.",Alecensa,alectinib,2015-12-11,2024-10-30,2024-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208434,208434.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,22,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],9,,,Drug,Alectinib,ncit:C101790,C101790,Alectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C101790'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
25,Statement,"The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.piqray', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Piqray (alpelisib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Piqray', 'drug_name_generic': 'alpelisib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526', 'application_number': 212526, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.piqray:0,"PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",2024-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.","HR+, HER2-negative, PIK3CA-mutated",advanced or metastatic breast cancer,Piqray (alpelisib) in combination with fulvestrant,,,,,,,,doc:fda.piqray,Document,Regulatory approval,Piqray (alpelisib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Piqray,alpelisib,,2024-10-30,2024-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526,212526.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,23,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],5,AND,"[{'id': 77, 'conceptType': 'Drug', 'name': 'Alpelisib', 'primaryCoding': {'id': 'ncit:C94214', 'code': 'C94214', 'name': 'Alpelisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C94214']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
26,Statement,"The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.piqray', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Piqray (alpelisib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Piqray', 'drug_name_generic': 'alpelisib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526', 'application_number': 212526, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.piqray:0,"PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",2024-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.","HR+, HER2-negative, PIK3CA-mutated",advanced or metastatic breast cancer,Piqray (alpelisib) in combination with fulvestrant,,,,,,,,doc:fda.piqray,Document,Regulatory approval,Piqray (alpelisib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Piqray,alpelisib,,2024-10-30,2024-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526,212526.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,24,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],5,AND,"[{'id': 77, 'conceptType': 'Drug', 'name': 'Alpelisib', 'primaryCoding': {'id': 'ncit:C94214', 'code': 'C94214', 'name': 'Alpelisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C94214']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
27,Statement,"The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.piqray', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Piqray (alpelisib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Piqray', 'drug_name_generic': 'alpelisib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526', 'application_number': 212526, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.piqray:0,"PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",2024-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to alpelisib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test, following progression on or after an endocrine-based regimen.","HR+, HER2-negative, PIK3CA-mutated",advanced or metastatic breast cancer,Piqray (alpelisib) in combination with fulvestrant,,,,,,,,doc:fda.piqray,Document,Regulatory approval,Piqray (alpelisib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Piqray,alpelisib,,2024-10-30,2024-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212526s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212526,212526.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,25,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],5,AND,"[{'id': 77, 'conceptType': 'Drug', 'name': 'Alpelisib', 'primaryCoding': {'id': 'ncit:C94214', 'code': 'C94214', 'name': 'Alpelisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C94214']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
28,Statement,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2021-05-21', 'access_date': '2024-10-30', 'publication_date': '2024-09-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210', 'application_number': 761210, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rybrevant:0,"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.",EGFR exon 20 insertion mutations,locally advanced or metastatic non-small cell lung cancer,Rybrevant (amivantamab-vmjw) in combination with carboplatin and pemetrexed,,,,,,,,doc:fda.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [package insert]. FDA.,"Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Rybrevant,amivantamab-vmjw,2021-05-21,2024-10-30,2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210,761210.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,26,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 86, 'name': 'EGFR Exon 20 (Insertion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': '20'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],6,AND,"[{'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
29,Statement,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2021-05-21', 'access_date': '2024-10-30', 'publication_date': '2024-09-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210', 'application_number': 761210, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rybrevant:1,"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.",EGFR exon 20 insertion mutations,locally advanced or metastatic non-small cell lung cancer,Rybrevant (amivantamab-vmjw),,,,,,2024-03-01,2021-05-21,doc:fda.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [package insert]. FDA.,"Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Rybrevant,amivantamab-vmjw,2021-05-21,2024-10-30,2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210,761210.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,27,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 86, 'name': 'EGFR Exon 20 (Insertion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': '20'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],108,,,Drug,Amivantamab,ncit:C124993,C124993,Amivantamab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
30,Statement,The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.trisenox', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trisenox (arsenic trioxide) [package insert]. FDA.', 'citation': 'Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.', 'company': 'Cephalon, Inc.', 'drug_name_brand': 'Trisenox', 'drug_name_generic': 'arsenic trioxide', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-10-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248', 'application_number': 21248, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trisenox:0,TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,2018-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf,The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,t(15;17) translocation or PML/RAR-alpha gene expression,low-risk acute promyelocytic leukemia (APL),Trisenox (arsenic trioxide),,,,,,,,doc:fda.trisenox,Document,Regulatory approval,Trisenox (arsenic trioxide) [package insert]. FDA.,"Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.","Cephalon, Inc.",Trisenox,arsenic trioxide,,2024-10-30,2020-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248,21248.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,28,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 79, 'name': 'PML::RARA', 'genes': [{'id': 42, 'name': 'PML', 'primaryCoding': {'id': 'hgnc:9113', 'code': 'HGNC:9113', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9113']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140464', 'code': 'ENSG00000140464', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140464']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5371', 'code': '5371', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5371']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_033238.3', 'code': 'NM_033238.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_033238.3']}}], 'extensions': [{'name': 'location', 'value': '15q24.1'}, {'name': 'location_sortable', 'value': '15q24.1'}]}, {'id': 48, 'name': 'RARA', 'primaryCoding': {'id': 'hgnc:9864', 'code': 'HGNC:9864', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9864']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000131759', 'code': 'ENSG00000131759', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000131759']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5914', 'code': '5914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5914']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000964.4', 'code': 'NM_000964.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000964.4']}}], 'extensions': [{'name': 'location', 'value': '17q21.2'}, {'name': 'location_sortable', 'value': '17q21.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",10,Disease,APL with PML-RARA,oncotree:APLPMLRARA,APLPMLRARA,APL with PML-RARA,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=APLPMLRARA'],[],93,,,Drug,Arsenic trioxide,ncit:C1005,C1005,Arsenic Trioxide,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1005'],[],"[{'name': 'therapy_strategy', 'value': ['PML::RARA inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
31,Statement,The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.trisenox', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trisenox (arsenic trioxide) [package insert]. FDA.', 'citation': 'Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.', 'company': 'Cephalon, Inc.', 'drug_name_brand': 'Trisenox', 'drug_name_generic': 'arsenic trioxide', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-10-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248', 'application_number': 21248, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trisenox:1,"TRISENOX is an arsenical indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",2000-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21248lbl.pdf,"The U.S. Food and Drug Administration granted approval to arsenic trioxide for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",t(15;17) translocation or PML/RAR-alpha gene expression,acute promyelocytic leukemia (APL),Trisenox (arsenic trioxide),,,,,,,,doc:fda.trisenox,Document,Regulatory approval,Trisenox (arsenic trioxide) [package insert]. FDA.,"Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.","Cephalon, Inc.",Trisenox,arsenic trioxide,,2024-10-30,2020-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248,21248.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,28,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 79, 'name': 'PML::RARA', 'genes': [{'id': 42, 'name': 'PML', 'primaryCoding': {'id': 'hgnc:9113', 'code': 'HGNC:9113', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9113']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140464', 'code': 'ENSG00000140464', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140464']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5371', 'code': '5371', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5371']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_033238.3', 'code': 'NM_033238.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_033238.3']}}], 'extensions': [{'name': 'location', 'value': '15q24.1'}, {'name': 'location_sortable', 'value': '15q24.1'}]}, {'id': 48, 'name': 'RARA', 'primaryCoding': {'id': 'hgnc:9864', 'code': 'HGNC:9864', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9864']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000131759', 'code': 'ENSG00000131759', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000131759']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5914', 'code': '5914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5914']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000964.4', 'code': 'NM_000964.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000964.4']}}], 'extensions': [{'name': 'location', 'value': '17q21.2'}, {'name': 'location_sortable', 'value': '17q21.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",10,Disease,APL with PML-RARA,oncotree:APLPMLRARA,APLPMLRARA,APL with PML-RARA,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=APLPMLRARA'],[],93,,,Drug,Arsenic trioxide,ncit:C1005,C1005,Arsenic Trioxide,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1005'],[],"[{'name': 'therapy_strategy', 'value': ['PML::RARA inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
32,Statement,The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.scemblix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Scemblix (asciminib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Scemblix', 'drug_name_generic': 'asciminib', 'first_published': None, 'access_date': '2025-01-10', 'publication_date': '2024-10-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358', 'application_number': 215358, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.scemblix:0,SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).,2022-10-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215358s001lbl.pdf,The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),Scemblix (asciminib),,,,,,,,doc:fda.scemblix,Document,Regulatory approval,Scemblix (asciminib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.",Novartis Pharmaceuticals Corporation.,Scemblix,asciminib,,2025-01-10,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358,215358.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,29,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],83,,,Drug,Asciminib,ncit:C114494,C114494,Asciminib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114494'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
33,Statement,The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.scemblix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Scemblix (asciminib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Scemblix', 'drug_name_generic': 'asciminib', 'first_published': None, 'access_date': '2025-01-10', 'publication_date': '2024-10-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358', 'application_number': 215358, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.scemblix:1,SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with Ph+ CML in CP with the T315I mutation.,2021-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf,The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation.,philadelphia chromosome-positive with the T315I mutation,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),Scemblix (asciminib),,,,,,,,doc:fda.scemblix,Document,Regulatory approval,Scemblix (asciminib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.",Novartis Pharmaceuticals Corporation.,Scemblix,asciminib,,2025-01-10,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358,215358.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,30,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}, {'id': 32, 'name': 'ABL1 p.T315I', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '5'}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],83,,,Drug,Asciminib,ncit:C114494,C114494,Asciminib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114494'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
34,Statement,"The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:0,"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",2021-10-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761034Orig1s042lbl.pdf,"The U.S. Food and Drug Administration granted approval to atezolizumab for the adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 1% of tumor cells, as determined by an FDA-approved test.",PD-L1 expression on >= 1% of tumor cells,non-small cell lung cancer,Tecentriq (atezolizumab),,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,31,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
35,Statement,"The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:1,"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",2020-05-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s027lbl.pdf,"The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%]),metastatic non-small cell lung cancer,Tecentriq (atezolizumab),,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,32,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 39, 'name': 'PD-L1 >= 50%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.5'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
36,Statement,"The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:1,"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",2020-05-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s027lbl.pdf,"The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%]),metastatic non-small cell lung cancer,Tecentriq (atezolizumab),,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,33,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 73, 'name': 'PD-L1 >= 10% TIIC', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor-infiltrating immune cells (TIIC)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.1'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
37,Statement,"The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:2,"TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.",2018-12-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761034s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.",no EGFR or ALK genomic tumor aberrations,metastatic non-squamous non-small cell lung cancer,"Tecentriq (atezolizumab) in combination with bevacizumab, paclitaxel, and carboplatin",,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,34,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],7,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 89, 'conceptType': 'Drug', 'name': 'Atezolizumab', 'primaryCoding': {'id': 'ncit:C106250', 'code': 'C106250', 'name': 'Atezolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
38,Statement,The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:3,TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.,2019-12-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s021lbl.pdf,The U.S. Food and Drug Administration granted approval to atezolizumab in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.,no EGFR or ALK genomic tumor aberrations,metastatic non-squamous non-small cell lung cancer,Tecentriq (atezolizumab) in combination with paclitaxel protein-bound and carboplatin,,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,35,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],8,AND,"[{'id': 89, 'conceptType': 'Drug', 'name': 'Atezolizumab', 'primaryCoding': {'id': 'ncit:C106250', 'code': 'C106250', 'name': 'Atezolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
39,Statement,The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:4,TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.,2017-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761034s001lbl.pdf,The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.,EGFR or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Tecentriq (atezolizumab),,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,36,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 72, 'name': 'EGFR somatic variants', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
40,Statement,The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:4,TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ.,2017-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761034s001lbl.pdf,The U.S. Food and Drug Administration granted approval to atezolizumab for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving atezolizumab.,EGFR or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Tecentriq (atezolizumab),,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,37,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,,,Drug,Atezolizumab,ncit:C106250,C106250,Atezolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
41,Statement,The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:5,TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,2020-07-30,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf,The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,BRAF V600,unresectable or metastatic melanoma,Tecentriq (atezolizumab) in combination with cobimetinib and vemurafenib,,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,38,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],9,AND,"[{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primaryCoding': {'id': 'ncit:C68923', 'code': 'C68923', 'name': 'Cobimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 89, 'conceptType': 'Drug', 'name': 'Atezolizumab', 'primaryCoding': {'id': 'ncit:C106250', 'code': 'C106250', 'name': 'Atezolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primaryCoding': {'id': 'ncit:C64768', 'code': 'C64768', 'name': 'Vemurafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
42,Statement,The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tecentriq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tecentriq (atezolizumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Tecentriq', 'drug_name_generic': 'atezolizumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034', 'application_number': 761034, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tecentriq:5,TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,2020-07-30,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s028lbl.pdf,The U.S. Food and Drug Administration granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.,BRAF V600,unresectable or metastatic melanoma,Tecentriq (atezolizumab) in combination with cobimetinib and vemurafenib,,,,,,,,doc:fda.tecentriq,Document,Regulatory approval,Tecentriq (atezolizumab) [package insert]. FDA.,"Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Genentech, Inc.",Tecentriq,atezolizumab,,2024-10-30,2024-04-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761034s053lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034,761034.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,39,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],9,AND,"[{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primaryCoding': {'id': 'ncit:C68923', 'code': 'C68923', 'name': 'Cobimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 89, 'conceptType': 'Drug', 'name': 'Atezolizumab', 'primaryCoding': {'id': 'ncit:C106250', 'code': 'C106250', 'name': 'Atezolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106250']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primaryCoding': {'id': 'ncit:C64768', 'code': 'C64768', 'name': 'Vemurafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
43,Statement,"The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ayvakit', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ayvakit (avapritinib) [package insert]. FDA.', 'citation': 'Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Blueprint Medicines Corporation.', 'drug_name_brand': 'Ayvakit', 'drug_name_generic': 'avapritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212608', 'application_number': 212608, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ayvakit:0,"AYVAKIT is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.",2021-06-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212608s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.","PDGFRA exon 18 mutation, including PDGFRA D842V",unresectable or metastatic GIST,Ayvakit (avapritinib),,,,,,,,doc:fda.ayvakit,Document,Regulatory approval,Ayvakit (avapritinib) [package insert]. FDA.,"Blueprint Medicines Corporation. Ayvakit (avapritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Blueprint Medicines Corporation.,Ayvakit,avapritinib,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212608s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212608,212608.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,40,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 11, 'name': 'PDGFRA p.D842V', 'genes': [{'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 55152093}, {'name': 'end_position', 'value': 55152093}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2525A>T'}, {'name': 'protein_change', 'value': 'p.D842V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '18'}, {'name': 'rsid', 'value': 'rs121908585'}, {'name': 'hgvsg', 'value': '4:g.55152093A>T'}]}]",22,Disease,Gastrointestinal Stromal Tumor,oncotree:GIST,GIST,Gastrointestinal Stromal Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST'],[],13,,,Drug,Avapritinib,ncit:C123827,C123827,Avapritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C123827'],[],"[{'name': 'therapy_strategy', 'value': ['KIT inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
44,Statement,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498', 'application_number': 210498, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mektovi:0,"MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",2018-06-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",BRAF V600E or V600K,unresectable or metastatic melanoma,Mektovi (binimetinib) in combination with encorafenib,,,,,,,,doc:fda.mektovi,Document,Regulatory approval,Mektovi (binimetinib) [package insert]. FDA.,"Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Array BioPharma, Inc.",Mektovi,binimetinib,,2024-10-30,2023-10-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498,210498.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,41,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
45,Statement,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498', 'application_number': 210498, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mektovi:0,"MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",2018-06-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",BRAF V600E or V600K,unresectable or metastatic melanoma,Mektovi (binimetinib) in combination with encorafenib,,,,,,,,doc:fda.mektovi,Document,Regulatory approval,Mektovi (binimetinib) [package insert]. FDA.,"Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Array BioPharma, Inc.",Mektovi,binimetinib,,2024-10-30,2023-10-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498,210498.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,42,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
46,Statement,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mektovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mektovi (binimetinib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Mektovi', 'drug_name_generic': 'binimetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498', 'application_number': 210498, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mektovi:1,"MEKTOVI is a kinase inhibitor indicated in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",2023-10-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.",BRAF V600E,metastatic non-small cell lung cancer,Mektovi (binimetinib) in combination with encorafenib,,,,,,,,doc:fda.mektovi,Document,Regulatory approval,Mektovi (binimetinib) [package insert]. FDA.,"Array BioPharma, Inc. Mektovi (binimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Array BioPharma, Inc.",Mektovi,binimetinib,,2024-10-30,2023-10-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210498s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210498,210498.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,43,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
47,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,704,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],143,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
48,Statement,The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.blincyto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Blincyto (blinatumomab) [package insert]. FDA.', 'citation': 'Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Amgen, Inc.', 'drug_name_brand': 'Blincyto', 'drug_name_generic': 'blinatumomab', 'first_published': '2024-12-03', 'access_date': '2024-10-30', 'publication_date': '2024-06-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557', 'application_number': 125557, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.blincyto:0,BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf,The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,CD19-positive,b-cell precursor acute lymphoblastic leukemia (ALL),Blincyto (blinatumomab),,,,,,,,doc:fda.blincyto,Document,Regulatory approval,Blincyto (blinatumomab) [package insert]. FDA.,"Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.","Amgen, Inc.",Blincyto,blinatumomab,2024-12-03,2024-10-30,2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557,125557.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,45,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 14, 'name': 'CD19 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD19'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],15,,,Drug,Blinatumomab,ncit:C62528,C62528,Blinatumomab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528'],[],"[{'name': 'therapy_strategy', 'value': ['CD19 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
49,Statement,The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.,"[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.blincyto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Blincyto (blinatumomab) [package insert]. FDA.', 'citation': 'Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Amgen, Inc.', 'drug_name_brand': 'Blincyto', 'drug_name_generic': 'blinatumomab', 'first_published': '2024-12-03', 'access_date': '2024-10-30', 'publication_date': '2024-06-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557', 'application_number': 125557, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.blincyto:1,BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).,2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf,The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).,CD19-positive,b-cell precursor acute lymphoblastic leukemia (ALL),Blincyto (blinatumomab),,,,,,,,doc:fda.blincyto,Document,Regulatory approval,Blincyto (blinatumomab) [package insert]. FDA.,"Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.","Amgen, Inc.",Blincyto,blinatumomab,2024-12-03,2024-10-30,2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557,125557.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,45,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 14, 'name': 'CD19 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD19'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],15,,,Drug,Blinatumomab,ncit:C62528,C62528,Blinatumomab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528'],[],"[{'name': 'therapy_strategy', 'value': ['CD19 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
50,Statement,The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.blincyto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Blincyto (blinatumomab) [package insert]. FDA.', 'citation': 'Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Amgen, Inc.', 'drug_name_brand': 'Blincyto', 'drug_name_generic': 'blinatumomab', 'first_published': '2024-12-03', 'access_date': '2024-10-30', 'publication_date': '2024-06-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557', 'application_number': 125557, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.blincyto:2,BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.,2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf,The U.S. Food and Drug Administration granted approval to blinatumomab for the treatment of adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.,CD19-positive philadelphia chromosome-negative,b-cell precusor acute lymphoblastic leukemia (ALL),Blincyto (blinatumomab),,,,,,,,doc:fda.blincyto,Document,Regulatory approval,Blincyto (blinatumomab) [package insert]. FDA.,"Amgen, Inc. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf. Revised June 2024. Accessed October 30, 2024.","Amgen, Inc.",Blincyto,blinatumomab,2024-12-03,2024-10-30,2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125557Orig1s028Correctedlbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125557,125557.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,46,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 15, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}, {'id': 14, 'name': 'CD19 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD19'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],15,,,Drug,Blinatumomab,ncit:C62528,C62528,Blinatumomab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62528'],[],"[{'name': 'therapy_strategy', 'value': ['CD19 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
51,Statement,"The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341', 'application_number': 203341, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.bosulif:0,"BOSULIF is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",2023-09-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf,"The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.",philadelphia chromosome-positive,philadelphia chromosome-positive chronic myelogenous leukemia (CML),Bosulif (bosutinib),,,,,,,,doc:fda.bosulif,Document,Regulatory approval,Bosulif (bosutinib) [package insert]. FDA.,"Pfizer, Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Bosulif,bosutinib,,2024-10-30,2023-09-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341,203341.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,47,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],16,,,Drug,Bosutinib,ncit:C60809,C60809,Bosutinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
52,Statement,"The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.bosulif', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bosulif (bosutinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Bosulif', 'drug_name_generic': 'bosutinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341', 'application_number': 203341, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.bosulif:1,"BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.",2023-09-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf,"The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult patients with accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",philadelphia chromosome-positive,philadelphia chromosome-positive chronic myelogenous leukemia (CML),Bosulif (bosutinib),,,,,,,,doc:fda.bosulif,Document,Regulatory approval,Bosulif (bosutinib) [package insert]. FDA.,"Pfizer, Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Bosulif,bosutinib,,2024-10-30,2023-09-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341,203341.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,47,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],16,,,Drug,Bosutinib,ncit:C60809,C60809,Bosutinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C60809'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
54,Statement,"The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [package insert]. FDA.', 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf. Revised June 2023. Accessed October 30, 2024.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-06-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388', 'application_number': 125388, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.adcetris:0,"ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",2023-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf,"The U.S. Food and Drug Administration granted approval to brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.",CD30-expressing,"systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified","Adcetris (brentuximab vedotin) in combination with cyclophosphamide, doxorubicin, and prednisone",,,,,,,,doc:fda.adcetris,Document,Regulatory approval,Adcetris (brentuximab vedotin) [package insert]. FDA.,"Seagen Inc. Adcetris (brentuximab vedotin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf. Revised June 2023. Accessed October 30, 2024.",Seagen Inc.,Adcetris,brentuximab vedotin,,2024-10-30,2023-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388,125388.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,48,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 0, 'name': 'CD30 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",3,Disease,Anaplastic Large Cell Lymphoma,oncotree:ALCL,ALCL,Anaplastic Large Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALCL'],[],11,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 0, 'conceptType': 'Drug', 'name': 'Brentuximab Vedotin', 'primaryCoding': {'id': 'ncit:C66944', 'code': 'C66944', 'name': 'Brentuximab Vedotin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
55,Statement,The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.adcetris', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Adcetris (brentuximab vedotin) [package insert]. FDA.', 'citation': 'Seagen Inc. Adcetris (brentuximab vedotin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf. Revised June 2023. Accessed October 30, 2024.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Adcetris', 'drug_name_generic': 'brentuximab vedotin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-06-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388', 'application_number': 125388, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.adcetris:1,ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.,2023-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf,The U.S. Food and Drug Administration granted approval to brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.,CD30-expressing,cutaneous analastplci large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF),Adcetris (brentuximab vedotin),,,,,,,,doc:fda.adcetris,Document,Regulatory approval,Adcetris (brentuximab vedotin) [package insert]. FDA.,"Seagen Inc. Adcetris (brentuximab vedotin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf. Revised June 2023. Accessed October 30, 2024.",Seagen Inc.,Adcetris,brentuximab vedotin,,2024-10-30,2023-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125388,125388.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,49,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 0, 'name': 'CD30 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD30'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",3,Disease,Anaplastic Large Cell Lymphoma,oncotree:ALCL,ALCL,Anaplastic Large Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALCL'],[],0,,,Drug,Brentuximab Vedotin,ncit:C66944,C66944,Brentuximab Vedotin,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66944'],[],"[{'name': 'therapy_strategy', 'value': ['target CD30 antigens'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
56,Statement,"The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.alunbrig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Alunbrig (brigatinib) [package insert]. FDA.', 'citation': 'Takeda Pharmaceuticals America, Inc. Alunbrig (brigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Takeda Pharmaceuticals America, Inc.', 'drug_name_brand': 'Alunbrig', 'drug_name_generic': 'brigatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-28', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208772', 'application_number': 208772, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.alunbrig:0,ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.,2020-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208772s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to brigatinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",ALK-positive,metastatic non-small cell lung cancer,Alunbrig (brigatinib),,,,,,,,doc:fda.alunbrig,Document,Regulatory approval,Alunbrig (brigatinib) [package insert]. FDA.,"Takeda Pharmaceuticals America, Inc. Alunbrig (brigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf. Revised February 2022. Accessed October 30, 2024.","Takeda Pharmaceuticals America, Inc.",Alunbrig,brigatinib,,2024-10-30,2022-02-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208772s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208772,208772.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,50,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],10,,,Drug,Brigatinib,ncit:C98831,C98831,Brigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98831'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
57,Statement,The U.S. Food and Drug Administration granted approval to capecitabine for the treatment of adult patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xeloda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xeloda (capecitabine) [package insert]. FDA.', 'citation': 'Genentech, Inc. Xeloda (capecitabine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Xeloda', 'drug_name_generic': 'capecitabine', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020896', 'application_number': 20896, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xeloda:0,XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.,2022-12-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf,The U.S. Food and Drug Administration granted approval to capecitabine for the treatment of adult patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.,HER2-overexpressing,metastatic gastric or gastroesophageal junction adenocarcinoma,Xeloda (capecitabine),,,,,,,,doc:fda.xeloda,Document,Regulatory approval,Xeloda (capecitabine) [package insert]. FDA.,"Genentech, Inc. Xeloda (capecitabine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Genentech, Inc.",Xeloda,capecitabine,,2024-10-30,2022-12-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020896s044s045s046s047s048s049s050s051lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020896,20896.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,51,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],38,,,Drug,Capecitabine,ncit:C1794,C1794,Capecitabine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794'],[],"[{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
58,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,52,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
59,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,53,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
60,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,54,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
61,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,55,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 90, 'name': 'AKT1 somatic variants', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
62,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,56,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 90, 'name': 'AKT1 somatic variants', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
63,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,57,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 90, 'name': 'AKT1 somatic variants', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
64,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,58,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 89, 'name': 'AKT1 amplification', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
65,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,59,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 89, 'name': 'AKT1 amplification', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
66,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,60,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 89, 'name': 'AKT1 amplification', 'genes': [{'id': 1, 'name': 'AKT1', 'primaryCoding': {'id': 'hgnc:391', 'code': 'HGNC:391', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:391']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001382430.1', 'code': 'NM_001382430.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001382430.1']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000142208', 'code': 'ENSG00000142208', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000142208']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:207', 'code': '207', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/207']}}], 'extensions': [{'name': 'location', 'value': '14q32.33'}, {'name': 'location_sortable', 'value': '14q32.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Amplification'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
67,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,61,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 91, 'name': 'PTEN nonsense variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Nonsense'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
68,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,62,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 91, 'name': 'PTEN nonsense variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Nonsense'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
69,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,63,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 91, 'name': 'PTEN nonsense variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Nonsense'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
70,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,64,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 92, 'name': 'PTEN frameshift variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Frameshift'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
71,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,65,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 92, 'name': 'PTEN frameshift variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Frameshift'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
72,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,66,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 92, 'name': 'PTEN frameshift variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Frameshift'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
73,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,67,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 93, 'name': 'PTEN splice site variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
74,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,68,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 93, 'name': 'PTEN splice site variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
75,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,69,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 93, 'name': 'PTEN splice site variants', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'requires_oncogenic', 'value': True}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
76,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,70,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 94, 'name': 'PTEN deletion', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Deletion'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
77,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,71,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 94, 'name': 'PTEN deletion', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Deletion'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
78,Statement,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truqap', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truqap (capivasertib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Truqap', 'drug_name_generic': 'capivasertib', 'first_published': '2023-11-16', 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197', 'application_number': 218197, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truqap:0,"TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to capivasertib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. The efficacy of capivasertib in combination with fulvestrant was evaluated in CAPItello-291 (NCT04305496), which described biomarker eligibility as PIK3CA/AKT1 activating mutations or PTEN loss of function alterations.","HR+, HER2-negative with one or more PIK3CA/AKT1/PTEN-alterations",locally advanced or metastatic breast cancer,Truqaf (capivasertib) in combination with fulvestrant,,,,,,,,doc:fda.truqap,Document,Regulatory approval,Truqap (capivasertib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Truqap (capivasertib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Truqap,capivasertib,2023-11-16,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218197,218197.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,72,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 94, 'name': 'PTEN deletion', 'genes': [{'id': 43, 'name': 'PTEN', 'primaryCoding': {'id': 'hgnc:9588', 'code': 'HGNC:9588', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9588']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000314.8', 'code': 'NM_000314.8', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000314.8']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171862', 'code': 'ENSG00000171862', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171862']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5728', 'code': '5728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5728']}}], 'extensions': [{'name': 'location', 'value': '10q23.31'}, {'name': 'location_sortable', 'value': '10q23.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number'}, {'name': 'present', 'value': True}, {'name': 'direction', 'value': 'Deletion'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],12,AND,"[{'id': 109, 'conceptType': 'Drug', 'name': 'Capivasertib', 'primaryCoding': {'id': 'ncit:C102564', 'code': 'C102564', 'name': 'Capivasertib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102564']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
79,Statement,"The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tabrecta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tabrecta (capmatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tabrecta', 'drug_name_generic': 'capmatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591', 'application_number': 213591, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tabrecta:0,TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.,2022-08-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.",MET exon 14 skipping,metastatic non-small cell lung cancer,Tabrecta (capmatinib),,,,,,,,doc:fda.tabrecta,Document,Regulatory approval,Tabrecta (capmatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tabrecta,capmatinib,,2024-10-30,2024-03-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591,213591.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,73,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 67, 'name': 'MET Exon 14 (Splice Site)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,,,Drug,Capmatinib,ncit:C90564,C90564,Capmatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C90564'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
80,Statement,"The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tabrecta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tabrecta (capmatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tabrecta', 'drug_name_generic': 'capmatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591', 'application_number': 213591, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tabrecta:0,TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.,2022-08-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to capmatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.",MET exon 14 skipping,metastatic non-small cell lung cancer,Tabrecta (capmatinib),,,,,,,,doc:fda.tabrecta,Document,Regulatory approval,Tabrecta (capmatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tabrecta,capmatinib,,2024-10-30,2024-03-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213591s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213591,213591.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,74,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 68, 'name': 'MET Exon 14 (Deletion)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,,,Drug,Capmatinib,ncit:C90564,C90564,Capmatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C90564'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
81,Statement,"The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [package insert]. FDA.', 'citation': 'Regeneron Pharmaceuticals, Inc. Libtayo (cemiplimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Regeneron Pharmaceuticals, Inc.', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097', 'application_number': 761097, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.libtayo:0,"LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",2022-11-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761097s014lbl.pdf,"The U.S. Food and Drug Administration granted approval to cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.","no EGFR, ALK or ROS1 aberrations",non-small cell lung cancer,Libtayo (cemiplimab) in combination with platinum-based chemotherapy,,,,,,,,doc:fda.libtayo,Document,Regulatory approval,Libtayo (cemiplimab) [package insert]. FDA.,"Regeneron Pharmaceuticals, Inc. Libtayo (cemiplimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Regeneron Pharmaceuticals, Inc.",Libtayo,cemiplimab,,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097,761097.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,75,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 46, 'name': 'Wild type ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],13,AND,"[{'id': 55, 'conceptType': 'Drug', 'name': 'Cemiplimab', 'primaryCoding': {'id': 'ncit:C121540', 'code': 'C121540', 'name': 'Cemiplimab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
82,Statement,"The U.S. Food and Drug Administration granted approval to cemiplimab for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.libtayo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Libtayo (cemiplimab) [package insert]. FDA.', 'citation': 'Regeneron Pharmaceuticals, Inc. Libtayo (cemiplimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Regeneron Pharmaceuticals, Inc.', 'drug_name_brand': 'Libtayo', 'drug_name_generic': 'cemiplimab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097', 'application_number': 761097, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.libtayo:1,"LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.",2021-02-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf,"The U.S. Food and Drug Administration granted approval to cemiplimab for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.","high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] with no EGFR, ALK or ROS1 aberrations",non-small cell lung cancer,Libtayo (cemiplimab),,,,,,,,doc:fda.libtayo,Document,Regulatory approval,Libtayo (cemiplimab) [package insert]. FDA.,"Regeneron Pharmaceuticals, Inc. Libtayo (cemiplimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Regeneron Pharmaceuticals, Inc.",Libtayo,cemiplimab,,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761097s023lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097,761097.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,76,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 39, 'name': 'PD-L1 >= 50%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.5'}]}, {'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],55,,,Drug,Cemiplimab,ncit:C121540,C121540,Cemiplimab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121540'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
83,Statement,The U.S. Food and Drug Administration granted approval to ceritinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zykadia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zykadia (ceritinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf. Revised October 2021. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Zykadia', 'drug_name_generic': 'ceritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-10-07', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211225', 'application_number': 211225, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zykadia:0,ZYKADIA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,2019-03-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf,The U.S. Food and Drug Administration granted approval to ceritinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,ALK-positive,metastatic non-small cell lung cancer,Zykadia (ceritinib),,,,,,,,doc:fda.zykadia,Document,Regulatory approval,Zykadia (ceritinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf. Revised October 2021. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Zykadia,ceritinib,,2024-10-30,2021-10-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211225s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211225,211225.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,77,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],106,,,Drug,Ceritinib,ncit:C115112,C115112,Ceritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115112'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
84,Statement,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with FOLFIRI for the first-line treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [package insert]. FDA.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.', 'company': 'ImClone LLC.', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-09-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084', 'application_number': 125084, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.erbitux:0,"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment.",2012-07-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with FOLFIRI for the first-line treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer as determined by an FDA-approved test.","K-Ras wild type, EGFR-expressing",metastatic colorectal cancer,Erbitux (cetuximab) in combination with FOLFIRI,,,,,,,,doc:fda.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [package insert]. FDA.,"ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.",ImClone LLC.,Erbitux,cetuximab,,2024-10-30,2021-09-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084,125084.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,78,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],14,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 27, 'conceptType': 'Drug', 'name': 'Irinotecan', 'primaryCoding': {'id': 'ncit:C62040', 'code': 'C62040', 'name': 'Irinotecan', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase I inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
85,Statement,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with irinotecan for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [package insert]. FDA.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.', 'company': 'ImClone LLC.', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-09-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084', 'application_number': 125084, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.erbitux:1,"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy.",2012-07-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with irinotecan for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal.","K-Ras wild-type, EGFR-expressing",metastatic colorectal cancer,Erbitux (cetuximab) in combination with irinotecan,,,,,,,,doc:fda.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [package insert]. FDA.,"ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.",ImClone LLC.,Erbitux,cetuximab,,2024-10-30,2021-09-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084,125084.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,79,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],15,AND,"[{'id': 27, 'conceptType': 'Drug', 'name': 'Irinotecan', 'primaryCoding': {'id': 'ncit:C62040', 'code': 'C62040', 'name': 'Irinotecan', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62040']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase I inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
86,Statement,"The U.S. Food and Drug Administration granted approval to cetuximab for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, as determined by an FDA-approved test, who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [package insert]. FDA.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.', 'company': 'ImClone LLC.', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-09-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084', 'application_number': 125084, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.erbitux:2,"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.",2012-07-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125084s225lbl.pdf,"The U.S. Food and Drug Administration granted approval to cetuximab for the treatment of patients with K-Ras wild-type, EGFR-expressing metastatic colorectal cancer, as determined by an FDA-approved test, who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.","K-Ras wild type, EGFR-expressing",metastatic colorectal cancer,Erbitux (cetuximab),,,,,,,,doc:fda.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [package insert]. FDA.,"ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.",ImClone LLC.,Erbitux,cetuximab,,2024-10-30,2021-09-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084,125084.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,80,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 24, 'name': 'EGFR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'EGFR'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],19,,,Drug,Cetuximab,ncit:C1723,C1723,Cetuximab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
87,Statement,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.erbitux', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Erbitux (cetuximab) [package insert]. FDA.', 'citation': 'ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.', 'company': 'ImClone LLC.', 'drug_name_brand': 'Erbitux', 'drug_name_generic': 'cetuximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-09-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084', 'application_number': 125084, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.erbitux:3,"ERBITUX is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",2021-09-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.",BRAF V600E,metastatic colorectal cancer,Erbitux (cetuximab) in combination with encorafenib,,,,,,,,doc:fda.erbitux,Document,Regulatory approval,Erbitux (cetuximab) [package insert]. FDA.,"ImClone LLC. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf. Revised September 2021. Accessed October 30, 2024.",ImClone LLC.,Erbitux,cetuximab,,2024-10-30,2021-09-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125084,125084.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,81,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],16,AND,"[{'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
88,Statement,The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [package insert]. FDA.', 'citation': 'Genentech USA, Inc. Cotellic (cobimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Genentech USA, Inc.', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-31', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192', 'application_number': 206192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.cotellic:0,"COTELLIC is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.",2015-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf,The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.,BRAF V600E or V600K,unresectable or metastatic melanoma,Cotellic (cobimetinib) in combination with vemurafenib,,,,,,,,doc:fda.cotellic,Document,Regulatory approval,Cotellic (cobimetinib) [package insert]. FDA.,"Genentech USA, Inc. Cotellic (cobimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf. Revised May 2023. Accessed October 30, 2024.","Genentech USA, Inc.",Cotellic,cobimetinib,,2024-10-30,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192,206192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,82,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],17,AND,"[{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primaryCoding': {'id': 'ncit:C68923', 'code': 'C68923', 'name': 'Cobimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primaryCoding': {'id': 'ncit:C64768', 'code': 'C64768', 'name': 'Vemurafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
89,Statement,The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.cotellic', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cotellic (cobimetinib) [package insert]. FDA.', 'citation': 'Genentech USA, Inc. Cotellic (cobimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Genentech USA, Inc.', 'drug_name_brand': 'Cotellic', 'drug_name_generic': 'cobimetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-31', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192', 'application_number': 206192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.cotellic:0,"COTELLIC is a kinase inhibitor indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.",2015-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206192s000lbl.pdf,The U.S. Food and Drug Administration granted approval to cobimetinib in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.,BRAF V600E or V600K,unresectable or metastatic melanoma,Cotellic (cobimetinib) in combination with vemurafenib,,,,,,,,doc:fda.cotellic,Document,Regulatory approval,Cotellic (cobimetinib) [package insert]. FDA.,"Genentech USA, Inc. Cotellic (cobimetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf. Revised May 2023. Accessed October 30, 2024.","Genentech USA, Inc.",Cotellic,cobimetinib,,2024-10-30,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206192s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206192,206192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,83,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],17,AND,"[{'id': 21, 'conceptType': 'Drug', 'name': 'Cobimetinib', 'primaryCoding': {'id': 'ncit:C68923', 'code': 'C68923', 'name': 'Cobimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68923']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 22, 'conceptType': 'Drug', 'name': 'Vemurafenib', 'primaryCoding': {'id': 'ncit:C64768', 'code': 'C64768', 'name': 'Vemurafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
90,Statement,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xalkori', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xalkori (crizotinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Xalkori', 'drug_name_generic': 'crizotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-07', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570', 'application_number': 202570, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xalkori:0,XALKORI is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.,2017-07-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.",ALK or ROS1-positive,metastatic non-small cell lung cancer,Xalkori (crizotinib),,,,,,,,doc:fda.xalkori,Document,Regulatory approval,Xalkori (crizotinib) [package insert]. FDA.,"Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Xalkori,crizotinib,,2024-10-30,2023-09-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,202570.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,84,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],102,,,Drug,Crizotinib,ncit:C74061,C74061,Crizotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'MET inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
91,Statement,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xalkori', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xalkori (crizotinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Xalkori', 'drug_name_generic': 'crizotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-07', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570', 'application_number': 202570, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xalkori:0,XALKORI is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.,2017-07-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.",ALK or ROS1-positive,metastatic non-small cell lung cancer,Xalkori (crizotinib),,,,,,,,doc:fda.xalkori,Document,Regulatory approval,Xalkori (crizotinib) [package insert]. FDA.,"Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Xalkori,crizotinib,,2024-10-30,2023-09-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,202570.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,85,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],102,,,Drug,Crizotinib,ncit:C74061,C74061,Crizotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'MET inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
92,Statement,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xalkori', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xalkori (crizotinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Xalkori', 'drug_name_generic': 'crizotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-07', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570', 'application_number': 202570, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xalkori:1,"XALKORI is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL.",2021-01-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.",ALK-positive,anaplastic large cell lymphoma (ALCL),Xalkori (crizotinib),,,,,,,,doc:fda.xalkori,Document,Regulatory approval,Xalkori (crizotinib) [package insert]. FDA.,"Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Xalkori,crizotinib,,2024-10-30,2023-09-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,202570.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,86,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",3,Disease,Anaplastic Large Cell Lymphoma,oncotree:ALCL,ALCL,Anaplastic Large Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALCL'],[],102,,,Drug,Crizotinib,ncit:C74061,C74061,Crizotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'MET inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
93,Statement,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xalkori', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xalkori (crizotinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Xalkori', 'drug_name_generic': 'crizotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-07', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570', 'application_number': 202570, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xalkori:2,"XALKORI is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.",2022-07-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf,"The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.",ALK-positive,"unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT)",Xalkori (crizotinib),,,,,,,,doc:fda.xalkori,Document,Regulatory approval,Xalkori (crizotinib) [package insert]. FDA.,"Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Xalkori,crizotinib,,2024-10-30,2023-09-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202570,202570.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,87,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",28,Disease,Inflammatory Myofibroblastic Tumor,oncotree:IMT,IMT,Inflammatory Myofibroblastic Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IMT'],[],102,,,Drug,Crizotinib,ncit:C74061,C74061,Crizotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C74061'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'MET inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
94,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:0,TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.,2013-05-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",BRAF V600E,unresectable or metastatic melanoma,Tafinlar (dabrafenib),,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,88,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],67,,,Drug,Dabrafenib,ncit:C82386,C82386,Dabrafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
95,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:1,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",2015-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202806s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",BRAF V600E or BRAF V600K,unresectable or metastatic melanoma,Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,89,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
96,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:1,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",2015-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202806s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",BRAF V600E or BRAF V600K,unresectable or metastatic melanoma,Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,90,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
97,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:2,"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",2018-04-30,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",BRAF V600E or BRAF V600K,melanoma,Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,89,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
98,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:2,"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",2018-04-30,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.",BRAF V600E or BRAF V600K,melanoma,Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,90,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
99,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,702,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],143,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
100,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:3,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",2017-06-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",BRAF V600E,metastatic non-small cell lung cancer,Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,91,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
101,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:4,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.",2018-05-04,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s010lbl.pdf,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.",BRAF V600E,locally advanced or metastatic anaplastic thyroid cancer (ATC),Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,92,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",4,Disease,Anaplastic Thyroid Cancer,oncotree:THAP,THAP,Anaplastic Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
102,Statement,The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:5,"TAFINLAR is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2022-06-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s022lbl.pdf,The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.,BRAF V600E,unresectable or metastatic solid tumors,Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,93,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
103,Statement,The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tafinlar', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tafinlar (dabrafenib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tafinlar', 'drug_name_generic': 'dabrafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806', 'application_number': 202806, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tafinlar:6,"TAFINLAR is indicated, in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",2023-03-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf,The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,BRAF V600E,low-grade glioma (LGG),Tafinlar (dabrafenib) in combination with trametinib,,,,,,,,doc:fda.tafinlar,Document,Regulatory approval,Tafinlar (dabrafenib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tafinlar,dabrafenib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202806s030lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202806,202806.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,94,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
104,Statement,"The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.vizimpro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vizimpro (dacomitinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Vizimpro (dacomitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf. Revised December 2020. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Vizimpro', 'drug_name_generic': 'dacomitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-12-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288', 'application_number': 211288, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vizimpro:0,VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.,2018-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",EGFR exon 19 deletion or exon 21 L858R substitution mutations,metastatic non-small cell lung cancer,Vizimpro (dacomitinib),,,,,,,,doc:fda.vizimpro,Document,Regulatory approval,Vizimpro (dacomitinib) [package insert]. FDA.,"Pfizer, Inc. Vizimpro (dacomitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf. Revised December 2020. Accessed October 30, 2024.","Pfizer, Inc.",Vizimpro,dacomitinib,,2024-10-30,2020-12-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288,211288.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,95,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],101,,,Drug,Dacomitinib,ncit:C53398,C53398,Dacomitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C53398'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
105,Statement,"The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.vizimpro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vizimpro (dacomitinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Vizimpro (dacomitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf. Revised December 2020. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Vizimpro', 'drug_name_generic': 'dacomitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-12-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288', 'application_number': 211288, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vizimpro:0,VIZIMPRO is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.,2018-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",EGFR exon 19 deletion or exon 21 L858R substitution mutations,metastatic non-small cell lung cancer,Vizimpro (dacomitinib),,,,,,,,doc:fda.vizimpro,Document,Regulatory approval,Vizimpro (dacomitinib) [package insert]. FDA.,"Pfizer, Inc. Vizimpro (dacomitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf. Revised December 2020. Accessed October 30, 2024.","Pfizer, Inc.",Vizimpro,dacomitinib,,2024-10-30,2020-12-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211288s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211288,211288.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,96,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],101,,,Drug,Dacomitinib,ncit:C53398,C53398,Dacomitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C53398'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
106,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:0,SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,2015-08-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021986s016s017lbledt.pdf,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,philadelphia chromosome-positive (Ph+),philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,97,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
107,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:0,SPRYCEL is a kinase inhibitor indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,2015-08-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021986s016s017lbledt.pdf,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,philadelphia chromosome-positive (Ph+),philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML),Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,98,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
108,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:1,"SPRYCEL is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.",2010-07-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf,"The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adult patients with chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.",philadelphia chromosome-positive,"chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,97,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
109,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:1,"SPRYCEL is a kinase inhibitor indicated for the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib.",2010-07-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf,"The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adult patients with chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.",philadelphia chromosome-positive,"chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML",Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,98,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
110,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:2,SPRYCEL is a kinase inhibitor indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,2006-06-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021986lbl.pdf,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,philadelphia chromosome-positive,philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,99,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
111,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:3,SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase.,2018-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,philadelphia chromosome-positive (Ph+),philadelphia chromosome-positive CML,Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,97,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
112,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of newly diagnosed adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:3,SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase.,2018-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of pediatric patients 1 year of age and older with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.,philadelphia chromosome-positive (Ph+),philadelphia chromosome-positive CML,Sprycel (dasatinib),,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,98,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
113,Statement,The U.S. Food and Drug Administration granted approval to dasatinib for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.,"[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.sprycel', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Sprycel (dasatinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Sprycel', 'drug_name_generic': 'dasatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986', 'application_number': 21986, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.sprycel:4,SPRYCEL is a kinase inhibitor indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.,2018-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf,"The U.S. Food and Drug Administration granted approval to dasatinib in combination with chemotherapy for the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This indication is based on CA180372 (NCT01460160), a multicenter, multiple-cohort study of pediatric patients with newly diagnosed B-cell precursor Ph+ ALL, where the backbone chemotherapy regimen was AIEOP-BFM ALL 2000 multi-agent chemotherapy protocol.",philadelphia chromosome-positive (Ph+),philadelphia chromosome-positive ALL,Sprycel (dasatinib) in combination with chemotherapy,,,,,,,,doc:fda.sprycel,Document,Regulatory approval,Sprycel (dasatinib) [package insert]. FDA.,"Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Sprycel,dasatinib,,2024-10-30,2023-02-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986,21986.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,99,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],84,,,Drug,Dasatinib,ncit:C38713,C38713,Dasatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38713'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
114,Statement,"The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [package insert]. FDA.', 'citation': 'GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline LLC.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174', 'application_number': 761174, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.jemperli:0,"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",2023-07-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H),primary advanced or recurrent endometrial cancer,Jemperli (dostarlimab) in combination with carboplatin and paclitaxel,,,,,,,,doc:fda.jemperli,Document,Regulatory approval,Jemperli (dostarlimab) [package insert]. FDA.,"GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.",GlaxoSmithKline LLC.,Jemperli,dostarlimab,,2024-10-30,2024-03-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174,761174.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,100,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],19,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 47, 'conceptType': 'Drug', 'name': 'Dostarlimab', 'primaryCoding': {'id': 'ncit:C126799', 'code': 'C126799', 'name': 'Dostarlimab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
115,Statement,"The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [package insert]. FDA.', 'citation': 'GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline LLC.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174', 'application_number': 761174, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.jemperli:0,"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",2023-07-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to dostarlimab in combination with carboplatin and paclitaxel, followed by dostarlimab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microstallite instability-high (MSI-H).",mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H),primary advanced or recurrent endometrial cancer,Jemperli (dostarlimab) in combination with carboplatin and paclitaxel,,,,,,,,doc:fda.jemperli,Document,Regulatory approval,Jemperli (dostarlimab) [package insert]. FDA.,"GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.",GlaxoSmithKline LLC.,Jemperli,dostarlimab,,2024-10-30,2024-03-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174,761174.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,101,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],19,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 47, 'conceptType': 'Drug', 'name': 'Dostarlimab', 'primaryCoding': {'id': 'ncit:C126799', 'code': 'C126799', 'name': 'Dostarlimab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
116,Statement,"The U.S. Food and Drug Administration granted approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [package insert]. FDA.', 'citation': 'GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline LLC.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174', 'application_number': 761174, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.jemperli:1,"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.",2023-02-09,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761174s003s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation.",dMMR,recurrent or advanced endometrial cancer,Jemperli (dostarlimab),,,,,,,,doc:fda.jemperli,Document,Regulatory approval,Jemperli (dostarlimab) [package insert]. FDA.,"GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.",GlaxoSmithKline LLC.,Jemperli,dostarlimab,,2024-10-30,2024-03-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174,761174.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,102,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],47,,,Drug,Dostarlimab,ncit:C126799,C126799,Dostarlimab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
117,Statement,"The U.S. Food and Drug Administration granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-Approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.jemperli', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Jemperli (dostarlimab) [package insert]. FDA.', 'citation': 'GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline LLC.', 'drug_name_brand': 'Jemperli', 'drug_name_generic': 'dostarlimab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174', 'application_number': 761174, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.jemperli:2,"JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2022-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761174s002lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to dostarlimab for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-Approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.",dMMR,recurrent or advanced solid tumors,Jemperli (dostarlimab),,,,,,,,doc:fda.jemperli,Document,Regulatory approval,Jemperli (dostarlimab) [package insert]. FDA.,"GlaxoSmithKline LLC. Jemperli (dostarlimab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf. Revised March 2024. Accessed October 30, 2024.",GlaxoSmithKline LLC.,Jemperli,dostarlimab,,2024-10-30,2024-03-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761174s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761174,761174.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,103,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],47,,,Drug,Dostarlimab,ncit:C126799,C126799,Dostarlimab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126799'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
118,Statement,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:0,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutations or ALK genomic aberrations,metastatic non-small cell lung cancer,Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,104,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],20,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
119,Statement,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:0,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutations or ALK genomic aberrations,metastatic non-small cell lung cancer,Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,105,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],21,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
120,Statement,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:0,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutations or ALK genomic aberrations,metastatic non-small cell lung cancer,Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,106,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],22,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
121,Statement,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:0,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutations or ALK genomic aberrations,metastatic non-small cell lung cancer,Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,107,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],23,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
122,Statement,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:0,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations.",2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with tremelimumab-actl and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, and multicenter study where patients received one of the following chemotherapy regimes: pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutations or ALK genomic aberrations,metastatic non-small cell lung cancer,Imfinzi (durvalumab) in combination with tremelimumab-actl and platinum-based chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,108,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],24,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 51, 'conceptType': 'Drug', 'name': 'Nab-paclitaxel', 'primaryCoding': {'id': 'ncit:C2688', 'code': 'C2688', 'name': 'Nab-paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
123,Statement,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with carboplatin and paclitaxel, followed by durvalumab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:1,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).",2024-06-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s045lbl.pdf,"The U.S. Food and Drug Administration granted approval to durvalumab in combination with carboplatin and paclitaxel, followed by durvalumab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).",mismatch repair deficient (dMMR),primary advanced or recurrent endometrial cancer,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,109,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],25,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
124,Statement,"The U.S. Food and Drug Administration granted approval to elacestrant for the treatment of patients who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.orserdu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Orserdu (elacestrant) [package insert]. FDA.', 'citation': 'Stemline Therapeutics, Inc. Orserdu (elacestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Stemline Therapeutics, Inc.', 'drug_name_brand': 'Orserdu', 'drug_name_generic': 'elacestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-09', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217639', 'application_number': 217639, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.orserdu:0,"ORSERDU is an estrogen receptor antagonist indicated for treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",2023-01-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s000correctedlbl.pdf,"The U.S. Food and Drug Administration granted approval to elacestrant for the treatment of patients who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.","ER-positive, HER2-negative, ESR1-mutated",advanced or metastatic breast cancer,Orserdu (elacestrant),,,,,,,,doc:fda.orserdu,Document,Regulatory approval,Orserdu (elacestrant) [package insert]. FDA.,"Stemline Therapeutics, Inc. Orserdu (elacestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf. Revised May 2023. Accessed October 30, 2024.","Stemline Therapeutics, Inc.",Orserdu,elacestrant,,2024-10-30,2023-11-09,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639Orig1s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217639,217639.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,110,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 58, 'name': 'ESR1 oncogenic variants', 'genes': [{'id': 19, 'name': 'ESR1', 'primaryCoding': {'id': 'hgnc:3467', 'code': 'HGNC:3467', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3467']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000125.4', 'code': 'NM_000125.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000125.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000091831', 'code': 'ENSG00000091831', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000091831']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2099', 'code': '2099', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2099']}}], 'extensions': [{'name': 'location', 'value': '6q25.1-q25.2'}, {'name': 'location_sortable', 'value': '06q25.1-q25.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '6'}, {'name': 'requires_oncogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],74,,,Drug,Elacestrant,ncit:C120211,C120211,Elacestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C120211'],[],"[{'name': 'therapy_strategy', 'value': ['ER signaling inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
125,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,111,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 107, 'name': 'IDH2 p.R140Q', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631934}, {'name': 'end_position', 'value': 90631934}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.419G>A'}, {'name': 'protein_change', 'value': 'p.R140Q'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913502'}, {'name': 'hgvsg', 'value': '15:g.90631934C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
126,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,112,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 108, 'name': 'IDH2 p.R140L', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631934}, {'name': 'end_position', 'value': 90631934}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.419G>T'}, {'name': 'protein_change', 'value': 'p.R140L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913502'}, {'name': 'hgvsg', 'value': '15:g.90631934C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
127,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,113,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 109, 'name': 'IDH2 p.R140G', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631935}, {'name': 'end_position', 'value': 90631935}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.418C>G'}, {'name': 'protein_change', 'value': 'p.R140G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs267606870'}, {'name': 'hgvsg', 'value': '15:g.90631935G>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
128,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,114,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 110, 'name': 'IDH2 p.R140W', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631935}, {'name': 'end_position', 'value': 90631935}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.418C>T'}, {'name': 'protein_change', 'value': 'p.R140W'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs267606870'}, {'name': 'hgvsg', 'value': '15:g.90631935G>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
129,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,115,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 111, 'name': 'IDH2 p.R172K', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.515G>A'}, {'name': 'protein_change', 'value': 'p.R172K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
130,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,116,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 112, 'name': 'IDH2 p.R172M', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.515G>T'}, {'name': 'protein_change', 'value': 'p.R172M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
131,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,117,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 113, 'name': 'IDH2 p.R172G', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.514A>G'}, {'name': 'protein_change', 'value': 'p.R172G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
132,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,118,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 114, 'name': 'IDH2 p.R172S', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631837}, {'name': 'end_position', 'value': 90631837}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.516G>C'}, {'name': 'protein_change', 'value': 'p.R172S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519736'}, {'name': 'hgvsg', 'value': '15:g.90631837C>G'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
133,Statement,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.idhifa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Idhifa (enasidenib) [package insert]. FDA.', 'citation': 'Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.', 'company': 'Celgene Corporation.', 'drug_name_brand': 'Idhifa', 'drug_name_generic': 'enasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606', 'application_number': 209606, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.idhifa:0,IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,2017-08-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf,The U.S. Food and Drug Administration granted approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,IDH2 mutation,relapsed or refractory acute myeloid leukemia (AML),Idhifa (enasidenib),,,,,,,,doc:fda.idhifa,Document,Regulatory approval,Idhifa (enasidenib) [package insert]. FDA.,"Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf. Revised December 2023. Accessed October 30, 2024.",Celgene Corporation.,Idhifa,enasidenib,,2024-10-30,2023-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209606s006lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209606,209606.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,119,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 115, 'name': 'IDH2 p.R172W', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.514A>T'}, {'name': 'protein_change', 'value': 'p.R172W'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],126,,,Drug,Enasidenib,ncit:C111573,C111573,Enasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C111573'],[],"[{'name': 'therapy_strategy', 'value': ['IDH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
134,Statement,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2018-06-27', 'access_date': '2025-01-10', 'publication_date': '2024-12-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496', 'application_number': 210496, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.braftovi:0,"BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",2018-06-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf,"The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",BRAF V600E or BRAF V600K,unresectable or metastatic melanoma,Braftovi (encorafenib) in combination with binimetinib,,,,,,,,doc:fda.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [package insert]. FDA.,"Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.","Array BioPharma, Inc.",Braftovi,encorafenib,2018-06-27,2025-01-10,2024-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,210496.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,41,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
135,Statement,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2018-06-27', 'access_date': '2025-01-10', 'publication_date': '2024-12-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496', 'application_number': 210496, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.braftovi:0,"BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",2018-06-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf,"The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",BRAF V600E or BRAF V600K,unresectable or metastatic melanoma,Braftovi (encorafenib) in combination with binimetinib,,,,,,,,doc:fda.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [package insert]. FDA.,"Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.","Array BioPharma, Inc.",Braftovi,encorafenib,2018-06-27,2025-01-10,2024-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,210496.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,42,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
136,Statement,"The U.S. Food and Drug Administration granted approval to cetuximab in combination with encorafenib for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2018-06-27', 'access_date': '2025-01-10', 'publication_date': '2024-12-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496', 'application_number': 210496, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.braftovi:1,"BRAFTOVI is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",2020-04-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",BRAF V600E,metastatic colorectal cancer,Braftovi (encorafenib) in combination with cetuximab,,,,,,,,doc:fda.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [package insert]. FDA.,"Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.","Array BioPharma, Inc.",Braftovi,encorafenib,2018-06-27,2025-01-10,2024-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,210496.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,81,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],16,AND,"[{'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
137,Statement,"The U.S. Food and Drug Administration granted approval to binimetinib in combination with encorafenib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2018-06-27', 'access_date': '2025-01-10', 'publication_date': '2024-12-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496', 'application_number': 210496, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.braftovi:2,"BRAFTOVI is a kinase inhibitor indicated in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",2023-10-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf,"The U.S. Food and Drug Administration granted approval to encorafenib in combination with binimetinib for the treatment of adult patients with metastatic non-small cell lung cancer with a BRAF V600E mutation, as detected by an FDA-approved test. Encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",BRAF V600E,metastatic non-small cell lung cancer,Braftovi (encorafenib) in combination with binimetinib,,,,,,,,doc:fda.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [package insert]. FDA.,"Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.","Array BioPharma, Inc.",Braftovi,encorafenib,2018-06-27,2025-01-10,2024-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,210496.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,43,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],10,AND,"[{'id': 17, 'conceptType': 'Drug', 'name': 'Binimetinib', 'primaryCoding': {'id': 'ncit:C84865', 'code': 'C84865', 'name': 'Binimetinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C84865']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
138,Statement,"The U.S. Food and Drug Administration granted approval to entrectinib for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725', 'application_number': 212725, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rozlytrek:0,ROZLYTREK is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.,2019-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to entrectinib for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.",ROS1-positive,metastatic non-small cell lung cancer,Rozlytrek (entrectinib),,,,,,,,doc:fda.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [package insert]. FDA.,"Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Genentech, Inc.",Rozlytrek,entrectinib,,2024-10-30,2024-01-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725,212725.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,120,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
139,Statement,"The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725', 'application_number': 212725, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rozlytrek:1,"ROZLYTREK is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",2023-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009Correctedlbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",NTRK gene fusion,solid tumors,Rozlytrek (entrectinib),,,,,,,,doc:fda.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [package insert]. FDA.,"Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Genentech, Inc.",Rozlytrek,entrectinib,,2024-10-30,2024-01-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725,212725.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,121,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 63, 'name': 'v::NTRK1', 'genes': [{'id': 35, 'name': 'NTRK1', 'primaryCoding': {'id': 'hgnc:8031', 'code': 'HGNC:8031', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002529.4', 'code': 'NM_002529.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000198400', 'code': 'ENSG00000198400', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000198400']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4914', 'code': '4914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4914']}}], 'extensions': [{'name': 'location', 'value': '1q23.1'}, {'name': 'location_sortable', 'value': '01q23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
140,Statement,"The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725', 'application_number': 212725, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rozlytrek:1,"ROZLYTREK is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",2023-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009Correctedlbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",NTRK gene fusion,solid tumors,Rozlytrek (entrectinib),,,,,,,,doc:fda.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [package insert]. FDA.,"Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Genentech, Inc.",Rozlytrek,entrectinib,,2024-10-30,2024-01-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725,212725.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,122,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 64, 'name': 'v::NTRK2', 'genes': [{'id': 36, 'name': 'NTRK2', 'primaryCoding': {'id': 'hgnc:8032', 'code': 'HGNC:8032', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000148053', 'code': 'ENSG00000148053', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000148053']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4915', 'code': '4915', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4915']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006180.6', 'code': 'NM_006180.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6']}}], 'extensions': [{'name': 'location', 'value': '9q21.33'}, {'name': 'location_sortable', 'value': '09q21.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
141,Statement,"The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rozlytrek', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rozlytrek (entrectinib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rozlytrek', 'drug_name_generic': 'entrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725', 'application_number': 212725, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rozlytrek:1,"ROZLYTREK is a kinase inhibitor indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",2023-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009Correctedlbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to entrectinib for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: (i) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, (ii) are metastatic or where surgical resection is likely to result in severe morbidity, and (iii) have progressed following treatment or have no satisfactory alternative therapy. Entrectinib's package insert further states that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",NTRK gene fusion,solid tumors,Rozlytrek (entrectinib),,,,,,,,doc:fda.rozlytrek,Document,Regulatory approval,Rozlytrek (entrectinib) [package insert]. FDA.,"Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Genentech, Inc.",Rozlytrek,entrectinib,,2024-10-30,2024-01-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212725s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212725,212725.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,123,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 65, 'name': 'v::NTRK3', 'genes': [{'id': 37, 'name': 'NTRK3', 'primaryCoding': {'id': 'hgnc:8033', 'code': 'HGNC:8033', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001012338.3', 'code': 'NM_001012338.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140538', 'code': 'ENSG00000140538', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140538']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4916', 'code': '4916', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4916']}}], 'extensions': [{'name': 'location', 'value': '15q25.3'}, {'name': 'location_sortable', 'value': '15q25.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],80,,,Drug,Entrectinib,ncit:C114984,C114984,Entrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114984'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition', 'ROS1 inhibition', 'NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
142,Statement,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [package insert]. FDA.', 'citation': 'Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Janssen Products, LP.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018', 'application_number': 212018, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.balversa:0,BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",susceptible FGFR3 genetic alterations,locally advanced or metastatic urothelial carcinoma (mUC),Balversa (erdafitinib),,,,,,,,doc:fda.balversa,Document,Regulatory approval,Balversa (erdafitinib) [package insert]. FDA.,"Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Janssen Products, LP.",Balversa,erdafitinib,,2024-10-30,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018,212018.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,124,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 99, 'name': 'FGFR3 p.R248C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1803564}, {'name': 'end_position', 'value': 1803564}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.742C>T'}, {'name': 'protein_change', 'value': 'p.R248C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '6'}, {'name': 'rsid', 'value': 'rs121913482'}, {'name': 'hgvsg', 'value': '4:g.1803564C>T'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
143,Statement,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [package insert]. FDA.', 'citation': 'Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Janssen Products, LP.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018', 'application_number': 212018, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.balversa:0,BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",susceptible FGFR3 genetic alterations,locally advanced or metastatic urothelial carcinoma (mUC),Balversa (erdafitinib),,,,,,,,doc:fda.balversa,Document,Regulatory approval,Balversa (erdafitinib) [package insert]. FDA.,"Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Janssen Products, LP.",Balversa,erdafitinib,,2024-10-30,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018,212018.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,125,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 100, 'name': 'FGFR3 p.S249C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1803568}, {'name': 'end_position', 'value': 1803568}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.746C>G'}, {'name': 'protein_change', 'value': 'p.S249C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '6'}, {'name': 'rsid', 'value': 'rs121913483'}, {'name': 'hgvsg', 'value': '4:g.1803568C>G'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
144,Statement,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [package insert]. FDA.', 'citation': 'Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Janssen Products, LP.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018', 'application_number': 212018, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.balversa:0,BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",susceptible FGFR3 genetic alterations,locally advanced or metastatic urothelial carcinoma (mUC),Balversa (erdafitinib),,,,,,,,doc:fda.balversa,Document,Regulatory approval,Balversa (erdafitinib) [package insert]. FDA.,"Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Janssen Products, LP.",Balversa,erdafitinib,,2024-10-30,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018,212018.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,126,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 101, 'name': 'FGFR3 p.G370C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1806089}, {'name': 'end_position', 'value': 1806089}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1108G>T'}, {'name': 'protein_change', 'value': 'p.G370C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '8'}, {'name': 'rsid', 'value': 'rs121913479'}, {'name': 'hgvsg', 'value': '4:g.1806089G>T'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
145,Statement,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [package insert]. FDA.', 'citation': 'Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Janssen Products, LP.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018', 'application_number': 212018, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.balversa:0,BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",susceptible FGFR3 genetic alterations,locally advanced or metastatic urothelial carcinoma (mUC),Balversa (erdafitinib),,,,,,,,doc:fda.balversa,Document,Regulatory approval,Balversa (erdafitinib) [package insert]. FDA.,"Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Janssen Products, LP.",Balversa,erdafitinib,,2024-10-30,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018,212018.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,127,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 102, 'name': 'FGFR3 p.Y373C', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 1806099}, {'name': 'end_position', 'value': 1806099}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.1118A>G'}, {'name': 'protein_change', 'value': 'p.Y373C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '8'}, {'name': 'rsid', 'value': 'rs121913485'}, {'name': 'hgvsg', 'value': '4:g.1806099A>G'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
146,Statement,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.balversa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Balversa (erdafitinib) [package insert]. FDA.', 'citation': 'Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.', 'company': 'Janssen Products, LP.', 'drug_name_brand': 'Balversa', 'drug_name_generic': 'erdafitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018', 'application_number': 212018, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.balversa:0,BALVERSA is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. BALVERSA is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Erdafitinib's product label states for patients to be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Furthermore, erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.",susceptible FGFR3 genetic alterations,locally advanced or metastatic urothelial carcinoma (mUC),Balversa (erdafitinib),,,,,,,,doc:fda.balversa,Document,Regulatory approval,Balversa (erdafitinib) [package insert]. FDA.,"Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed October 30, 2024.","Janssen Products, LP.",Balversa,erdafitinib,,2024-10-30,2024-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018,212018.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,128,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 97, 'name': 'FGFR3::TACC3', 'genes': [{'id': 24, 'name': 'FGFR3', 'primaryCoding': {'id': 'hgnc:3690', 'code': 'HGNC:3690', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3690']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000068078', 'code': 'ENSG00000068078', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000068078']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2261', 'code': '2261', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2261']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000142.5', 'code': 'NM_000142.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000142.5']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}, {'id': 51, 'name': 'TACC3', 'primaryCoding': {'id': 'hgnc:11524', 'code': 'HGNC:11524', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11524']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006342.3', 'code': 'NM_006342.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006342.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000013810', 'code': 'ENSG00000013810', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000013810']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:10460', 'code': '10460', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/10460']}}], 'extensions': [{'name': 'location', 'value': '4p16.3'}, {'name': 'location_sortable', 'value': '04p16.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",8,Disease,Bladder Urothelial Carcinoma,oncotree:BLCA,BLCA,Bladder Urothelial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BLCA'],[],110,,,Drug,Erdafitinib,ncit:C103273,C103273,Erdafitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103273'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
147,Statement,"The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tarceva', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tarceva (erlotinib) [package insert]. FDA.', 'citation': 'OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.', 'company': 'OSI Pharmaceuticals, LLC.', 'drug_name_brand': 'Tarceva', 'drug_name_generic': 'erlotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2016-10-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743', 'application_number': 21743, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tarceva:0,"TARCEVA is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. TARCEVA is not recommended for use in combination with platinum-based chemotherapy.",2016-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,"The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.",EGFR exon 19 deletions or exon 21 L858R,metastatic non-small cell lung cancer,Tarceva (erlotinib),,,,,,,,doc:fda.tarceva,Document,Regulatory approval,Tarceva (erlotinib) [package insert]. FDA.,"OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.","OSI Pharmaceuticals, LLC.",Tarceva,erlotinib,,2024-10-30,2016-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743,21743.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,129,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],12,,,Drug,Erlotinib,ncit:C65530,C65530,Erlotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
148,Statement,"The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tarceva', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tarceva (erlotinib) [package insert]. FDA.', 'citation': 'OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.', 'company': 'OSI Pharmaceuticals, LLC.', 'drug_name_brand': 'Tarceva', 'drug_name_generic': 'erlotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2016-10-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743', 'application_number': 21743, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tarceva:0,"TARCEVA is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. TARCEVA is not recommended for use in combination with platinum-based chemotherapy.",2016-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,"The U.S. Food and Drug Administration granted approval to erlotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test, receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. Erlotnib's product label further states that safety and efficacy of erlotnib have not been established in patients with NSCLC whose tumors have other EGFR mutations. Furthermore, the product label states that it is not recommended for use in combination with platinum-based chemotherapy.",EGFR exon 19 deletions or exon 21 L858R,metastatic non-small cell lung cancer,Tarceva (erlotinib),,,,,,,,doc:fda.tarceva,Document,Regulatory approval,Tarceva (erlotinib) [package insert]. FDA.,"OSI Pharmaceuticals, LLC. Tarceva (erlotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf. Revised October 2016. Accessed October 30, 2024.","OSI Pharmaceuticals, LLC.",Tarceva,erlotinib,,2024-10-30,2016-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021743,21743.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,130,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],12,,,Drug,Erlotinib,ncit:C65530,C65530,Erlotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
149,Statement,"The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:0,"AFINITOR is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.",2012-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf,"The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.","HR+, HER2-negative",breast cancer,Afinitor (everolimus),,,,,,,,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,131,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,AND,"[{'id': 4, 'conceptType': 'Drug', 'name': 'Everolimus', 'primaryCoding': {'id': 'ncit:C48387', 'code': 'C48387', 'name': 'Everolimus', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
150,Statement,"The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:0,"AFINITOR is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.",2012-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf,"The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.","HR+, HER2-negative",breast cancer,Afinitor (everolimus),,,,,,,,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,132,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,AND,"[{'id': 4, 'conceptType': 'Drug', 'name': 'Everolimus', 'primaryCoding': {'id': 'ncit:C48387', 'code': 'C48387', 'name': 'Everolimus', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
151,Statement,"The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:0,"AFINITOR is a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole.",2012-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf,"The U.S. Food and Drug Administration granted approval to everolimus in combination with exemestane for the treatment of patients who are postmenopausal women with advanced hormone receptor-positive, HER2 negative breast cancer after failure of treatment with letrozole or anastrozole.","HR+, HER2-negative",breast cancer,Afinitor (everolimus),,,,,,,,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,133,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,AND,"[{'id': 4, 'conceptType': 'Drug', 'name': 'Everolimus', 'primaryCoding': {'id': 'ncit:C48387', 'code': 'C48387', 'name': 'Everolimus', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
152,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:0,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s034lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.","HR+, HER2-negative",breast cancer,Faslodex (fulvestrant),,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,134,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
153,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:0,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s034lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.","HR+, HER2-negative",breast cancer,Faslodex (fulvestrant),,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,135,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
154,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:0,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s034lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer not previously treated with endocrine therapy.","HR+, HER2-negative",breast cancer,Faslodex (fulvestrant),,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,136,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
155,Statement,The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:1,FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.,2002-04-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21344lbl.pdf,The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.,HR+,breast cancer,Faslodex (fulvestrant),,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,137,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
156,Statement,The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:1,FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.,2002-04-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21344lbl.pdf,The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.,HR+,breast cancer,Faslodex (fulvestrant),,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,138,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
157,Statement,The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:1,FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy.,2002-04-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21344lbl.pdf,The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.,HR+,breast cancer,Faslodex (fulvestrant),,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,139,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],30,,,Drug,Fulvestrant,ncit:C1379,C1379,Fulvestrant,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379'],[],"[{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
158,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:2,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.",2019-03-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344s037lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with ribociclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,140,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
159,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:2,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.",2019-03-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344s037lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with ribociclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,141,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
160,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:2,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.",2019-03-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021344s037lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with ribociclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,142,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
161,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:3,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with palbociclib or abemaciclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,143,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
162,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:3,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with palbociclib or abemaciclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,144,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
163,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:3,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with palbociclib or abemaciclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,145,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
164,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:3,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with palbociclib or abemaciclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,9,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],3,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
165,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:3,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with palbociclib or abemaciclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,10,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],3,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
166,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.faslodex', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Faslodex (fulvestrant) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Faslodex', 'drug_name_generic': 'fulvestrant', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344', 'application_number': 21344, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.faslodex:3,"FASLODEX is an estrogen receptor antagonist indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.",2017-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021344s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Faslodex (fulvestrant) in combination with palbociclib or abemaciclib,,,,,,,,doc:fda.faslodex,Document,Regulatory approval,Faslodex (fulvestrant) [package insert]. FDA.,"AstraZeneca UK Limited. Faslodex (fulvestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf. Revised January 2021. Accessed October 30, 2024.",AstraZeneca UK Limited.,Faslodex,fulvestrant,,2024-10-30,2021-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021344,21344.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,11,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],3,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
167,Statement,"The U.S. Food and Drug Administration granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Futibatinib's package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lytgobi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lytgobi (futibatinib) [package insert]. FDA.', 'citation': 'Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Taiho Pharmaceutical Co., Ltd.', 'drug_name_brand': 'Lytgobi', 'drug_name_generic': 'futibatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-04-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214801', 'application_number': 214801, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lytgobi:0,"LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2022-09-30,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf,"The U.S. Food and Drug Administration granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Futibatinib's package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",FGFR2 gene fusions or other rearrangements,"unresectable, locally or metastatic intrahepatic cholangiocarcinoma",Lytgobi (futibatinib),,,,,,,,doc:fda.lytgobi,Document,Regulatory approval,Lytgobi (futibatinib) [package insert]. FDA.,"Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Taiho Pharmaceutical Co., Ltd.",Lytgobi,futibatinib,,2024-10-30,2024-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214801s002lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214801,214801.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,146,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 52, 'name': 'FGFR2::v', 'genes': [{'id': 23, 'name': 'FGFR2', 'primaryCoding': {'id': 'hgnc:3689', 'code': 'HGNC:3689', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000141.5', 'code': 'NM_000141.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000066468', 'code': 'ENSG00000066468', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000066468']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2263', 'code': '2263', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2263']}}], 'extensions': [{'name': 'location', 'value': '10q26.13'}, {'name': 'location_sortable', 'value': '10q26.13'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",29,Disease,Intrahepatic Cholangiocarcinoma,oncotree:IHCH,IHCH,Intrahepatic Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IHCH'],[],58,,,Drug,Futibatinib,ncit:C114283,C114283,Futibatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114283'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
168,Statement,"The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Iressa (gefitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf. Revised May 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-05-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995', 'application_number': 206995, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.iressa:0,IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.,2015-07-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.",EGFR exon 19 deletions or exon 21 (L858R) substitution mutations,metastatic non-small cell lung cancer,Iressa (gefitinib),,,,,,,,doc:fda.iressa,Document,Regulatory approval,Iressa (gefitinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Iressa (gefitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf. Revised May 2021. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Iressa,gefitinib,,2024-10-30,2021-05-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995,206995.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,147,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],33,,,Drug,Gefitinib,ncit:C1855,C1855,Gefitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1855'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
169,Statement,"The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.iressa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iressa (gefitinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Iressa (gefitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf. Revised May 2021. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Iressa', 'drug_name_generic': 'gefitinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-05-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995', 'application_number': 206995, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.iressa:0,IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.,2015-07-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206995s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gefitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Gefitinib's package insert includes the following limitation of use: safety and efficacy of gefitinib have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.",EGFR exon 19 deletions or exon 21 (L858R) substitution mutations,metastatic non-small cell lung cancer,Iressa (gefitinib),,,,,,,,doc:fda.iressa,Document,Regulatory approval,Iressa (gefitinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Iressa (gefitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf. Revised May 2021. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Iressa,gefitinib,,2024-10-30,2021-05-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206995,206995.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,148,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],33,,,Drug,Gefitinib,ncit:C1855,C1855,Gefitinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1855'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
170,Statement,The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mylotarg', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA.', 'citation': 'Wyeth Pharmaceuticals LLC. Mylotarg (gemtuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf. Revised June 2022. Accessed October 30, 2024.', 'company': 'Wyeth Pharmaceuticals LLC.', 'drug_name_brand': 'Mylotarg', 'drug_name_generic': 'gemtuzumab ozogamicin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060', 'application_number': 761060, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mylotarg:0,MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older.,2020-06-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf,The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).,CD33-positive,acute myeloid leukemia,Mylotarg (gemtuzumab ozogamicin),,,,,,,,doc:fda.mylotarg,Document,Regulatory approval,Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA.,"Wyeth Pharmaceuticals LLC. Mylotarg (gemtuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf. Revised June 2022. Accessed October 30, 2024.",Wyeth Pharmaceuticals LLC.,Mylotarg,gemtuzumab ozogamicin,,2024-10-30,2020-06-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060,761060.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,149,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 55, 'name': 'CD33 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD33'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],69,,,Drug,Gemtuzumab ozogamicin,ncit:C1806,C1806,Gemtuzumab Ozogamicin,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1806'],[],"[{'name': 'therapy_strategy', 'value': ['CD33 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
171,Statement,The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 1 month or older with newly-diagnosed CD33-positive acute myeloid leukemia (AML).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mylotarg', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA.', 'citation': 'Wyeth Pharmaceuticals LLC. Mylotarg (gemtuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf. Revised June 2022. Accessed October 30, 2024.', 'company': 'Wyeth Pharmaceuticals LLC.', 'drug_name_brand': 'Mylotarg', 'drug_name_generic': 'gemtuzumab ozogamicin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060', 'application_number': 761060, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mylotarg:1,MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.,2017-09-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf,The U.S. Food and Drug Administration granted approval to gemtuzumab ozogamicin for the treatment of adult and pediatric patients aged 2 years and older with relapsed or refractory CD33-positive acute myeloid leukemia (AML).,CD33-positive,acute myeloid leukemia,Mylotarg (gemtuzumab ozogamicin),,,,,,,,doc:fda.mylotarg,Document,Regulatory approval,Mylotarg (gemtuzumab ozogamicin) [package insert]. FDA.,"Wyeth Pharmaceuticals LLC. Mylotarg (gemtuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf. Revised June 2022. Accessed October 30, 2024.",Wyeth Pharmaceuticals LLC.,Mylotarg,gemtuzumab ozogamicin,,2024-10-30,2020-06-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761060,761060.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,149,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 55, 'name': 'CD33 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD33'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],69,,,Drug,Gemtuzumab ozogamicin,ncit:C1806,C1806,Gemtuzumab Ozogamicin,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1806'],[],"[{'name': 'therapy_strategy', 'value': ['CD33 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
172,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,150,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 66, 'name': 'FLT3-ITD', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'requires_oncogenic', 'value': True}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
173,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,151,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 85, 'name': 'FLT3 p.D835Y', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2503G>T'}, {'name': 'protein_change', 'value': 'p.D835Y'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>A'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
174,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,152,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 116, 'name': 'FLT3 p.D835A', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2504A>C'}, {'name': 'protein_change', 'value': 'p.D835A'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>G'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
175,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,153,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 117, 'name': 'FLT3 p.D835E', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592640}, {'name': 'end_position', 'value': 28592640}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.2505T>G'}, {'name': 'protein_change', 'value': 'p.D835E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913487'}, {'name': 'hgvsg', 'value': '13:g.28592640A>C'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
176,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,154,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 118, 'name': 'FLT3 p.D835H', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2503G>C'}, {'name': 'protein_change', 'value': 'p.D835H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>G'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
177,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,155,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 119, 'name': 'FLT3 p.D835N', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2503G>A'}, {'name': 'protein_change', 'value': 'p.D835N'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>T'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
178,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,156,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 120, 'name': 'FLT3 p.D835S', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'TC'}, {'name': 'alternate_allele', 'value': 'CT'}, {'name': 'cdna_change', 'value': 'c.2503_2504delinsAG'}, {'name': 'protein_change', 'value': 'p.D835S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'ENST00000241453.7:c.2503_2504delinsAG'}, {'name': 'hgvsg', 'value': '13:g.28592641_28592642delinsCT'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
179,Statement,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.xospata', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Xospata (gilteritinib) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Xospata', 'drug_name_generic': 'gilteritinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-01-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349', 'application_number': 211349, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.xospata:0,XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.,2018-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to gilteritinib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by an FDA-approved test.",FLT3 mutation,relapsed or refractory acute myeloid leukemia,Xospata (gilteritinib),,,,,,,,doc:fda.xospata,Document,Regulatory approval,Xospata (gilteritinib) [package insert]. FDA.,"Astellas Pharma US, Inc. Xospata (gilteritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf. Revised January 2022. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Xospata,gilteritinib,,2024-10-30,2022-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211349s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211349,211349.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,157,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 121, 'name': 'FLT3 p.D835V', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2504A>T'}, {'name': 'protein_change', 'value': 'p.D835V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>A'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],104,,,Drug,Gilteritinib,ncit:C116722,C116722,Gilteritinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116722'],[],"[{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
180,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:0,Gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,2006-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s016lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia,Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,158,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
181,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:0,Gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,2006-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s016lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia,Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,159,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
182,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:1,"Gleevec is a kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.",2003-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf,"The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.",philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia,Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,158,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
183,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:1,"Gleevec is a kinase inhibitor indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.",2003-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf,"The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.",philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia,Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,159,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
184,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:2,Gleevec is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).,2006-10-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).,philadelphia chromosome-positive,philadelphia chromosome-positive acute lymphoblastic leukemia,Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,160,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
185,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:3,Gleevec is a kinase inhibitor indicated for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.,2013-01-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021588s037lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.,philadelphia chromosome-positive,philadelphia chromosome-positive acute lymphoblastic leukemia,Gleevec (imatinib) in combination with chemotherapy,,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,160,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
186,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:4,Gleevec is a kinase inhibitor indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,2006-10-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,platelet-derived growth factor receptor (PDGFR) gene re-arrangements,myelodyplastic/myeloproliferative diseases (MDS/MPD),Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,161,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 28, 'name': 'PDGFRA rearrangements', 'genes': [{'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
187,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:4,Gleevec is a kinase inhibitor indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,2006-10-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.,platelet-derived growth factor receptor (PDGFR) gene re-arrangements,myelodyplastic/myeloproliferative diseases (MDS/MPD),Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,162,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 29, 'name': 'PDGFRB rearrangements', 'genes': [{'id': 40, 'name': 'PDGFRB', 'primaryCoding': {'id': 'hgnc:8804', 'code': 'HGNC:8804', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8804']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000113721', 'code': 'ENSG00000113721', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000113721']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5159', 'code': '5159', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5159']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002609.4', 'code': 'NM_002609.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002609.4']}}], 'extensions': [{'name': 'location', 'value': '5q32'}, {'name': 'location_sortable', 'value': '05q32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
188,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:5,Gleevec is a kinase inhibitor indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.,2006-10-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.,without the D816V c-Kit mutation or with the c-Kit mutational status unknown,aggressive systemic mastocytosis (ASM),Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,163,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 122, 'name': 'KIT p.D816V', 'genes': [{'id': 30, 'name': 'KIT', 'primaryCoding': {'id': 'hgnc:6342', 'code': 'HGNC:6342', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6342']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157404', 'code': 'ENSG00000157404', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157404']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3815', 'code': '3815', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3815']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000222.3', 'code': 'NM_000222.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000222.3']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'chromosome', 'value': '4'}, {'name': 'start_position', 'value': 55599321}, {'name': 'end_position', 'value': 55599321}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2447A>T'}, {'name': 'protein_change', 'value': 'p.D816V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '17'}, {'name': 'rsid', 'value': 'rs121913507'}, {'name': 'hgvsg', 'value': '4:g.55599321A>T'}]}]",42,Disease,Aggressive Systemic Mastocytosis,oncotree:ASM,ASM,Aggressive Systemic Mastocytosis,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASM'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
189,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:6,Gleevec is a kinase inhibitor indicated for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.,2006-10-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021588s011s012s013s014s017lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRa fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRa fusion kinase negative or unknown.,FIP1L1-PDGFRa fusion kinase and for patients ... who are FIP1L1-PDGFRa fusion kinase negative or unknown,hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL),Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,164,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 30, 'name': 'FIP1L1::PDGFRA', 'genes': [{'id': 25, 'name': 'FIP1L1', 'primaryCoding': {'id': 'hgnc:19124', 'code': 'HGNC:19124', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19124']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_030917.4', 'code': 'NM_030917.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_030917.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000145216', 'code': 'ENSG00000145216', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000145216']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:81608', 'code': '81608', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/81608']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}, {'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",12,Disease,"Chronic Eosinophilic Leukemia, NOS",oncotree:CELNOS,CELNOS,"Chronic Eosinophilic Leukemia, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CELNOS'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
190,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:7,Gleevec is a kinase inhibitor indicated for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,2003-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021588lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).,Kit (CD117) positive,unresectable and/or metastatic maligant gastrointestinal stromal tumors (GIST),Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,165,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 31, 'name': 'CD117 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD117'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",22,Disease,Gastrointestinal Stromal Tumor,oncotree:GIST,GIST,Gastrointestinal Stromal Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
191,Statement,The U.S. Food and Drug Administration granted approval to imatinib for the adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gleevec', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gleevec (imatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Gleevec', 'drug_name_generic': 'imatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588', 'application_number': 21588, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gleevec:8,Gleevec is a kinase inhibitor indicated for the adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.,2012-01-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021588s035lbl.pdf,The U.S. Food and Drug Administration granted approval to imatinib for the adjuvant treatment of adult patients following resection of Kit (CD117) positive gastrointestinal stromal tumors (GIST).,Kit (CD117) positive,GIST,Gleevec (imatinib),,,,,,,,doc:fda.gleevec,Document,Regulatory approval,Gleevec (imatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Gleevec,imatinib,,2024-10-30,2024-03-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021588s062lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588,21588.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,166,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 30, 'name': 'FIP1L1::PDGFRA', 'genes': [{'id': 25, 'name': 'FIP1L1', 'primaryCoding': {'id': 'hgnc:19124', 'code': 'HGNC:19124', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19124']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_030917.4', 'code': 'NM_030917.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_030917.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000145216', 'code': 'ENSG00000145216', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000145216']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:81608', 'code': '81608', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/81608']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}, {'id': 39, 'name': 'PDGFRA', 'primaryCoding': {'id': 'hgnc:8803', 'code': 'HGNC:8803', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8803']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006206.6', 'code': 'NM_006206.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006206.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000134853', 'code': 'ENSG00000134853', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000134853']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5156', 'code': '5156', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5156']}}], 'extensions': [{'name': 'location', 'value': '4q12'}, {'name': 'location_sortable', 'value': '04q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",22,Disease,Gastrointestinal Stromal Tumor,oncotree:GIST,GIST,Gastrointestinal Stromal Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST'],[],41,,,Drug,Imatinib,ncit:C62035,C62035,Imatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62035'],[],"[{'name': 'therapy_strategy', 'value': ['Bcr-Abl inhibition', 'c-Kit inhibition', 'PDGF-R inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
192,Statement,"The U.S. Food and Drug Administration granted accelerated approval to infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.truseltiq', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Truseltiq (infigratinib) [package insert]. FDA.', 'citation': 'QED Therapeutics, Inc. Truseltiq (infigratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed October 30, 2024.', 'company': 'QED Therapeutics, Inc.', 'drug_name_brand': 'Truseltiq', 'drug_name_generic': 'infigratinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-05-28', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214622', 'application_number': 214622, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.truseltiq:0,"TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",2021-05-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to infigratinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response. Furthermore, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",FGFR2 fusion or other rearrangement,unresectable locally advanced or metastatic cholangiocarcinoma,Truseltiq (infigratinib),,,,,,,,doc:fda.truseltiq,Document,Regulatory approval,Truseltiq (infigratinib) [package insert]. FDA.,"QED Therapeutics, Inc. Truseltiq (infigratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf. Revised May 2021. Accessed October 30, 2024.","QED Therapeutics, Inc.",Truseltiq,infigratinib,,2024-10-30,2021-05-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214622,214622.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,167,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 52, 'name': 'FGFR2::v', 'genes': [{'id': 23, 'name': 'FGFR2', 'primaryCoding': {'id': 'hgnc:3689', 'code': 'HGNC:3689', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000141.5', 'code': 'NM_000141.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000066468', 'code': 'ENSG00000066468', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000066468']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2263', 'code': '2263', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2263']}}], 'extensions': [{'name': 'location', 'value': '10q26.13'}, {'name': 'location_sortable', 'value': '10q26.13'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],127,,,Drug,Infigratinib,ncit:C88302,C88302,Infigratinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88302'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
193,Statement,The U.S. Food and Drug Administration granted approval to inotuzumab ozogamicin for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.besponsa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Besponsa (inotuzumab ozogamicin) [package insert]. FDA.', 'citation': 'Wyeth Pharmaceuticals LLC. Besponsa (inotuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Wyeth Pharmaceuticals LLC.', 'drug_name_brand': 'Besponsa', 'drug_name_generic': 'inotuzumab ozogamicin', 'first_published': '2017-08-17', 'access_date': '2024-10-30', 'publication_date': '2024-03-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040', 'application_number': 761040, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.besponsa:0,BESPONSA is a CD22-directed antibody and cytotoxic drug conjugate indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.,2024-03-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf,The U.S. Food and Drug Administration granted approval to inotuzumab ozogamicin for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).,CD22-positive,B-cell precursor acute lymphoblastic leukemia (ALL),Besponsa (inotuzumab ozogamicin),,,,,,,,doc:fda.besponsa,Document,Regulatory approval,Besponsa (inotuzumab ozogamicin) [package insert]. FDA.,"Wyeth Pharmaceuticals LLC. Besponsa (inotuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Wyeth Pharmaceuticals LLC.,Besponsa,inotuzumab ozogamicin,2017-08-17,2024-10-30,2024-03-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761040s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761040,761040.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,168,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 13, 'name': 'CD22 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD22'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],14,,,Drug,Inotuzumab ozogamicin,ncit:C71542,C71542,Inotuzumab Ozogamicin,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71542'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
194,Statement,The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.,"[{'id': 4, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.', 'date': '2025-04-30'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2011-03-25', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377', 'application_number': 125377, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.yervoy:0,YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.,2018-07-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf,The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.,microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),metastatic colorectal cancer,Yervoy (ipilimumab) in combination with nivolumab,,,,,,2025-04-08,2018-07-10,doc:fda.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Yervoy,ipilimumab,2011-03-25,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,125377.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,169,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
195,Statement,The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.,"[{'id': 4, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.', 'date': '2025-04-30'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2011-03-25', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377', 'application_number': 125377, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.yervoy:0,YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.,2018-07-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s096lbl.pdf,The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in combination with nivolumab.,microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),metastatic colorectal cancer,Yervoy (ipilimumab) in combination with nivolumab,,,,,,2025-04-08,2018-07-10,doc:fda.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Yervoy,ipilimumab,2011-03-25,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,125377.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,507,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
196,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2011-03-25', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377', 'application_number': 125377, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.yervoy:1,"YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab.",2020-05-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s109lbl.pdf,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>=1%), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",PD-L1 >= 1% and no EGFR or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Yervoy (ipilimumab) in combination with nivolumab,,,,,,2020-05-15,,doc:fda.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Yervoy,ipilimumab,2011-03-25,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,125377.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,171,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
197,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2011-03-25', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377', 'application_number': 125377, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.yervoy:2,"YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.",2020-05-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",no EGFR or ALK genomic tumor aberrations,metastatic or recurrent non-small cell lung cancer,Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy,,,,,,2020-05-26,,doc:fda.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Yervoy,ipilimumab,2011-03-25,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,125377.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,172,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],30,AND,"[{'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
198,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2011-03-25', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377', 'application_number': 125377, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.yervoy:2,"YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.",2020-05-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",no EGFR or ALK genomic tumor aberrations,metastatic or recurrent non-small cell lung cancer,Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy,,,,,,2020-05-26,,doc:fda.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Yervoy,ipilimumab,2011-03-25,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,125377.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,173,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],31,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
199,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.yervoy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Yervoy (ipilimumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Yervoy', 'drug_name_generic': 'ipilimumab', 'first_published': '2011-03-25', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377', 'application_number': 125377, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.yervoy:2,"YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.",2020-05-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",no EGFR or ALK genomic tumor aberrations,metastatic or recurrent non-small cell lung cancer,Yervoy (ipilimumab) in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy,,,,,,2020-05-26,,doc:fda.yervoy,Document,Regulatory approval,Yervoy (ipilimumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Yervoy (ipilimumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Yervoy,ipilimumab,2011-03-25,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125377s133lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125377,125377.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,174,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],32,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
200,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,175,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
201,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,176,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
202,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,177,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
203,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,178,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
204,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,179,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
205,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,180,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
206,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,181,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
207,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,182,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
208,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,183,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
209,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:0,"TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with in combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",2022-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211192s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",susceptible IDH1 mutation,acute myeloid leukemia,Tibsovo (ivosidenib) in combination with azacitidine or as monotherapy,,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,184,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],33,AND,"[{'id': 91, 'conceptType': 'Drug', 'name': 'Azacitidine', 'primaryCoding': {'id': 'ncit:C288', 'code': 'C288', 'name': 'Azacitidine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C288']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Hypomethylating agent chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 92, 'conceptType': 'Drug', 'name': 'Ivosidenib', 'primaryCoding': {'id': 'ncit:C114383', 'code': 'C114383', 'name': 'Ivosidenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
210,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:1,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.,2018-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory AML,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,175,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
211,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:1,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.,2018-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory AML,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,176,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
212,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:1,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.,2018-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory AML,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,177,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
213,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:1,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.,2018-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory AML,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,178,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
214,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib as a monotherapy or in combination with azacitidine for the treatment of adult patients newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:1,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory AML.,2018-07-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory AML,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,179,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
215,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:2,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory myelodysplastic syndromes,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,185,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
216,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:2,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory myelodysplastic syndromes,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,186,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
217,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:2,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory myelodysplastic syndromes,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,187,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
218,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:2,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory myelodysplastic syndromes,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,188,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
219,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:2,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes.,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory myelodysplastic syndromes,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,189,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
220,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:3,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",susceptible IDH1 mutation,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,190,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
221,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:3,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",susceptible IDH1 mutation,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,191,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
222,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:3,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",susceptible IDH1 mutation,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,192,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
223,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:3,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",susceptible IDH1 mutation,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,193,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
224,Statement,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tibsovo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tibsovo (ivosidenib) [package insert]. FDA.', 'citation': 'Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.', 'company': 'Agios Pharmaceuticals, Inc.', 'drug_name_brand': 'Tibsovo', 'drug_name_generic': 'ivosidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-10-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192', 'application_number': 211192, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tibsovo:3,TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated.,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated with a susceptible IDH1 mutation, as detected by an FDA-approved test. This indication is based on Study AG120-C-005 (NCT02989857), a randomized, multicenter, double-blind, placebo-controlled clinical trial consisting of 185 adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation. The product label notes that, across both arms of the trial, patients primarily had R132 variants: R132C (70% of patients), R132L (15%), R132G (12%), R132H (1.1%), and R132S (1.6%).",susceptible IDH1 mutation,locally advanced or metastatic cholangiocarcinoma,Tibsovo (ivosidenib),,,,,,,,doc:fda.tibsovo,Document,Regulatory approval,Tibsovo (ivosidenib) [package insert]. FDA.,"Agios Pharmaceuticals, Inc. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed October 30, 2024.","Agios Pharmaceuticals, Inc.",Tibsovo,ivosidenib,,2024-10-30,2023-10-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211192,211192.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,194,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],92,,,Drug,Ivosidenib,ncit:C114383,C114383,Ivosidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114383'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
225,Statement,"The U.S. Food and Drug Administration granted approval to lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, a trastuzumab.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tykerb', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tykerb (lapatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tykerb', 'drug_name_generic': 'lapatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-03-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059', 'application_number': 22059, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tykerb:0,"TYKERB is a kinase inhibitor indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.",2007-03-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022059lbl.pdf,"The U.S. Food and Drug Administration granted approval to lapatinib in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, a trastuzumab.",HER2 overexpression,advanced or metastatic breast cancer,Tykerb (lapatinib) in combination with capecitabine,,,,,,,,doc:fda.tykerb,Document,Regulatory approval,Tykerb (lapatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tykerb,lapatinib,,2024-10-30,2022-03-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,22059.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,195,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],34,AND,"[{'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 96, 'conceptType': 'Drug', 'name': 'Lapatinib', 'primaryCoding': {'id': 'ncit:C26653', 'code': 'C26653', 'name': 'Lapatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
226,Statement,The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tykerb', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tykerb (lapatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tykerb', 'drug_name_generic': 'lapatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-03-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059', 'application_number': 22059, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tykerb:1,TYKERB is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,2010-01-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf,The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,"HR+, HER2 overexpression",metastatic breast cancer,Tykerb (lapatinib) in combination with letrozole,,,,,,,,doc:fda.tykerb,Document,Regulatory approval,Tykerb (lapatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tykerb,lapatinib,,2024-10-30,2022-03-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,22059.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,196,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],35,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 96, 'conceptType': 'Drug', 'name': 'Lapatinib', 'primaryCoding': {'id': 'ncit:C26653', 'code': 'C26653', 'name': 'Lapatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
227,Statement,The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tykerb', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tykerb (lapatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tykerb', 'drug_name_generic': 'lapatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-03-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059', 'application_number': 22059, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tykerb:1,TYKERB is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,2010-01-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf,The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,"HR+, HER2 overexpression",metastatic breast cancer,Tykerb (lapatinib) in combination with letrozole,,,,,,,,doc:fda.tykerb,Document,Regulatory approval,Tykerb (lapatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tykerb,lapatinib,,2024-10-30,2022-03-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,22059.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,197,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],35,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 96, 'conceptType': 'Drug', 'name': 'Lapatinib', 'primaryCoding': {'id': 'ncit:C26653', 'code': 'C26653', 'name': 'Lapatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
228,Statement,The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tykerb', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tykerb (lapatinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tykerb', 'drug_name_generic': 'lapatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-03-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059', 'application_number': 22059, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tykerb:1,TYKERB is a kinase inhibitor indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,2010-01-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s3s6lbl.pdf,The U.S. Food and Drug Administration granted approval to lapatinib in combination with letrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive metastatic breast cancers that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib's product label notes that lapatinib in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.,"HR+, HER2 overexpression",metastatic breast cancer,Tykerb (lapatinib) in combination with letrozole,,,,,,,,doc:fda.tykerb,Document,Regulatory approval,Tykerb (lapatinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf. Revised March 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tykerb,lapatinib,,2024-10-30,2022-03-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022059s031lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022059,22059.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,198,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],35,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 96, 'conceptType': 'Drug', 'name': 'Lapatinib', 'primaryCoding': {'id': 'ncit:C26653', 'code': 'C26653', 'name': 'Lapatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C26653']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
229,Statement,"The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 5, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.', 'date': '2025-04-30'}]","[{'id': 'doc:fda.vitrakvi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vitrakvi (larotrectinib) [package insert]. FDA.', 'citation': 'Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Loxo Oncology, Inc.', 'drug_name_brand': 'Vitrakvi', 'drug_name_generic': 'larotrectinib', 'first_published': '2018-11-26', 'access_date': '2025-04-30', 'publication_date': '2025-04-09', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861', 'application_number': 210861, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vitrakvi:0,"VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test.",2018-11-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",NTRK gene fusion,solid tumors,Vitrakvi (larotrectinib),,,,,,2025-04-09,2018-11-26,doc:fda.vitrakvi,Document,Regulatory approval,Vitrakvi (larotrectinib) [package insert]. FDA.,"Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.","Loxo Oncology, Inc.",Vitrakvi,larotrectinib,2018-11-26,2025-04-30,2025-04-09,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861,210861.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,199,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 63, 'name': 'v::NTRK1', 'genes': [{'id': 35, 'name': 'NTRK1', 'primaryCoding': {'id': 'hgnc:8031', 'code': 'HGNC:8031', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002529.4', 'code': 'NM_002529.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000198400', 'code': 'ENSG00000198400', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000198400']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4914', 'code': '4914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4914']}}], 'extensions': [{'name': 'location', 'value': '1q23.1'}, {'name': 'location_sortable', 'value': '01q23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],100,,,Drug,Larotrectinib,ncit:C115977,C115977,Larotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
230,Statement,"The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 5, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.', 'date': '2025-04-30'}]","[{'id': 'doc:fda.vitrakvi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vitrakvi (larotrectinib) [package insert]. FDA.', 'citation': 'Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Loxo Oncology, Inc.', 'drug_name_brand': 'Vitrakvi', 'drug_name_generic': 'larotrectinib', 'first_published': '2018-11-26', 'access_date': '2025-04-30', 'publication_date': '2025-04-09', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861', 'application_number': 210861, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vitrakvi:0,"VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test.",2018-11-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",NTRK gene fusion,solid tumors,Vitrakvi (larotrectinib),,,,,,2025-04-09,2018-11-26,doc:fda.vitrakvi,Document,Regulatory approval,Vitrakvi (larotrectinib) [package insert]. FDA.,"Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.","Loxo Oncology, Inc.",Vitrakvi,larotrectinib,2018-11-26,2025-04-30,2025-04-09,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861,210861.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,200,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 64, 'name': 'v::NTRK2', 'genes': [{'id': 36, 'name': 'NTRK2', 'primaryCoding': {'id': 'hgnc:8032', 'code': 'HGNC:8032', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000148053', 'code': 'ENSG00000148053', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000148053']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4915', 'code': '4915', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4915']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006180.6', 'code': 'NM_006180.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6']}}], 'extensions': [{'name': 'location', 'value': '9q21.33'}, {'name': 'location_sortable', 'value': '09q21.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],100,,,Drug,Larotrectinib,ncit:C115977,C115977,Larotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
231,Statement,"The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 5, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.', 'date': '2025-04-30'}]","[{'id': 'doc:fda.vitrakvi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vitrakvi (larotrectinib) [package insert]. FDA.', 'citation': 'Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Loxo Oncology, Inc.', 'drug_name_brand': 'Vitrakvi', 'drug_name_generic': 'larotrectinib', 'first_published': '2018-11-26', 'access_date': '2025-04-30', 'publication_date': '2025-04-09', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861', 'application_number': 210861, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vitrakvi:0,"VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test.",2018-11-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to larotrectinib for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Larotrectinib's product label specifies to select patients for therapy based on an FDA-approved test.",NTRK gene fusion,solid tumors,Vitrakvi (larotrectinib),,,,,,2025-04-09,2018-11-26,doc:fda.vitrakvi,Document,Regulatory approval,Vitrakvi (larotrectinib) [package insert]. FDA.,"Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf. Revised April 2025. Accessed April 30, 2025.","Loxo Oncology, Inc.",Vitrakvi,larotrectinib,2018-11-26,2025-04-30,2025-04-09,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210861s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210861,210861.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,201,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 65, 'name': 'v::NTRK3', 'genes': [{'id': 37, 'name': 'NTRK3', 'primaryCoding': {'id': 'hgnc:8033', 'code': 'HGNC:8033', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001012338.3', 'code': 'NM_001012338.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140538', 'code': 'ENSG00000140538', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140538']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4916', 'code': '4916', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4916']}}], 'extensions': [{'name': 'location', 'value': '15q25.3'}, {'name': 'location_sortable', 'value': '15q25.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],100,,,Drug,Larotrectinib,ncit:C115977,C115977,Larotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C115977'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
232,Statement,The U.S. Food and Drug Administration granted approval to lenalidomide for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.revlimid', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revlimid (lenalidomide) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Revlimid (lenalidomide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Revlimid', 'drug_name_generic': 'lenalidomide', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-24', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880', 'application_number': 21880, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.revlimid:0,REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.,2005-12-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021880lbl.pdf,The U.S. Food and Drug Administration granted approval to lenalidomide for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.,5q deletion,transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS),Revlimid (lenalidomide),,,,,,,,doc:fda.revlimid,Document,Regulatory approval,Revlimid (lenalidomide) [package insert]. FDA.,"Bristol-Myers Squibb Company. Revlimid (lenalidomide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Bristol-Myers Squibb Company.,Revlimid,lenalidomide,,2024-10-30,2023-03-24,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021880s067lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021880,21880.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,202,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 61, 'name': '5q deletion', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Copy Number (arm level)'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '5'}, {'name': 'direction', 'value': 'Deletion'}, {'name': 'arm', 'value': 'q'}]}]",43,Disease,Myelodysplastic Syndromes,oncotree:MDS,MDS,Myelodysplastic Syndromes,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MDS'],[],79,,,Drug,Lenalidomide,ncit:C2668,C2668,Lenalidomide,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2668'],[],"[{'name': 'therapy_strategy', 'value': ['Angiogenesis inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
233,Statement,"The U.S. Food and Drug Administration granted approval to lorlatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lorbrena', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lorbrena (lorlatinib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf. Revised March 2021. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Lorbrena', 'drug_name_generic': 'lorlatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210868', 'application_number': 210868, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lorbrena:0,LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,2021-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to lorlatinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.",ALK-positive,metastatic non-small cell lung cancer,Lorbrena (lorlatinib),,,,,,,,doc:fda.lorbrena,Document,Regulatory approval,Lorbrena (lorlatinib) [package insert]. FDA.,"Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf. Revised March 2021. Accessed October 30, 2024.","Pfizer, Inc.",Lorbrena,lorlatinib,,2024-10-30,2021-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210868,210868.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,203,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],56,,,Drug,Lorlatinib,ncit:C113655,C113655,Lorlatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C113655'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
234,Statement,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.margenza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Margenza (margetuximab-cmkb) [package insert]. FDA.', 'citation': 'MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'MacroGenics, Inc.', 'drug_name_brand': 'Margenza', 'drug_name_generic': 'margetuximab-cmkb', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150', 'application_number': 761150, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.margenza:0,"MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.",2020-12-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",HER2-positive,metastatic breast cancer,Margenza (margetuximab-cmkb) in combination with chemotherapy,,,,,,,,doc:fda.margenza,Document,Regulatory approval,Margenza (margetuximab-cmkb) [package insert]. FDA.,"MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.","MacroGenics, Inc.",Margenza,margetuximab-cmkb,,2024-10-30,2023-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150,761150.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,204,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],36,AND,"[{'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 128, 'conceptType': 'Drug', 'name': 'Margetuximab', 'primaryCoding': {'id': 'ncit:C91733', 'code': 'C91733', 'name': 'Margetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C91733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
235,Statement,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.margenza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Margenza (margetuximab-cmkb) [package insert]. FDA.', 'citation': 'MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'MacroGenics, Inc.', 'drug_name_brand': 'Margenza', 'drug_name_generic': 'margetuximab-cmkb', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150', 'application_number': 761150, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.margenza:0,"MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.",2020-12-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",HER2-positive,metastatic breast cancer,Margenza (margetuximab-cmkb) in combination with chemotherapy,,,,,,,,doc:fda.margenza,Document,Regulatory approval,Margenza (margetuximab-cmkb) [package insert]. FDA.,"MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.","MacroGenics, Inc.",Margenza,margetuximab-cmkb,,2024-10-30,2023-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150,761150.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,205,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],37,AND,"[{'id': 129, 'conceptType': 'Drug', 'name': 'Eribulin', 'primaryCoding': {'id': 'ncit:C96748', 'code': 'C96748', 'name': 'Eribulin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C96748']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Tubulin polymerization inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 128, 'conceptType': 'Drug', 'name': 'Margetuximab', 'primaryCoding': {'id': 'ncit:C91733', 'code': 'C91733', 'name': 'Margetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C91733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
236,Statement,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.margenza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Margenza (margetuximab-cmkb) [package insert]. FDA.', 'citation': 'MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'MacroGenics, Inc.', 'drug_name_brand': 'Margenza', 'drug_name_generic': 'margetuximab-cmkb', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150', 'application_number': 761150, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.margenza:0,"MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.",2020-12-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",HER2-positive,metastatic breast cancer,Margenza (margetuximab-cmkb) in combination with chemotherapy,,,,,,,,doc:fda.margenza,Document,Regulatory approval,Margenza (margetuximab-cmkb) [package insert]. FDA.,"MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.","MacroGenics, Inc.",Margenza,margetuximab-cmkb,,2024-10-30,2023-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150,761150.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,206,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],38,AND,"[{'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 128, 'conceptType': 'Drug', 'name': 'Margetuximab', 'primaryCoding': {'id': 'ncit:C91733', 'code': 'C91733', 'name': 'Margetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C91733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
237,Statement,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.margenza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Margenza (margetuximab-cmkb) [package insert]. FDA.', 'citation': 'MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'MacroGenics, Inc.', 'drug_name_brand': 'Margenza', 'drug_name_generic': 'margetuximab-cmkb', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150', 'application_number': 761150, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.margenza:0,"MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2- positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.",2020-12-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to margetuximab-cmkb in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. This indication is based on SOPHIA (NCT02492711), a randomized, multicenter, open-label trial of 536 patients with IHC 3+ or ISH-amplified HER2+ metastatic breast cancer who had received prior treatment with other anti-HER2 therapies. Randomization within the trial was stratified by chemotherapy choice (capecitabine, eribulin, gemcitabine, or vinorelbine).",HER2-positive,metastatic breast cancer,Margenza (margetuximab-cmkb) in combination with chemotherapy,,,,,,,,doc:fda.margenza,Document,Regulatory approval,Margenza (margetuximab-cmkb) [package insert]. FDA.,"MacroGenics, Inc. Margenza (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf. Revised May 2023. Accessed October 30, 2024.","MacroGenics, Inc.",Margenza,margetuximab-cmkb,,2024-10-30,2023-05-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761150s005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761150,761150.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,207,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],39,AND,"[{'id': 128, 'conceptType': 'Drug', 'name': 'Margetuximab', 'primaryCoding': {'id': 'ncit:C91733', 'code': 'C91733', 'name': 'Margetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C91733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 117, 'conceptType': 'Drug', 'name': 'Vinorelbine', 'primaryCoding': {'id': 'ncit:C1275', 'code': 'C1275', 'name': 'Vinorelbine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1275']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
238,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,208,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 66, 'name': 'FLT3-ITD', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'variant_annotation', 'value': 'Internal Tandem Duplication (ITD)'}, {'name': 'requires_oncogenic', 'value': True}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
239,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,209,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 85, 'name': 'FLT3 p.D835Y', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2503G>T'}, {'name': 'protein_change', 'value': 'p.D835Y'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
240,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,210,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 116, 'name': 'FLT3 p.D835A', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2504A>C'}, {'name': 'protein_change', 'value': 'p.D835A'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>G'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
241,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,211,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 117, 'name': 'FLT3 p.D835E', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592640}, {'name': 'end_position', 'value': 28592640}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.2505T>G'}, {'name': 'protein_change', 'value': 'p.D835E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913487'}, {'name': 'hgvsg', 'value': '13:g.28592640A>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
242,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,212,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 118, 'name': 'FLT3 p.D835H', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2503G>C'}, {'name': 'protein_change', 'value': 'p.D835H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>G'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
243,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,213,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 119, 'name': 'FLT3 p.D835N', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592642}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2503G>A'}, {'name': 'protein_change', 'value': 'p.D835N'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121913488'}, {'name': 'hgvsg', 'value': '13:g.28592642C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
244,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,214,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 120, 'name': 'FLT3 p.D835S', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592642}, {'name': 'reference_allele', 'value': 'TC'}, {'name': 'alternate_allele', 'value': 'CT'}, {'name': 'cdna_change', 'value': 'c.2503_2504delinsAG'}, {'name': 'protein_change', 'value': 'p.D835S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'ENST00000241453.7:c.2503_2504delinsAG'}, {'name': 'hgvsg', 'value': '13:g.28592641_28592642delinsCT'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
245,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,215,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 121, 'name': 'FLT3 p.D835V', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592641}, {'name': 'end_position', 'value': 28592641}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2504A>T'}, {'name': 'protein_change', 'value': 'p.D835V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121909646'}, {'name': 'hgvsg', 'value': '13:g.28592641T>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
246,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,216,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 123, 'name': 'FLT3 p.I836del', 'genes': [{'id': 26, 'name': 'FLT3', 'primaryCoding': {'id': 'hgnc:3765', 'code': 'HGNC:3765', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3765']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000122025', 'code': 'ENSG00000122025', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000122025']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2322', 'code': '2322', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2322']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004119.3', 'code': 'NM_004119.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004119.3']}}], 'extensions': [{'name': 'location', 'value': '13q12.2'}, {'name': 'location_sortable', 'value': '13q12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'start_position', 'value': 28592635}, {'name': 'end_position', 'value': 28592637}, {'name': 'reference_allele', 'value': 'ATG'}, {'name': 'alternate_allele', 'value': '-'}, {'name': 'cdna_change', 'value': 'c.2508_2510del'}, {'name': 'protein_change', 'value': 'p.I836del'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '20'}, {'name': 'hgvsg', 'value': '13:g.28592635_28592637del'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
247,Statement,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rydapt', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rydapt (midostaurin) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Rydapt', 'drug_name_generic': 'midostaurin', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-05-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997', 'application_number': 207997, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rydapt:0,"RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation- positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.",2017-04-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to midostaurin in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test. Midostaurin's product label notes that midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.",FLT3 mutation-positive,acute myeloid leukemia,Rydapt (midostaurin) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation,,,,,,,,doc:fda.rydapt,Document,Regulatory approval,Rydapt (midostaurin) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Rydapt (midostaurin) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf. Revised May 2023. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Rydapt,midostaurin,,2024-10-30,2023-05-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207997s010lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207997,207997.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,217,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 125, 'name': 'CDK12 oncogenic variants', 'genes': [{'id': 14, 'name': 'CDK12', 'primaryCoding': {'id': 'hgnc:24224', 'code': 'HGNC:24224', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000167258', 'code': 'ENSG00000167258', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000167258']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:51755', 'code': '51755', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/51755']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_016507.4', 'code': 'NM_016507.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],40,AND,"[{'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 68, 'conceptType': 'Drug', 'name': 'Daunorubicin', 'primaryCoding': {'id': 'ncit:C62091', 'code': 'C62091', 'name': 'Daunorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62091']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 82, 'conceptType': 'Drug', 'name': 'Midostaurin', 'primaryCoding': {'id': 'ncit:C1872', 'code': 'C1872', 'name': 'Midostaurin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1872']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FLT3 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
248,Statement,"The U.S. Food and Drug Administration granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.exkivity', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Exkivity (mobocertinib) [package insert]. FDA.', 'citation': 'Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Takeda Pharmaceuticals America, Inc.', 'drug_name_brand': 'Exkivity', 'drug_name_generic': 'mobocertinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process', 'application_number': 215310, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.exkivity:0,"EXKIVITY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",2021-09-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",EGFR exon 20 insertion mutations,locally advanced or metastatic non-small cell lung cancer,Exkivity (mobocertinib),,,,,,,,doc:fda.exkivity,Document,Regulatory approval,Exkivity (mobocertinib) [package insert]. FDA.,"Takeda Pharmaceuticals America, Inc. Exkivity (mobocertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Takeda Pharmaceuticals America, Inc.",Exkivity,mobocertinib,,2024-10-30,2023-09-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215310s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process,215310.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,218,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 86, 'name': 'EGFR Exon 20 (Insertion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Insertion'}, {'name': 'exon', 'value': '20'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],130,,,Drug,Mobocertinib,ncit:C126752,C126752,Mobocertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C126752'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
249,Statement,"The U.S. Food and Drug Administration granted approval to neratinib for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [package insert]. FDA.', 'citation': 'Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed October 30, 2024.', 'company': 'Puma Biotechnology, Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-06-28', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051', 'application_number': 208051, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.nerlynx:0,"NERLYNX is a kinase inhibitor indicated as a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.",2019-10-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208051s004lbl.pdf,"The U.S. Food and Drug Administration granted approval to neratinib for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab based therapy.",HER2-positive,early-stage breast cancer,Nerlynx (neratinib),,,,,,,,doc:fda.nerlynx,Document,Regulatory approval,Nerlynx (neratinib) [package insert]. FDA.,"Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed October 30, 2024.","Puma Biotechnology, Inc.",Nerlynx,neratinib,,2024-10-30,2021-06-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051,208051.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,219,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,,,Drug,Neratinib,ncit:C49094,C49094,Neratinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
250,Statement,The U.S. Food and Drug Administration granted approval to neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.nerlynx', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Nerlynx (neratinib) [package insert]. FDA.', 'citation': 'Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed October 30, 2024.', 'company': 'Puma Biotechnology, Inc.', 'drug_name_brand': 'Nerlynx', 'drug_name_generic': 'neratinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-06-28', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051', 'application_number': 208051, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.nerlynx:1,"NERLYNX is a kinase inhibitor indicated in combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.",2020-02-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208051s005s006lbl.pdf,The U.S. Food and Drug Administration granted approval to neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.,HER2-positive,advanced or metastatic breast cancer,Nerlynx (neratinib) in combination with capecitabine,,,,,,,,doc:fda.nerlynx,Document,Regulatory approval,Nerlynx (neratinib) [package insert]. FDA.,"Puma Biotechnology, Inc. Nerlynx (neratinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf. Revised June 2021. Accessed October 30, 2024.","Puma Biotechnology, Inc.",Nerlynx,neratinib,,2024-10-30,2021-06-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208051,208051.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,220,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],41,AND,"[{'id': 70, 'conceptType': 'Drug', 'name': 'Neratinib', 'primaryCoding': {'id': 'ncit:C49094', 'code': 'C49094', 'name': 'Neratinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49094']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
251,Statement,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068', 'application_number': 22068, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tasigna:0,Tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,2018-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid (Ph+ CML),Tasigna (nilotinib),,,,,,,,doc:fda.tasigna,Document,Regulatory approval,Tasigna (nilotinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tasigna,nilotinib,,2024-10-30,2024-02-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,22068.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,221,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],88,,,Drug,Nilotinib,ncit:C48375,C48375,Nilotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
252,Statement,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068', 'application_number': 22068, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tasigna:0,Tasigna is a kinase inhibitor indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,2018-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid (Ph+ CML),Tasigna (nilotinib),,,,,,,,doc:fda.tasigna,Document,Regulatory approval,Tasigna (nilotinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tasigna,nilotinib,,2024-10-30,2024-02-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,22068.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,222,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],88,,,Drug,Nilotinib,ncit:C48375,C48375,Nilotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
253,Statement,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068', 'application_number': 22068, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tasigna:1,Tasigna is a kinase inhibitor indicated for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.,2007-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.,philadelphia chromosome-positive,chronic phase or accelerated phase Ph+ CML,Tasigna (nilotinib),,,,,,,,doc:fda.tasigna,Document,Regulatory approval,Tasigna (nilotinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tasigna,nilotinib,,2024-10-30,2024-02-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,22068.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,221,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],88,,,Drug,Nilotinib,ncit:C48375,C48375,Nilotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
254,Statement,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068', 'application_number': 22068, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tasigna:1,Tasigna is a kinase inhibitor indicated for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.,2007-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdf,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.,philadelphia chromosome-positive,chronic phase or accelerated phase Ph+ CML,Tasigna (nilotinib),,,,,,,,doc:fda.tasigna,Document,Regulatory approval,Tasigna (nilotinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tasigna,nilotinib,,2024-10-30,2024-02-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,22068.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,222,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],88,,,Drug,Nilotinib,ncit:C48375,C48375,Nilotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
255,Statement,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zejula', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zejula (niraparib) [package insert]. FDA.', 'citation': 'GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline.', 'drug_name_brand': 'Zejula', 'drug_name_generic': 'niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876', 'application_number': 214876, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zejula:0,"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",deleterious or suspected deleterious germline BRCA-mutated,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",Zejula (niraparib),,,,,,,,doc:fda.zejula,Document,Regulatory approval,Zejula (niraparib) [package insert]. FDA.,"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",GlaxoSmithKline.,Zejula,niraparib,,2024-10-30,2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876,214876.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,223,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],6,,,Drug,Niraparib,ncit:C80059,C80059,Niraparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
256,Statement,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zejula', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zejula (niraparib) [package insert]. FDA.', 'citation': 'GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline.', 'drug_name_brand': 'Zejula', 'drug_name_generic': 'niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876', 'application_number': 214876, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zejula:0,"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",deleterious or suspected deleterious germline BRCA-mutated,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",Zejula (niraparib),,,,,,,,doc:fda.zejula,Document,Regulatory approval,Zejula (niraparib) [package insert]. FDA.,"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",GlaxoSmithKline.,Zejula,niraparib,,2024-10-30,2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876,214876.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,224,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],6,,,Drug,Niraparib,ncit:C80059,C80059,Niraparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
257,Statement,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zejula', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zejula (niraparib) [package insert]. FDA.', 'citation': 'GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline.', 'drug_name_brand': 'Zejula', 'drug_name_generic': 'niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876', 'application_number': 214876, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zejula:0,"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",deleterious or suspected deleterious germline BRCA-mutated,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",Zejula (niraparib),,,,,,,,doc:fda.zejula,Document,Regulatory approval,Zejula (niraparib) [package insert]. FDA.,"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",GlaxoSmithKline.,Zejula,niraparib,,2024-10-30,2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876,214876.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,225,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],6,,,Drug,Niraparib,ncit:C80059,C80059,Niraparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
258,Statement,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zejula', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zejula (niraparib) [package insert]. FDA.', 'citation': 'GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline.', 'drug_name_brand': 'Zejula', 'drug_name_generic': 'niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876', 'application_number': 214876, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zejula:0,"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",deleterious or suspected deleterious germline BRCA-mutated,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",Zejula (niraparib),,,,,,,,doc:fda.zejula,Document,Regulatory approval,Zejula (niraparib) [package insert]. FDA.,"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",GlaxoSmithKline.,Zejula,niraparib,,2024-10-30,2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876,214876.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,226,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],6,,,Drug,Niraparib,ncit:C80059,C80059,Niraparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
259,Statement,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zejula', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zejula (niraparib) [package insert]. FDA.', 'citation': 'GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline.', 'drug_name_brand': 'Zejula', 'drug_name_generic': 'niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876', 'application_number': 214876, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zejula:0,"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",deleterious or suspected deleterious germline BRCA-mutated,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",Zejula (niraparib),,,,,,,,doc:fda.zejula,Document,Regulatory approval,Zejula (niraparib) [package insert]. FDA.,"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",GlaxoSmithKline.,Zejula,niraparib,,2024-10-30,2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876,214876.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,227,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],6,,,Drug,Niraparib,ncit:C80059,C80059,Niraparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
260,Statement,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zejula', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zejula (niraparib) [package insert]. FDA.', 'citation': 'GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'GlaxoSmithKline.', 'drug_name_brand': 'Zejula', 'drug_name_generic': 'niraparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-26', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876', 'application_number': 214876, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zejula:0,"ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA.",2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to niraparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Niraparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for niraparib.",deleterious or suspected deleterious germline BRCA-mutated,"recurrent epithelial ovarian, fallopian tubem or primary peritoneal cancer",Zejula (niraparib),,,,,,,,doc:fda.zejula,Document,Regulatory approval,Zejula (niraparib) [package insert]. FDA.,"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf. Revised April 2023. Accessed October 30, 2024.",GlaxoSmithKline.,Zejula,niraparib,,2024-10-30,2023-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214876s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214876,214876.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,228,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],6,,,Drug,Niraparib,ncit:C80059,C80059,Niraparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80059'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
261,Statement,"The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:0,"OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.",2024-10-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s127lbl.pdf,"The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",no known EGFR mutations or ALK rearrangement,non-small cell lung cancer,Opdivo (nivolumab) in combination with platinum-doublet chemotherapy,,,,,,2024-10-03,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,229,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],42,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
262,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:1,"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab.",2020-05-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s080lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (>= 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.",PD-L1 (>= 1%),non-small cell lung cancer,nivolumab in combination with ipilimumab,,,,,,2020-05-15,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,230,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
263,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,231,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
264,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,232,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
265,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,233,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
266,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,234,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
267,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,235,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
268,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,236,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
269,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,237,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
270,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,238,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
271,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,239,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
272,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,240,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
273,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,241,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
274,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:0,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-12-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,242,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
275,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,243,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
276,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,244,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
277,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,245,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
278,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,246,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
279,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,247,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 51, 'name': 'HRD', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Homologous Recombination'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
280,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,248,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
281,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,249,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
282,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,250,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
283,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,251,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
284,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,252,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 51, 'name': 'HRD', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Homologous Recombination'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
285,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,253,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
286,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,254,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
287,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,255,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
288,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,256,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
289,Statement,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:1,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",HRD-positive defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability,"advanced epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib) in combination with bevacizumab,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,257,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 51, 'name': 'HRD', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Homologous Recombination'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],43,AND,"[{'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
290,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,231,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
291,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,232,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
292,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,233,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
293,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,234,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
294,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,235,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
295,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,236,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
296,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,237,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
297,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,238,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
298,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,239,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
299,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,240,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
300,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,241,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
301,Statement,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:2,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2023-09-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s029lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",deleterious or suspected deleterious germline or somatic BRCA-mutated,"relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer",Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,242,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
302,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:3,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2022-03-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"deleterious or suspected deleterious gBRCAm, HER2-negative",high risk early breast cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,258,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
303,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:3,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2022-03-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s023lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"deleterious or suspected deleterious gBRCAm, HER2-negative",high risk early breast cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,259,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
304,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:4,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Olaparib's product label states that patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. The product label also states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","deleterious or suspected deleterious gBRCAm, HER2-negative",metastatic breast cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,258,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
305,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCAm human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:4,"Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",2018-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf,"The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Olaparib's product label states that patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. The product label also states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.","deleterious or suspected deleterious gBRCAm, HER2-negative",metastatic breast cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,259,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
306,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:5,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2019-12-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558Orig1s010lblrpl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious gBRCAm,metastatic pancreatic adenocarcinoma,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,260,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",52,Disease,Pancreatic Adenocarcinoma,oncotree:PAAD,PAAD,Pancreatic Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
307,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:5,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2019-12-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558Orig1s010lblrpl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious gBRCAm,metastatic pancreatic adenocarcinoma,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,261,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",52,Disease,Pancreatic Adenocarcinoma,oncotree:PAAD,PAAD,Pancreatic Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
308,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,262,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
309,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,263,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
310,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,264,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
311,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,265,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
312,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,266,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
313,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,267,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 104, 'name': 'ATM pathogenic variants', 'genes': [{'id': 3, 'name': 'ATM', 'primaryCoding': {'id': 'hgnc:795', 'code': 'HGNC:795', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000051.4', 'code': 'NM_000051.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149311', 'code': 'ENSG00000149311', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149311']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:472', 'code': '472', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/472']}}], 'extensions': [{'name': 'location', 'value': '11q22.3'}, {'name': 'location_sortable', 'value': '11q22.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
314,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,268,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 105, 'name': 'ATM oncogenic variants', 'genes': [{'id': 3, 'name': 'ATM', 'primaryCoding': {'id': 'hgnc:795', 'code': 'HGNC:795', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000051.4', 'code': 'NM_000051.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149311', 'code': 'ENSG00000149311', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149311']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:472', 'code': '472', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/472']}}], 'extensions': [{'name': 'location', 'value': '11q22.3'}, {'name': 'location_sortable', 'value': '11q22.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
315,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,269,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 106, 'name': 'BARD1 pathogenic variants', 'genes': [{'id': 5, 'name': 'BARD1', 'primaryCoding': {'id': 'hgnc:952', 'code': 'HGNC:952', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:952']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000465.4', 'code': 'NM_000465.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000465.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138376', 'code': 'ENSG00000138376', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138376']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:580', 'code': '580', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/580']}}], 'extensions': [{'name': 'location', 'value': '2q35'}, {'name': 'location_sortable', 'value': '02q35'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
316,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,270,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 4, 'name': 'BARD1 oncogenic variants', 'genes': [{'id': 5, 'name': 'BARD1', 'primaryCoding': {'id': 'hgnc:952', 'code': 'HGNC:952', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:952']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000465.4', 'code': 'NM_000465.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000465.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138376', 'code': 'ENSG00000138376', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138376']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:580', 'code': '580', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/580']}}], 'extensions': [{'name': 'location', 'value': '2q35'}, {'name': 'location_sortable', 'value': '02q35'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
317,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,271,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 5, 'name': 'BRIP1 oncogenic variants', 'genes': [{'id': 11, 'name': 'BRIP1', 'primaryCoding': {'id': 'hgnc:20473', 'code': 'HGNC:20473', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20473']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_032043.3', 'code': 'NM_032043.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_032043.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000136492', 'code': 'ENSG00000136492', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000136492']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:83990', 'code': '83990', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/83990']}}], 'extensions': [{'name': 'location', 'value': '17q23.2'}, {'name': 'location_sortable', 'value': '17q23.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
318,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,272,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 6, 'name': 'BRIP1 pathogenic variants', 'genes': [{'id': 11, 'name': 'BRIP1', 'primaryCoding': {'id': 'hgnc:20473', 'code': 'HGNC:20473', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20473']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_032043.3', 'code': 'NM_032043.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_032043.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000136492', 'code': 'ENSG00000136492', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000136492']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:83990', 'code': '83990', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/83990']}}], 'extensions': [{'name': 'location', 'value': '17q23.2'}, {'name': 'location_sortable', 'value': '17q23.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
319,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,273,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 7, 'name': 'CDK12 pathogenic variants', 'genes': [{'id': 14, 'name': 'CDK12', 'primaryCoding': {'id': 'hgnc:24224', 'code': 'HGNC:24224', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000167258', 'code': 'ENSG00000167258', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000167258']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:51755', 'code': '51755', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/51755']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_016507.4', 'code': 'NM_016507.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
320,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,274,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 125, 'name': 'CDK12 oncogenic variants', 'genes': [{'id': 14, 'name': 'CDK12', 'primaryCoding': {'id': 'hgnc:24224', 'code': 'HGNC:24224', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000167258', 'code': 'ENSG00000167258', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000167258']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:51755', 'code': '51755', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/51755']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_016507.4', 'code': 'NM_016507.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
321,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,275,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 126, 'name': 'CHEK1 pathogenic variants', 'genes': [{'id': 15, 'name': 'CHEK1', 'primaryCoding': {'id': 'hgnc:1925', 'code': 'HGNC:1925', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1925']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001114122.3', 'code': 'NM_001114122.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001114122.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149554', 'code': 'ENSG00000149554', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149554']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1111', 'code': '1111', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1111']}}], 'extensions': [{'name': 'location', 'value': '11q24.2'}, {'name': 'location_sortable', 'value': '11q24.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
322,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,276,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 127, 'name': 'CHEK1 oncogenic variants', 'genes': [{'id': 15, 'name': 'CHEK1', 'primaryCoding': {'id': 'hgnc:1925', 'code': 'HGNC:1925', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1925']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001114122.3', 'code': 'NM_001114122.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001114122.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149554', 'code': 'ENSG00000149554', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149554']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1111', 'code': '1111', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1111']}}], 'extensions': [{'name': 'location', 'value': '11q24.2'}, {'name': 'location_sortable', 'value': '11q24.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
323,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,277,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 128, 'name': 'CHEK2 pathogenic variants', 'genes': [{'id': 16, 'name': 'CHEK2', 'primaryCoding': {'id': 'hgnc:16627', 'code': 'HGNC:16627', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000183765', 'code': 'ENSG00000183765', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000183765']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:11200', 'code': '11200', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/11200']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007194.4', 'code': 'NM_007194.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007194.4']}}], 'extensions': [{'name': 'location', 'value': '22q12.1'}, {'name': 'location_sortable', 'value': '22q12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '22'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
324,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,278,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 129, 'name': 'CHEK2 oncogenic variants', 'genes': [{'id': 16, 'name': 'CHEK2', 'primaryCoding': {'id': 'hgnc:16627', 'code': 'HGNC:16627', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000183765', 'code': 'ENSG00000183765', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000183765']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:11200', 'code': '11200', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/11200']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007194.4', 'code': 'NM_007194.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007194.4']}}], 'extensions': [{'name': 'location', 'value': '22q12.1'}, {'name': 'location_sortable', 'value': '22q12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '22'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
325,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,279,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 130, 'name': 'FANCL pathogenic variants', 'genes': [{'id': 21, 'name': 'FANCL', 'primaryCoding': {'id': 'hgnc:20748', 'code': 'HGNC:20748', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20748']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_018062.4', 'code': 'NM_018062.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_018062.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000115392', 'code': 'ENSG00000115392', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000115392']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:55120', 'code': '55120', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/55120']}}], 'extensions': [{'name': 'location', 'value': '2p16.1'}, {'name': 'location_sortable', 'value': '02p16.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
326,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,280,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 131, 'name': 'FANCL oncogenic variants', 'genes': [{'id': 21, 'name': 'FANCL', 'primaryCoding': {'id': 'hgnc:20748', 'code': 'HGNC:20748', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:20748']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_018062.4', 'code': 'NM_018062.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_018062.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000115392', 'code': 'ENSG00000115392', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000115392']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:55120', 'code': '55120', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/55120']}}], 'extensions': [{'name': 'location', 'value': '2p16.1'}, {'name': 'location_sortable', 'value': '02p16.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
327,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,281,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 132, 'name': 'PALB2 pathogenic variants', 'genes': [{'id': 38, 'name': 'PALB2', 'primaryCoding': {'id': 'hgnc:26144', 'code': 'HGNC:26144', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26144']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000083093', 'code': 'ENSG00000083093', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000083093']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:79728', 'code': '79728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/79728']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_024675.4', 'code': 'NM_024675.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_024675.4']}}], 'extensions': [{'name': 'location', 'value': '16p12.2'}, {'name': 'location_sortable', 'value': '16p12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
328,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,282,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 133, 'name': 'PALB2 oncogenic variants', 'genes': [{'id': 38, 'name': 'PALB2', 'primaryCoding': {'id': 'hgnc:26144', 'code': 'HGNC:26144', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26144']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000083093', 'code': 'ENSG00000083093', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000083093']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:79728', 'code': '79728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/79728']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_024675.4', 'code': 'NM_024675.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_024675.4']}}], 'extensions': [{'name': 'location', 'value': '16p12.2'}, {'name': 'location_sortable', 'value': '16p12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
329,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,283,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 134, 'name': 'RAD51B pathogenic variants', 'genes': [{'id': 44, 'name': 'RAD51B', 'primaryCoding': {'id': 'hgnc:9822', 'code': 'HGNC:9822', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9822']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182185', 'code': 'ENSG00000182185', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182185']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5890', 'code': '5890', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5890']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_133510.4', 'code': 'NM_133510.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_133510.4']}}], 'extensions': [{'name': 'location', 'value': '14q24.1'}, {'name': 'location_sortable', 'value': '14q24.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
330,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,284,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 135, 'name': 'RAD51B oncogenic variants', 'genes': [{'id': 44, 'name': 'RAD51B', 'primaryCoding': {'id': 'hgnc:9822', 'code': 'HGNC:9822', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9822']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182185', 'code': 'ENSG00000182185', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182185']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5890', 'code': '5890', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5890']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_133510.4', 'code': 'NM_133510.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_133510.4']}}], 'extensions': [{'name': 'location', 'value': '14q24.1'}, {'name': 'location_sortable', 'value': '14q24.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],87,,,Drug,Talazoparib,ncit:C95733,C95733,Talazoparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
331,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,285,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 136, 'name': 'RAD51C pathogenic variants', 'genes': [{'id': 45, 'name': 'RAD51C', 'primaryCoding': {'id': 'hgnc:9820', 'code': 'HGNC:9820', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9820']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_058216.3', 'code': 'NM_058216.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_058216.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000108384', 'code': 'ENSG00000108384', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000108384']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5889', 'code': '5889', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5889']}}], 'extensions': [{'name': 'location', 'value': '17q22'}, {'name': 'location_sortable', 'value': '17q22'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
332,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,286,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 137, 'name': 'RAD51C oncogenic variants', 'genes': [{'id': 45, 'name': 'RAD51C', 'primaryCoding': {'id': 'hgnc:9820', 'code': 'HGNC:9820', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9820']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_058216.3', 'code': 'NM_058216.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_058216.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000108384', 'code': 'ENSG00000108384', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000108384']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5889', 'code': '5889', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5889']}}], 'extensions': [{'name': 'location', 'value': '17q22'}, {'name': 'location_sortable', 'value': '17q22'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
333,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,287,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 138, 'name': 'RAD51D pathogenic variants', 'genes': [{'id': 46, 'name': 'RAD51D', 'primaryCoding': {'id': 'hgnc:9823', 'code': 'HGNC:9823', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9823']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000185379', 'code': 'ENSG00000185379', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000185379']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5892', 'code': '5892', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5892']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002878.4', 'code': 'NM_002878.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002878.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
334,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,288,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 139, 'name': 'RAD51D oncogenic variants', 'genes': [{'id': 46, 'name': 'RAD51D', 'primaryCoding': {'id': 'hgnc:9823', 'code': 'HGNC:9823', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9823']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000185379', 'code': 'ENSG00000185379', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000185379']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5892', 'code': '5892', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5892']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002878.4', 'code': 'NM_002878.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002878.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
335,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,289,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 140, 'name': 'RAD54L pathogenic variants', 'genes': [{'id': 47, 'name': 'RAD54L', 'primaryCoding': {'id': 'hgnc:9826', 'code': 'HGNC:9826', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9826']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_003579.4', 'code': 'NM_003579.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_003579.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000085999', 'code': 'ENSG00000085999', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000085999']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:8438', 'code': '8438', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/8438']}}], 'extensions': [{'name': 'location', 'value': '1p34.1'}, {'name': 'location_sortable', 'value': '01p34.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '1'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
336,Statement,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:6,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2020-05-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib),,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,290,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 141, 'name': 'RAD54L oncogenic variants', 'genes': [{'id': 47, 'name': 'RAD54L', 'primaryCoding': {'id': 'hgnc:9826', 'code': 'HGNC:9826', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9826']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_003579.4', 'code': 'NM_003579.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_003579.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000085999', 'code': 'ENSG00000085999', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000085999']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:8438', 'code': '8438', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/8438']}}], 'extensions': [{'name': 'location', 'value': '1p34.1'}, {'name': 'location_sortable', 'value': '01p34.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '1'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,,,Drug,Olaparib,ncit:C71721,C71721,Olaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
337,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,291,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
338,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,292,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
339,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,293,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
340,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,294,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],45,AND,"[{'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
341,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,295,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
342,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,296,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
343,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,297,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
344,Statement,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lynparza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lynparza (olaparib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Lynparza', 'drug_name_generic': 'olaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558', 'application_number': 208558, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lynparza:7,Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,2023-05-31,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf,The U.S. Food and Drug Administration granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib's product label states to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,deleterious or suspected deleterious BRCA-mutated,metastatic castration-resistant prostate cancer,Lynparza (olaparib) in combination with abiraterone and prednisolone or prednisone,,,,,,,,doc:fda.lynparza,Document,Regulatory approval,Lynparza (olaparib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf. Revised November 2023. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Lynparza,olaparib,,2024-10-30,2023-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558,208558.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,298,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],46,AND,"[{'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 7, 'conceptType': 'Drug', 'name': 'Abiraterone acetate', 'primaryCoding': {'id': 'ncit:C68845', 'code': 'C68845', 'name': 'Abiraterone Acetate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68845']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 46, 'conceptType': 'Drug', 'name': 'Olaparib', 'primaryCoding': {'id': 'ncit:C71721', 'code': 'C71721', 'name': 'Olaparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
345,Statement,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rezlidhia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rezlidhia (olutasidenib) [package insert]. FDA.', 'citation': 'Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Metrics Contract Services.', 'drug_name_brand': 'Rezlidhia', 'drug_name_generic': 'olutasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814', 'application_number': 215814, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rezlidhia:0,REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory acute myeloid leukemia (AML),Rezlidhia (olutasidenib),,,,,,,,doc:fda.rezlidhia,Document,Regulatory approval,Rezlidhia (olutasidenib) [package insert]. FDA.,"Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.",Metrics Contract Services.,Rezlidhia,olutasidenib,,2024-10-30,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814,215814.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,299,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],131,,,Drug,Olutasidenib,ncit:C129687,C129687,Olutasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C129687'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
346,Statement,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rezlidhia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rezlidhia (olutasidenib) [package insert]. FDA.', 'citation': 'Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Metrics Contract Services.', 'drug_name_brand': 'Rezlidhia', 'drug_name_generic': 'olutasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814', 'application_number': 215814, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rezlidhia:0,REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory acute myeloid leukemia (AML),Rezlidhia (olutasidenib),,,,,,,,doc:fda.rezlidhia,Document,Regulatory approval,Rezlidhia (olutasidenib) [package insert]. FDA.,"Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.",Metrics Contract Services.,Rezlidhia,olutasidenib,,2024-10-30,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814,215814.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,300,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],131,,,Drug,Olutasidenib,ncit:C129687,C129687,Olutasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C129687'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
347,Statement,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rezlidhia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rezlidhia (olutasidenib) [package insert]. FDA.', 'citation': 'Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Metrics Contract Services.', 'drug_name_brand': 'Rezlidhia', 'drug_name_generic': 'olutasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814', 'application_number': 215814, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rezlidhia:0,REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory acute myeloid leukemia (AML),Rezlidhia (olutasidenib),,,,,,,,doc:fda.rezlidhia,Document,Regulatory approval,Rezlidhia (olutasidenib) [package insert]. FDA.,"Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.",Metrics Contract Services.,Rezlidhia,olutasidenib,,2024-10-30,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814,215814.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,301,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],131,,,Drug,Olutasidenib,ncit:C129687,C129687,Olutasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C129687'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
348,Statement,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rezlidhia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rezlidhia (olutasidenib) [package insert]. FDA.', 'citation': 'Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Metrics Contract Services.', 'drug_name_brand': 'Rezlidhia', 'drug_name_generic': 'olutasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814', 'application_number': 215814, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rezlidhia:0,REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory acute myeloid leukemia (AML),Rezlidhia (olutasidenib),,,,,,,,doc:fda.rezlidhia,Document,Regulatory approval,Rezlidhia (olutasidenib) [package insert]. FDA.,"Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.",Metrics Contract Services.,Rezlidhia,olutasidenib,,2024-10-30,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814,215814.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,302,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],131,,,Drug,Olutasidenib,ncit:C129687,C129687,Olutasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C129687'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
349,Statement,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rezlidhia', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rezlidhia (olutasidenib) [package insert]. FDA.', 'citation': 'Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Metrics Contract Services.', 'drug_name_brand': 'Rezlidhia', 'drug_name_generic': 'olutasidenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814', 'application_number': 215814, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rezlidhia:0,REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to olutasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test.",susceptible IDH1 mutation,relapsed or refractory acute myeloid leukemia (AML),Rezlidhia (olutasidenib),,,,,,,,doc:fda.rezlidhia,Document,Regulatory approval,Rezlidhia (olutasidenib) [package insert]. FDA.,"Metrics Contract Services. Rezlidhia (olutasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf. Revised December 2022. Accessed October 30, 2024.",Metrics Contract Services.,Rezlidhia,olutasidenib,,2024-10-30,2022-12-01,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215814,215814.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,303,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],131,,,Drug,Olutasidenib,ncit:C129687,C129687,Olutasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C129687'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
350,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:0,"TAGRISSO is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2020-12-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R mutations,non-small cell lung cancer,Tagrisso (osimertinib),,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,304,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
351,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:0,"TAGRISSO is a kinase inhibitor indicated for adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2020-12-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R mutations,non-small cell lung cancer,Tagrisso (osimertinib),,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,305,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
352,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:1,"TAGRISSO is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2018-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R mutations,metastatic non-small cell lung cancer,Tagrisso (osimertinib),,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,305,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
353,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:1,"TAGRISSO is a kinase inhibitor indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2018-04-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R mutations,metastatic non-small cell lung cancer,Tagrisso (osimertinib),,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,304,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
354,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:2,"TAGRISSO is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2024-02-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",EGFR exon 19 deletions or exon 21 L858R mutations,locally advanced or metastatic non-small cell lung cancer,Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy,,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,306,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],47,AND,"[{'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
355,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:2,"TAGRISSO is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2024-02-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",EGFR exon 19 deletions or exon 21 L858R mutations,locally advanced or metastatic non-small cell lung cancer,Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy,,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,307,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
356,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:2,"TAGRISSO is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2024-02-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",EGFR exon 19 deletions or exon 21 L858R mutations,locally advanced or metastatic non-small cell lung cancer,Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy,,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,308,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
357,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:2,"TAGRISSO is a kinase inhibitor indicated in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2024-02-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This indication is based on FLAURA2 (NCT04035486), a randomized, multicenter, and open-label trial where patients were randomized to receive either osimertinib or osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin.",EGFR exon 19 deletions or exon 21 L858R mutations,locally advanced or metastatic non-small cell lung cancer,Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy,,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,309,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],47,AND,"[{'id': 86, 'conceptType': 'Drug', 'name': 'Osimertinib', 'primaryCoding': {'id': 'ncit:C116377', 'code': 'C116377', 'name': 'Osimertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
358,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:3,"TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.",2017-03-30,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy.",EGFR T790M,metastatic non-small cell lung cancer,Tagrisso (osimertinib),,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,310,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 70, 'name': 'EGFR p.T790M', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55249071}, {'name': 'end_position', 'value': 55249071}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.2369C>T'}, {'name': 'protein_change', 'value': 'p.T790M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '20'}, {'name': 'rsid', 'value': 'rs121434569'}, {'name': 'hgvsg', 'value': '7:g.55249071C>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
359,Statement,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103', 'application_number': 207103, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibrance:0,"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2019-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207103s015lbl.pdf,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.","HR+, HER2-negative",advanced or metastatic breast cancer,Ibrance (palbociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [package insert]. FDA.,"Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Ibrance,palbociclib,,2024-10-30,2023-09-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,207103.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,311,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],49,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
360,Statement,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103', 'application_number': 207103, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibrance:0,"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2019-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207103s015lbl.pdf,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.","HR+, HER2-negative",advanced or metastatic breast cancer,Ibrance (palbociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [package insert]. FDA.,"Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Ibrance,palbociclib,,2024-10-30,2023-09-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,207103.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,312,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],49,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
361,Statement,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103', 'application_number': 207103, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibrance:0,"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2019-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207103s015lbl.pdf,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with an aromatase inhibitor as an initial endocrine-based therapy for treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on PALOMA-2 (NCT01740427), an international, randomized, double-blind, parallel-group, multicenter study of palbociclib plus letrozole versus placebo plus letrozole.","HR+, HER2-negative",advanced or metastatic breast cancer,Ibrance (palbociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [package insert]. FDA.,"Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Ibrance,palbociclib,,2024-10-30,2023-09-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,207103.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,313,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],49,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
362,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103', 'application_number': 207103, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibrance:1,"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy.",2016-02-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207103s002lbl.pdf,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Ibrance (palbociclib) in combination with fulvestrant,,,,,,,,doc:fda.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [package insert]. FDA.,"Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Ibrance,palbociclib,,2024-10-30,2023-09-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,207103.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,143,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
363,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103', 'application_number': 207103, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibrance:1,"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy.",2016-02-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207103s002lbl.pdf,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Ibrance (palbociclib) in combination with fulvestrant,,,,,,,,doc:fda.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [package insert]. FDA.,"Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Ibrance,palbociclib,,2024-10-30,2023-09-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,207103.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,144,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
364,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with either palbociclib or abemaciclib for the treatment of patients who are women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with disease after endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ibrance', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibrance (palbociclib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Ibrance', 'drug_name_generic': 'palbociclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-09-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103', 'application_number': 207103, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibrance:1,"IBRANCE is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy.",2016-02-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207103s002lbl.pdf,"The U.S. Food and Drug Administration granted approval to palbociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.","HR+, HER2-negative",advanced or metastatic breast cancer,Ibrance (palbociclib) in combination with fulvestrant,,,,,,,,doc:fda.ibrance,Document,Regulatory approval,Ibrance (palbociclib) [package insert]. FDA.,"Pfizer, Inc. Ibrance (palbociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf. Revised September 2023. Accessed October 30, 2024.","Pfizer, Inc.",Ibrance,palbociclib,,2024-10-30,2023-09-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207103s017s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207103,207103.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,145,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],28,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
365,Statement,"The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.vectibix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vectibix (panitumumab) [package insert]. FDA.', 'citation': 'Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.', 'company': 'Amgen, Inc.', 'drug_name_brand': 'Vectibix', 'drug_name_generic': 'panitumumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-08-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147', 'application_number': 125147, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vectibix:0,Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) in combination with FOLFOX for first-line treatment. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf,"The U.S. Food and Drug Administration granted approval to panitumumab in combination with FOLFOX for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS, as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC). The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use),metastatic colorectal cancer,Vectibix (panitumumab) in combination with folfox,,,,,,,,doc:fda.vectibix,Document,Regulatory approval,Vectibix (panitumumab) [package insert]. FDA.,"Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.","Amgen, Inc.",Vectibix,panitumumab,,2024-10-30,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147,125147.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,314,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 26, 'name': 'Wild type HRAS', 'genes': [{'id': 27, 'name': 'HRAS', 'primaryCoding': {'id': 'hgnc:5173', 'code': 'HGNC:5173', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005343.4', 'code': 'NM_005343.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005343.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000174775', 'code': 'ENSG00000174775', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000174775']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3265', 'code': '3265', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3265']}}], 'extensions': [{'name': 'location', 'value': '11p15.5'}, {'name': 'location_sortable', 'value': '11p15.5'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],50,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 97, 'conceptType': 'Drug', 'name': 'Panitumumab', 'primaryCoding': {'id': 'ncit:C1857', 'code': 'C1857', 'name': 'Panitumumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
366,Statement,"The U.S. Food and Drug Administration granted approval to panitumumab for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.vectibix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vectibix (panitumumab) [package insert]. FDA.', 'citation': 'Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.', 'company': 'Amgen, Inc.', 'drug_name_brand': 'Vectibix', 'drug_name_generic': 'panitumumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-08-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147', 'application_number': 125147, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vectibix:1,"Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. Limitation of Use: Vectibix is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf,"The U.S. Food and Drug Administration granted approval to panitumumab for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC)following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. The product label specifies a limitation of use that panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.",wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use),metastatic colorectal cancer,Vectibix (panitumumab),,,,,,,,doc:fda.vectibix,Document,Regulatory approval,Vectibix (panitumumab) [package insert]. FDA.,"Amgen, Inc. Vectibix (panitumumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf. Revised April 2021. Accessed October 30, 2024.","Amgen, Inc.",Vectibix,panitumumab,,2024-10-30,2021-08-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125147,125147.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,315,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 26, 'name': 'Wild type HRAS', 'genes': [{'id': 27, 'name': 'HRAS', 'primaryCoding': {'id': 'hgnc:5173', 'code': 'HGNC:5173', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5173']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005343.4', 'code': 'NM_005343.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005343.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000174775', 'code': 'ENSG00000174775', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000174775']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3265', 'code': '3265', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3265']}}], 'extensions': [{'name': 'location', 'value': '11p15.5'}, {'name': 'location_sortable', 'value': '11p15.5'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 25, 'name': 'Wild type KRAS', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],97,,,Drug,Panitumumab,ncit:C1857,C1857,Panitumumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1857'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
367,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:0,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.",2018-08-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.",no EGFR or ALK genomic tumor aberrations,metastatic non-squamous non-small cell lung cancer,Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,316,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],51,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
368,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:0,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.",2018-08-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125514s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.",no EGFR or ALK genomic tumor aberrations,metastatic non-squamous non-small cell lung cancer,Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,317,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],52,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
369,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:1,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) >=1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.",2019-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s047lbl.pdf,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.","no EGFR or ALK genomic tumor aberrations, and PD-L1 [Tumor Proportion Score (TPS) >= 1%",non-small cell lung cancer,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,318,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
370,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. The product label further states that patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:2,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS >=1%) as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with disease progression on or after platinum containing chemotherapy. The product label further states that patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.",PD-L1 [Tumor Proportion Score (TPS) >= 1%,metastatic non-small cell lung cancer,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,319,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 33, 'name': 'PD-L1 >= 1%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Tumor Proportion Score (TPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.01'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
371,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:3,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) >=1] as determined by an FDA-approved test.",PD-L1 [Combined Positive Score (CPS)] >= 1%,"metastatic or unresectable, recurrent HNSCC",Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,320,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",25,Disease,Head and Neck Squamous Cell Carcinoma,oncotree:HNSC,HNSC,Head and Neck Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HNSC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
372,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:4,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",MSI-H or dMMR,unresectable or metastatic ... solid tumors,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,321,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
373,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:4,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.",MSI-H or dMMR,unresectable or metastatic ... solid tumors,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,322,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
374,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:5,KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.",MSI-H or dMMR,unresectable or metastatic ... colorectal cancer,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,323,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
375,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:5,KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), as determined by an FDA-approved test.",MSI-H or dMMR,unresectable or metastatic ... colorectal cancer,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,324,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
376,Statement,"The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:6,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.",HER2-positive... whose tumors express PD-L1 (CPS >= 1),locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,"Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy",,,,,,2025-03-19,2023-11-16,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,325,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],53,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
377,Statement,"The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. The product label notes that this indication is approved under accelerated approval based on tumor response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:6,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-811 (NCT03615326), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of chemotherapy between either cisplatin and 5-fu, or oxaliplatin and capecitabine.",HER2-positive... whose tumors express PD-L1 (CPS >= 1),locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocracinoma,"Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy",,,,,,2025-03-19,2023-11-16,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,326,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],54,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
378,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:7,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.",HER2-negative,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,Keytruda (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,327,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],55,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
379,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:7,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This indication is based on KEYNOTE-859 (NCT03675737), a multicenter, randomized, double-blind, placebo-controlled trial where patients received investigator's choice of combination chemotherapy of either cisplatin and 5-fu or oxaliplatin and capecitabine.",HER2-negative,locally advanced unresectable or metastatic ... gastric or gastroesophageal junction (GEJ) adenocarcinoma,Keytruda (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,328,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],56,AND,"[{'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
380,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:8,KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10) as determined by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.",PD-L1 (CPS >= 10),locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,329,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 41, 'name': 'PD-L1 (CPS) >= 10', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '10'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
381,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:8,KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10) as determined by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS >=10), as determined by an FDA-approved test.",PD-L1 (CPS >= 10),locally advanced or metastatic esophageal or gastroesophageal junction carcinoma,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,330,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 41, 'name': 'PD-L1 (CPS) >= 10', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '10'}]}]",74,Disease,Esophageal Adenocarcinoma,oncotree:ESCA,ESCA,Esophageal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ESCA'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
382,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,331,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],57,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
383,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,332,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],57,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
384,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,333,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],58,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
385,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,334,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],58,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
386,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,335,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],59,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
387,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,336,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],59,AND,"[{'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
388,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,337,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],60,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
389,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:9,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy with or without bevacizumab for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test. This indication is based on KEYNOTE-826 (NCT03635567), a multicenter, randomized, double-blind, placebo-controlled trial where patients received one of the following as the chemotherapy portion of their treatment regimen: cisplatin and paclitaxel; bevacizumab, cisplatin, and paclitaxel; carboplatin and paclitaxel; bevacizumab, carboplatin, and paclitaxel.",PD-L1 (CPS >= 1),"persistent, recurrent, or metastatic cervical cancer",Keytruda (pembrolizumab) in combination with chemotherapy and with or without bevacizumab,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,338,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],60,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 11, 'conceptType': 'Drug', 'name': 'Bevacizumab', 'primaryCoding': {'id': 'ncit:C2039', 'code': 'C2039', 'name': 'Bevacizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2039']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
390,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:10,KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.",PD-L1 (CPS >= 1),recurrent or metastatic cervical cancer,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,339,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",72,Disease,Cervical Adenocarcinoma,oncotree:CEAD,CEAD,Cervical Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CEAD'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
391,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:10,KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1) as determined by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.",PD-L1 (CPS >= 1),recurrent or metastatic cervical cancer,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,340,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 42, 'name': 'PD-L1 (CPS) >= 1', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '1'}]}]",73,Disease,Cervical Squamous Cell Carcinoma,oncotree:CESC,CESC,Cervical Squamous Cell Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CESC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
392,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:11,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDA-approved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",pMMR or not MSI-H,advanced endometrial carcinoma,Keytruda (pembrolizumab) in combination with lenvatinib,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,341,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 142, 'name': 'MSI-L', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-low (MSI-L)'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],61,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 132, 'conceptType': 'Drug', 'name': 'Lenvatinib', 'primaryCoding': {'id': 'ncit:C95124', 'code': 'C95124', 'name': 'Lenvatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95124']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
393,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:12,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",MSI-H or dMMR,advanced endometrial carcinoma,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,342,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 37, 'name': 'pMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Proficient'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
394,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:12,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with advanced endometrial carcinoma that is mismatch repair deficient (MMRd) or microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",MSI-H or dMMR,advanced endometrial carcinoma,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,343,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",18,Disease,Endometrial Carcinoma,oncotree:UCEC,UCEC,Endometrial Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=UCEC'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
395,Statement,"The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The product label states that the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established and that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, it states that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:13,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",,,"The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. The product label states that the safety and effectiveness of pembrolizumab in pediatric patients with TMB-H central nervous system cancers have not been established and that this indication is approved under accelerated approval based on tumor response rate and durability of response. Furthermore, it states that continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",TMB-H [>= 10 mutations / megabase],unresectable or metastatic ... solid tumors,Keytruda (pembrolizumab),,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,344,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 144, 'name': 'TMB-H (>= 10 mutations / Mb)', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Tumor mutational burden'}, {'name': 'present', 'value': True}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],48,,,Drug,Pembrolizumab,ncit:C106432,C106432,Pembrolizumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
396,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then pembrolizumab continued as a single agent as adjuvant treatment after surgery, of patients with high-risk early-stage triple negative breast cancer (TNBC). This indication is based on KEYNOTE-522 (NCT03036488), a randomized (2:1), multicenter, double-blind, placebo-controlled trial where the chemotherapy regimen consisted of carboplatin, paclitaxel, doxorubicin, and cyclophosphamide.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:14,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then pembrolizumab continued as a single agent as adjuvant treatment after surgery, of patients with high-risk early-stage triple negative breast cancer (TNBC). This indication is based on KEYNOTE-522 (NCT03036488), a randomized (2:1), multicenter, double-blind, placebo-controlled trial where the chemotherapy regimen consisted of carboplatin, paclitaxel, doxorubicin, and cyclophosphamide.",triple-negative,high-risk early-stage triple-negative breast cancer,Keytruda (pembrolizumab) in combination with chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,345,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 44, 'name': 'PR negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 43, 'name': 'ER negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],62,AND,"[{'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
397,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:15,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS >=10) as determined by an FDA approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.","triple-negative, PD-L1 (CPS >= 10)",locally recurrent unresectable or metastatic triple-negative breast cancer,Keytruda (pembrolizumab) in combination with chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,346,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 44, 'name': 'PR negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 41, 'name': 'PD-L1 (CPS) >= 10', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '10'}]}, {'id': 43, 'name': 'ER negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],63,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
398,Statement,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.keytruda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Keytruda (pembrolizumab) [package insert]. FDA.', 'citation': 'Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Merck Sharp & Dohme Corp.', 'drug_name_brand': 'Keytruda', 'drug_name_generic': 'pembrolizumab', 'first_published': '2014-09-04', 'access_date': '2025-04-30', 'publication_date': '2025-04-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514', 'application_number': 125514, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.keytruda:15,"KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS >=10) as determined by an FDA approved test.",,,"The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (CPS >= 10), as determined by an FDA approved test. This indication is based on KEYNOTE-355 (NCT02819518), a multicenter, double-blind, randomized, placebo-controlled trial where patients received either paclitaxel and paclitaxel protein-bound, or gemcitabine and carboplatin.","triple-negative, PD-L1 (CPS >= 10)",locally recurrent unresectable or metastatic triple-negative breast cancer,Keytruda (pembrolizumab) in combination with chemotherapy,,,,,,,,doc:fda.keytruda,Document,Regulatory approval,Keytruda (pembrolizumab) [package insert]. FDA.,"Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Merck Sharp & Dohme Corp.,Keytruda,pembrolizumab,2014-09-04,2025-04-30,2025-04-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125514s174lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125514,125514.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,347,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 44, 'name': 'PR negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 41, 'name': 'PD-L1 (CPS) >= 10', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'PD-L1'}, {'name': 'unit', 'value': 'Combined Positive Score (CPS)'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '10'}]}, {'id': 43, 'name': 'ER negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],64,AND,"[{'id': 48, 'conceptType': 'Drug', 'name': 'Pembrolizumab', 'primaryCoding': {'id': 'ncit:C106432', 'code': 'C106432', 'name': 'Pembrolizumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106432']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
399,Statement,"The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [package insert]. FDA.', 'citation': 'Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Incyte Corporation.', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-04-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736', 'application_number': 213736, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.pemazyre:0,"PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2020-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",FGFR2 fusion or other rearrangement,unresectable locally advanced or metastatic cholangiocarcinoma,Pemazyre (pemigatinib),,,,,,,,doc:fda.pemazyre,Document,Regulatory approval,Pemazyre (pemigatinib) [package insert]. FDA.,"Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Incyte Corporation.,Pemazyre,pemigatinib,,2024-10-30,2020-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736,213736.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,348,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 52, 'name': 'FGFR2::v', 'genes': [{'id': 23, 'name': 'FGFR2', 'primaryCoding': {'id': 'hgnc:3689', 'code': 'HGNC:3689', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000141.5', 'code': 'NM_000141.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000066468', 'code': 'ENSG00000066468', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000066468']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2263', 'code': '2263', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2263']}}], 'extensions': [{'name': 'location', 'value': '10q26.13'}, {'name': 'location_sortable', 'value': '10q26.13'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],133,,,Drug,Pemigatinib,ncit:C121553,C121553,Pemigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121553'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
400,Statement,"The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [package insert]. FDA.', 'citation': 'Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Incyte Corporation.', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-04-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736', 'application_number': 213736, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.pemazyre:0,"PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2020-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",FGFR2 fusion or other rearrangement,unresectable locally advanced or metastatic cholangiocarcinoma,Pemazyre (pemigatinib),,,,,,,,doc:fda.pemazyre,Document,Regulatory approval,Pemazyre (pemigatinib) [package insert]. FDA.,"Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Incyte Corporation.,Pemazyre,pemigatinib,,2024-10-30,2020-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736,213736.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,349,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 53, 'name': 'FGFR2 rearrangements', 'genes': [{'id': 23, 'name': 'FGFR2', 'primaryCoding': {'id': 'hgnc:3689', 'code': 'HGNC:3689', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3689']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000141.5', 'code': 'NM_000141.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000141.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000066468', 'code': 'ENSG00000066468', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000066468']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2263', 'code': '2263', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2263']}}], 'extensions': [{'name': 'location', 'value': '10q26.13'}, {'name': 'location_sortable', 'value': '10q26.13'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],133,,,Drug,Pemigatinib,ncit:C121553,C121553,Pemigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121553'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
401,Statement,The U.S. Food and Drug Administration granted approval to pemigatinib for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.pemazyre', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Pemazyre (pemigatinib) [package insert]. FDA.', 'citation': 'Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.', 'company': 'Incyte Corporation.', 'drug_name_brand': 'Pemazyre', 'drug_name_generic': 'pemigatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-04-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736', 'application_number': 213736, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.pemazyre:1,PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.,2022-08-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf,The U.S. Food and Drug Administration granted approval to pemigatinib for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.,FGFR1 rearrangement,relapsed or refractory myeloid/lymphoid neoplasms (MLNs),Pemazyre (pemigatinib),,,,,,,,doc:fda.pemazyre,Document,Regulatory approval,Pemazyre (pemigatinib) [package insert]. FDA.,"Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed October 30, 2024.",Incyte Corporation.,Pemazyre,pemigatinib,,2024-10-30,2020-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213736,213736.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,350,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 69, 'name': 'FGFR1 rearrangements', 'genes': [{'id': 22, 'name': 'FGFR1', 'primaryCoding': {'id': 'hgnc:3688', 'code': 'HGNC:3688', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3688']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000077782', 'code': 'ENSG00000077782', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000077782']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2260', 'code': '2260', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2260']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_023110.3', 'code': 'NM_023110.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_023110.3']}}], 'extensions': [{'name': 'location', 'value': '8p11.23'}, {'name': 'location_sortable', 'value': '08p11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",44,Disease,Myeloid/Lymphoid Neoplasms,oncotree:MLN,MLN,Myeloid/Lymphoid Neoplasms,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MLN'],[],133,,,Drug,Pemigatinib,ncit:C121553,C121553,Pemigatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C121553'],[],"[{'name': 'therapy_strategy', 'value': ['FGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
402,Statement,The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:0,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,2012-06-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf,The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,HER2-positive,metastatic breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and docetaxel,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
403,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:1,"PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.",2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,352,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],66,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
404,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:1,"PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.",2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,353,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],67,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
405,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:2,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with docetaxel for treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with docetaxel for the treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,HER2-positive,metastatic breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with docetaxel,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,351,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],65,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
406,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,354,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],68,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
407,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,355,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],69,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
408,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,356,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
409,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,357,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],71,AND,"[{'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
410,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,358,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],72,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
411,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,359,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],73,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
412,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,353,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],67,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
413,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,360,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],74,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
414,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:0,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,352,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],66,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
415,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:0,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,"locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive)",Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,353,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],67,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
416,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,360,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],74,AND,"[{'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
417,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,354,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],68,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
418,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,355,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],69,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
419,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,356,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],70,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
420,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,357,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],71,AND,"[{'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
421,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,358,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],72,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
422,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,359,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],73,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
423,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the neoadjuvant treatment patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. This indication is based on Berenice (NCT02132949), a two-arm randomized study where HER2-positive was defined as a score of 3+ IHC or ISH amplification ratio of 2.0 or greater, as determined by a central laboratory. Patients received two potential chemotherapy regimens as part of the combination therapy: cyclophosphamide, doxorubicin, and paclitaxel; or cyclophosphamide, docetaxel, epirubicin, and 5-fu.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.phesgo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Phesgo', 'drug_name_generic': 'pertuzumab and trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-06-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170', 'application_number': 761170, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.phesgo:1,"PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for use in combination with chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.",2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel. The FeDeriCa study (NCT03493854) demonstrated comparable pharmacokinetics and safety profiles between Phesgo and intravenous pertuzumab and intravenous trastuzumab.",HER2-positive,early breast cancer,Phesgo (pertuzumab and trastuzumab) in combination with chemotherapy,,,,,,,,doc:fda.phesgo,Document,Regulatory approval,Phesgo (pertuzumab and trastuzumab) [package insert]. FDA.,"Genentech, Inc. Phesgo (pertuzumab and trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed October 30, 2024.","Genentech, Inc.",Phesgo,pertuzumab and trastuzumab,,2024-10-30,2020-06-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761170,761170.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,352,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],66,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
424,Statement,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,352,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],66,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
425,Statement,The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.perjeta', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Perjeta (pertuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Perjeta', 'drug_name_generic': 'pertuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-01-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409', 'application_number': 125409, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.perjeta:2,PERJETA is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.,2017-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125409s113s118lbl.pdf,"The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence. This indication is based on Aphinity (NCT01358877) a multicenter, randomized, double-blind, placebo-controlled study where patients received one of the following anthracycline-based or non-anthracycline-based chemotherapy regimens: (1) cyclophosphamide, epirubicin, docetaxel, 5-fu; (2) cyclophosphamide, epirubicin, paclitaxel, 5-fu; (3) cyclophosphamide, doxorubicin, docetaxel, 5-fu; (4) cyclophosphamide, doxorubicin, paclitaxel, 5-fu; (5) doxorubicin, cyclophosphamide, docetaxel; (6) epirubicin, cyclophosphamide, docetaxel; (7) doxorubicin, cyclophosphamide, paclitaxel; (8) epirubicin, cyclophosphamide, paclitaxel; (9) carboplatin, docetaxel.",HER2-positive,early stage breast cancer,Perjeta (pertuzumab) in combination with trastuzumab and chemotherapy,,,,,,,,doc:fda.perjeta,Document,Regulatory approval,Perjeta (pertuzumab) [package insert]. FDA.,"Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed October 30, 2024.","Genentech, Inc.",Perjeta,pertuzumab,,2024-10-30,2020-01-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125409,125409.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,353,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],67,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 76, 'conceptType': 'Drug', 'name': 'Epirubicin', 'primaryCoding': {'id': 'ncit:C62028', 'code': 'C62028', 'name': 'Epirubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62028']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 75, 'conceptType': 'Drug', 'name': 'Pertuzumab', 'primaryCoding': {'id': 'ncit:C38692', 'code': 'C38692', 'name': 'Pertuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C38692']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 24, 'conceptType': 'Drug', 'name': 'Docetaxel', 'primaryCoding': {'id': 'ncit:C1526', 'code': 'C1526', 'name': 'Docetaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1526']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
426,Statement,"The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [package insert]. FDA.', 'citation': 'Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Takeda Pharmaceuticals America, Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2012-12-14', 'access_date': '2024-10-30', 'publication_date': '2024-03-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469', 'application_number': 203469, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.iclusig:0,"ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",2024-03-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The product label notes that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). This indication is based on PhALLCON (NCT03589326), a randomized, active-controlled, multicenter, open-label trial in which chemotherapy regimens were: vincristine and dexamethasone (induction, cycles 1 to 3); methotrexate and cytarabine (consolidation, cycles 4 to 9, alternating methotrexate and cytarabine); and vincristine and prednisone (maintenance, cycles 10 to 20).",Ph+,Ph+ ALL,Iclusig (ponatinib) in combination with chemotherapy,,,,,,,,doc:fda.iclusig,Document,Regulatory approval,Iclusig (ponatinib) [package insert]. FDA.,"Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.","Takeda Pharmaceuticals America, Inc.",Iclusig,ponatinib,2012-12-14,2024-10-30,2024-03-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,203469.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,361,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],75,AND,"[{'id': 43, 'conceptType': 'Drug', 'name': 'Ponatinib', 'primaryCoding': {'id': 'ncit:C95777', 'code': 'C95777', 'name': 'Ponatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 63, 'conceptType': 'Drug', 'name': 'Cytarabine', 'primaryCoding': {'id': 'ncit:C408', 'code': 'C408', 'name': 'Cytarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C408']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['DNA Polymerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 65, 'conceptType': 'Drug', 'name': 'Methotrexate', 'primaryCoding': {'id': 'ncit:C642', 'code': 'C642', 'name': 'Methotrexate', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C642']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
427,Statement,The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [package insert]. FDA.', 'citation': 'Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Takeda Pharmaceuticals America, Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2012-12-14', 'access_date': '2024-10-30', 'publication_date': '2024-03-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469', 'application_number': 203469, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.iclusig:1,ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with as monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.,2024-03-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf,The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.,Ph+ and T315I,Ph+ ALL,Iclusig (ponatinib),,,,,,,,doc:fda.iclusig,Document,Regulatory approval,Iclusig (ponatinib) [package insert]. FDA.,"Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.","Takeda Pharmaceuticals America, Inc.",Iclusig,ponatinib,2012-12-14,2024-10-30,2024-03-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,203469.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,362,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}, {'id': 32, 'name': 'ABL1 p.T315I', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '5'}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],43,,,Drug,Ponatinib,ncit:C95777,C95777,Ponatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
428,Statement,"The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase. The product label states the following limitations of use: ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.iclusig', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Iclusig (ponatinib) [package insert]. FDA.', 'citation': 'Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Takeda Pharmaceuticals America, Inc.', 'drug_name_brand': 'Iclusig', 'drug_name_generic': 'ponatinib', 'first_published': '2012-12-14', 'access_date': '2024-10-30', 'publication_date': '2024-03-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469', 'application_number': 203469, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.iclusig:2,"ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase). Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.",2016-11-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf,"The U.S. Food and Drug Administration granted approval to ponatinib for the treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or blast phase. The product label states the following limitations of use: ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.",T315I-positive,CML,Iclusig (ponatinib),,,,,,,,doc:fda.iclusig,Document,Regulatory approval,Iclusig (ponatinib) [package insert]. FDA.,"Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed October 30, 2024.","Takeda Pharmaceuticals America, Inc.",Iclusig,ponatinib,2012-12-14,2024-10-30,2024-03-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469,203469.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,363,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 32, 'name': 'ABL1 p.T315I', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'start_position', 'value': 133748283}, {'name': 'end_position', 'value': 133748283}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.944C>T'}, {'name': 'protein_change', 'value': 'p.T315I'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '5'}, {'name': 'rsid', 'value': 'rs121913459'}, {'name': 'hgvsg', 'value': '9:g.133748283C>T'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],43,,,Drug,Ponatinib,ncit:C95777,C95777,Ponatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95777'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
429,Statement,"The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gavreto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gavreto (pralsetinib) [package insert]. FDA.', 'citation': 'Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Blueprint Medicines Corporation.', 'drug_name_brand': 'Gavreto', 'drug_name_generic': 'pralsetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721', 'application_number': 213721, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gavreto:0,GAVRETO is a kinase inhibitor indicated for treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC).,2023-08-09,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf,"The U.S. Food and Drug Administration granted approval to pralsetinib for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as detected by an FDA approved test (NSCLC).",RET fusion-positive,non-small cell lung cancer,Gavreto (pralsetinib),,,,,,,,doc:fda.gavreto,Document,Regulatory approval,Gavreto (pralsetinib) [package insert]. FDA.,"Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Blueprint Medicines Corporation.,Gavreto,pralsetinib,,2024-10-30,2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721,213721.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,364,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],32,,,Drug,Pralsetinib,ncit:C132295,C132295,Pralsetinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132295'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
430,Statement,"The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). This indication is based on ARROW (NCT03037385), a multicenter, open-label, multi-cohort clinical trial where all enrolled patients had papillary thyroid cancer.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.gavreto', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Gavreto (pralsetinib) [package insert]. FDA.', 'citation': 'Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Blueprint Medicines Corporation.', 'drug_name_brand': 'Gavreto', 'drug_name_generic': 'pralsetinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721', 'application_number': 213721, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.gavreto:1,GAVRETO is a kinase inhibitor indicated for treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).,2021-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). This indication is based on ARROW (NCT03037385), a multicenter, open-label, multi-cohort clinical trial where all enrolled patients had papillary thyroid cancer.",RET fusion-positive,advanced or metastatic... thyroid cancer,Gavreto (pralsetinib),,,,,,,,doc:fda.gavreto,Document,Regulatory approval,Gavreto (pralsetinib) [package insert]. FDA.,"Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Blueprint Medicines Corporation.,Gavreto,pralsetinib,,2024-10-30,2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213721s015lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213721,213721.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,365,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",75,Disease,Papillary Thyroid Cancer,oncotree:THPA,THPA,Papillary Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THPA'],[],32,,,Drug,Pralsetinib,ncit:C132295,C132295,Pralsetinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132295'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
431,Statement,The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.cyramza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cyramza (ramucirumab) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Cyramza', 'drug_name_generic': 'ramucirumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477', 'application_number': 125477, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.cyramza:0,"CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.",2020-05-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf,The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.,EGFR exon 19 deletions or exon 21 (L858R),metastatic non-small cell lung cancer,Cyramza (ramucirumab) in combination with erlotinib,,,,,,,,doc:fda.cyramza,Document,Regulatory approval,Cyramza (ramucirumab) [package insert]. FDA.,"Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.",Eli and Lily Company.,Cyramza,ramucirumab,,2024-10-30,2022-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477,125477.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,366,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],76,AND,"[{'id': 23, 'conceptType': 'Drug', 'name': 'Ramucirumab', 'primaryCoding': {'id': 'ncit:C70792', 'code': 'C70792', 'name': 'Ramucirumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C70792']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF/VEGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 12, 'conceptType': 'Drug', 'name': 'Erlotinib', 'primaryCoding': {'id': 'ncit:C65530', 'code': 'C65530', 'name': 'Erlotinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
432,Statement,The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.cyramza', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Cyramza (ramucirumab) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Cyramza', 'drug_name_generic': 'ramucirumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477', 'application_number': 125477, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.cyramza:0,"CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.",2020-05-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125477s034lbl.pdf,The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.,EGFR exon 19 deletions or exon 21 (L858R),metastatic non-small cell lung cancer,Cyramza (ramucirumab) in combination with erlotinib,,,,,,,,doc:fda.cyramza,Document,Regulatory approval,Cyramza (ramucirumab) [package insert]. FDA.,"Eli and Lily Company. Cyramza (ramucirumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf. Revised March 2022. Accessed October 30, 2024.",Eli and Lily Company.,Cyramza,ramucirumab,,2024-10-30,2022-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125477,125477.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,367,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],76,AND,"[{'id': 23, 'conceptType': 'Drug', 'name': 'Ramucirumab', 'primaryCoding': {'id': 'ncit:C70792', 'code': 'C70792', 'name': 'Ramucirumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C70792']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['VEGF/VEGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 12, 'conceptType': 'Drug', 'name': 'Erlotinib', 'primaryCoding': {'id': 'ncit:C65530', 'code': 'C65530', 'name': 'Erlotinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C65530']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
433,Statement,The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb.', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-06-13', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213', 'application_number': 218213, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.augtyro:0,AUGTYRO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,2023-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf,The U.S. Food and Drug Administration granted approval to repotrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,ROS1-positive,locally advanced or metastatic non-small cell lung cancer,Augtyro (repotrectinib),,,,,,,,doc:fda.augtyro,Document,Regulatory approval,Augtyro (repotrectinib) [package insert]. FDA.,"Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.",Bristol-Myers Squibb.,Augtyro,repotrectinib,,2024-10-30,2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213,218213.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,368,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],134,,,Drug,Repotrectinib,ncit:C133821,C133821,Repotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C133821'],[],"[{'name': 'therapy_strategy', 'value': ['ROS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
434,Statement,"The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb.', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-06-13', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213', 'application_number': 218213, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.augtyro:1,"AUGTYRO is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",NTRK gene fusions,solid tumors,Augtyro (repotrectinib),,,,,,,2024-06-13,doc:fda.augtyro,Document,Regulatory approval,Augtyro (repotrectinib) [package insert]. FDA.,"Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.",Bristol-Myers Squibb.,Augtyro,repotrectinib,,2024-10-30,2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213,218213.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,369,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 63, 'name': 'v::NTRK1', 'genes': [{'id': 35, 'name': 'NTRK1', 'primaryCoding': {'id': 'hgnc:8031', 'code': 'HGNC:8031', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8031']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002529.4', 'code': 'NM_002529.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002529.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000198400', 'code': 'ENSG00000198400', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000198400']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4914', 'code': '4914', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4914']}}], 'extensions': [{'name': 'location', 'value': '1q23.1'}, {'name': 'location_sortable', 'value': '01q23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],134,,,Drug,Repotrectinib,ncit:C133821,C133821,Repotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C133821'],[],"[{'name': 'therapy_strategy', 'value': ['ROS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
435,Statement,"The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb.', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-06-13', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213', 'application_number': 218213, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.augtyro:1,"AUGTYRO is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",NTRK gene fusions,solid tumors,Augtyro (repotrectinib),,,,,,,2024-06-13,doc:fda.augtyro,Document,Regulatory approval,Augtyro (repotrectinib) [package insert]. FDA.,"Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.",Bristol-Myers Squibb.,Augtyro,repotrectinib,,2024-10-30,2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213,218213.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,370,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 64, 'name': 'v::NTRK2', 'genes': [{'id': 36, 'name': 'NTRK2', 'primaryCoding': {'id': 'hgnc:8032', 'code': 'HGNC:8032', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8032']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000148053', 'code': 'ENSG00000148053', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000148053']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4915', 'code': '4915', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4915']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006180.6', 'code': 'NM_006180.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006180.6']}}], 'extensions': [{'name': 'location', 'value': '9q21.33'}, {'name': 'location_sortable', 'value': '09q21.33'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],134,,,Drug,Repotrectinib,ncit:C133821,C133821,Repotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C133821'],[],"[{'name': 'therapy_strategy', 'value': ['ROS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
436,Statement,"The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.augtyro', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Augtyro (repotrectinib) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Bristol-Myers Squibb.', 'drug_name_brand': 'Augtyro', 'drug_name_generic': 'repotrectinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-06-13', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213', 'application_number': 218213, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.augtyro:1,"AUGTYRO is a kinase inhibitor indicated for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to repotrectinib for the treatment of adult and pedatric patients 12 years of age and older with solid tumors that (i) have a neutrophic tyrosine receptor kinase (NTRK) gene fusion and (ii) are locally advanced or metastatic or where surgical resection is likely to result in severe morbility, and (iii) have progressed following treatment or have no satisfactory alternative therapy. The product label notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",NTRK gene fusions,solid tumors,Augtyro (repotrectinib),,,,,,,2024-06-13,doc:fda.augtyro,Document,Regulatory approval,Augtyro (repotrectinib) [package insert]. FDA.,"Bristol-Myers Squibb. Augtyro (repotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf. Revised June 2024. Accessed October 30, 2024.",Bristol-Myers Squibb.,Augtyro,repotrectinib,,2024-10-30,2024-06-13,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218213s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218213,218213.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,371,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 65, 'name': 'v::NTRK3', 'genes': [{'id': 37, 'name': 'NTRK3', 'primaryCoding': {'id': 'hgnc:8033', 'code': 'HGNC:8033', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8033']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001012338.3', 'code': 'NM_001012338.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001012338.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000140538', 'code': 'ENSG00000140538', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000140538']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4916', 'code': '4916', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4916']}}], 'extensions': [{'name': 'location', 'value': '15q25.3'}, {'name': 'location_sortable', 'value': '15q25.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],134,,,Drug,Repotrectinib,ncit:C133821,C133821,Repotrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C133821'],[],"[{'name': 'therapy_strategy', 'value': ['ROS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
437,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:0,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,372,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],77,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
438,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:0,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,373,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],77,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
439,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:0,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,374,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],77,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
440,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:0,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,375,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],78,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
441,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:0,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,376,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],78,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
442,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:0,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This indication is based on MONALEESA-2 (NCT01958021) and MONALEESA-7 (NCT02278120), where either anastrozole or letrozole were chosen for aromatase inhibiton.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,377,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],78,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
443,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:1,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as either an initial endocrine-based therapy or following disease progression on endocrine therapy.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with fulvestrant,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,140,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
444,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:1,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as either an initial endocrine-based therapy or following disease progression on endocrine therapy.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with fulvestrant,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,141,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
445,Statement,"The U.S. Food and Drug Administration granted approval to fulvestrant in combination with ribociclib for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy or following disease progression on endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:1,"KISQALI is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.",2021-12-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209092s008lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as either an initial endocrine-based therapy or following disease progression on endocrine therapy.","HR-positive, HER2-negative",advanced or metastatic breast cancer,Kisqali (ribociclib) in combination with fulvestrant,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,142,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],27,AND,"[{'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
446,Statement,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:0,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B- cell NHL as a single agent.",2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).",CD20-positive,B-cell Non-Hodgkin's Lymphoma (NHL),Rituxan (rituximab),,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,378,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],60,,,Drug,Rituximab,ncit:C1702,C1702,Rituximab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702'],[],"[{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
447,Statement,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:1,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.",2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",CD20-positive,B-cell Non-Hodgkin's Lymphoma (NHL),Rituxan (rituximab) in combination with chemotherapy,,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,379,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],79,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
448,Statement,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:1,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.",2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",CD20-positive,B-cell Non-Hodgkin's Lymphoma (NHL),Rituxan (rituximab) in combination with chemotherapy,,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,380,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],80,AND,"[{'id': 8, 'conceptType': 'Drug', 'name': 'Prednisolone', 'primaryCoding': {'id': 'ncit:C769', 'code': 'C769', 'name': 'Prednisolone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C769']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
449,Statement,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:1,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.",2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell Non-Hodgkin's Lymphoma (NHL) in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. This indication is based on 3 randomized, controlled trials that enrolled 1,662 patients where patients received either CVP (cyclophosphamide, vincristine, and prednisolone), CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone), or FCM (cyclophosphamide, fludarabine, mitoxantrone).",CD20-positive,B-cell Non-Hodgkin's Lymphoma (NHL),Rituxan (rituximab) in combination with chemotherapy,,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,381,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],81,AND,"[{'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 135, 'conceptType': 'Drug', 'name': 'Fludarabine', 'primaryCoding': {'id': 'ncit:C1094', 'code': 'C1094', 'name': 'Fludarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1094']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 124, 'conceptType': 'Drug', 'name': 'Mitoxantrone', 'primaryCoding': {'id': 'ncit:C62050', 'code': 'C62050', 'name': 'Mitoxantrone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C62050']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
451,Statement,"The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:2,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL) non-progressing (including stable disease), low-grade, CD20 positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with non-progressing (including stable disease), low-grade, CD20 positive, B-cell Non-Hodgkin's Lymphoma (NHL) as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",CD20 positive,Non-Hodgkin's Lymphoma (NHL),Rituxan (rituximab),,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,382,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],82,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
452,Statement,"The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:3,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with Non-Hodgkin's Lymphoma (NHL) previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.",2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens for the treatment of adult patients with previously untreated diffuse large B-cell, CD20-positive Non-Hodgkin's Lymphoma (NHL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrolled of 1854 patients. The product label did not specify the name of the clinical trial name (Study 9) that administered an anthracycline-containing chemotherapy regimen, or what the specific regimen was.",CD20-positive,diffuse large B-cell Non-Hodgkin's Lymhpoma (NHL),"Rituxan (rituximab) in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.",,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,382,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",76,Disease,Non-Hodgkin Lymphoma,oncotree:NHL,NHL,Non-Hodgkin Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NHL'],[],82,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
453,Statement,"The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:4,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.",2021-12-02,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",CD20-positive,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",Rituxan (rituximab) in combination with chemotherapy,,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,383,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",77,Disease,Diffuse Large B-Cell Lymphoma,oncotree:DLBCLNOS,DLBCLNOS,Diffuse Large B-Cell Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=DLBCLNOS'],[],82,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
454,Statement,"The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:4,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.",2021-12-02,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",CD20-positive,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",Rituxan (rituximab) in combination with chemotherapy,,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,384,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",78,Disease,Burkitt Lymphoma,oncotree:BL,BL,Burkitt Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BL'],[],82,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
455,Statement,"The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:4,"RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.",2021-12-02,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5465lbl.pdf,"The U.S. Food and Drug Administration granted approval to rituximab in combination with chemotherapy for the treatment of pediatric patients aged 6 months and older with previously untreated, advanced state, CD20-positive: diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL). This indication is based on three randomized, active-controlled, open-label, multicenter studies with a collective enrollment of 1854 patients where patients received either CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or other anthracycline-based chemotherapy regimens.",CD20-positive,"mature B-cell NHL and mature B-cell acute leukemia (B-AL) previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)",Rituxan (rituximab) in combination with chemotherapy,,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,385,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",79,Disease,Mature B-Cell Neoplasms,oncotree:MBN,MBN,Mature B-Cell Neoplasms,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MBN'],[],82,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 2, 'conceptType': 'Drug', 'name': 'Doxorubicin', 'primaryCoding': {'id': 'ncit:C456', 'code': 'C456', 'name': 'Doxorubicin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C456']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 122, 'conceptType': 'Drug', 'name': 'Prednisone', 'primaryCoding': {'id': 'ncit:C770', 'code': 'C770', 'name': 'Prednisone', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C770']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Corticosteroid'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 61, 'conceptType': 'Drug', 'name': 'Vincristine', 'primaryCoding': {'id': 'ncit:C933', 'code': 'C933', 'name': 'Vincristine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C933']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Vinca alkaloid chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
456,Statement,The U.S. Food and Drug Administration granted approval to rituximab in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rituxan', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rituxan (rituximab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Rituxan', 'drug_name_generic': 'rituximab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2021-12-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705', 'application_number': 103705, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rituxan:5,RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).,2018-04-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103705s5453lbl.pdf,The U.S. Food and Drug Administration granted approval to rituximab in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).,CD20-positive,Chronic Lymphocytic Leuekmia (CLL),Rituxan (rituximab) in combination with fludarabine and cyclophosphamide (FC),,,,,,,,doc:fda.rituxan,Document,Regulatory approval,Rituxan (rituximab) [package insert]. FDA.,"Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.","Genentech, Inc.",Rituxan,rituximab,,2024-10-30,2021-12-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705,103705.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,386,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 54, 'name': 'CD20 +', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CD20'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",84,Disease,Chronic Lymphocytic Leukemia,ncit:C3163,C3163,Chronic Lymphocytic Leukemia,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C3163'],"[{'relation': 'broadMatch', 'coding': {'id': 'oncotree:CLLSLL', 'code': 'CLLSLL', 'name': 'Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma', 'system': 'https://oncotree.mskcc.org', 'systemVersion': 'oncotree_2021_11_02', 'iris': ['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CLLSLL']}}]",83,AND,"[{'id': 59, 'conceptType': 'Drug', 'name': 'Cyclophosphamide', 'primaryCoding': {'id': 'ncit:C405', 'code': 'C405', 'name': 'Cyclophosphamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C405']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Alkylating chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 135, 'conceptType': 'Drug', 'name': 'Fludarabine', 'primaryCoding': {'id': 'ncit:C1094', 'code': 'C1094', 'name': 'Fludarabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1094']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 60, 'conceptType': 'Drug', 'name': 'Rituximab', 'primaryCoding': {'id': 'ncit:C1702', 'code': 'C1702', 'name': 'Rituximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1702']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CD20 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
457,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,387,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
458,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,388,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
459,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,389,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
460,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,390,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
461,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,391,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
462,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,392,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
463,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,393,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
464,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,394,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
465,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,395,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
466,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,396,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
467,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,397,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
468,Statement,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:0,"RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",2018-04-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to rucaparib for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",deleterious BRCA mutation (germline and/or somatic),"epithelial ovarian, fallopian tube, or primary peritoneal cancer",Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,398,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
469,Statement,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:1,RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,2020-05-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",deleterious BRCA mutation (germline and/or somatic),metastatic castration-resistant prostate cancer,Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,399,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 47, 'name': 'BRCA1 oncogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
470,Statement,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:1,RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,2020-05-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",deleterious BRCA mutation (germline and/or somatic),metastatic castration-resistant prostate cancer,Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,400,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
471,Statement,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:1,RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,2020-05-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",deleterious BRCA mutation (germline and/or somatic),metastatic castration-resistant prostate cancer,Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,401,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
472,Statement,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rubraca', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rubraca (rucaparib) [package insert]. FDA.', 'citation': 'Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Clovis Oncology, Inc.', 'drug_name_brand': 'Rubraca', 'drug_name_generic': 'rucaparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-12-21', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115', 'application_number': 209115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rubraca:1,RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,2020-05-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib. Furthermore, it states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",deleterious BRCA mutation (germline and/or somatic),metastatic castration-resistant prostate cancer,Rubraca (rucaparib),,,,,,,,doc:fda.rubraca,Document,Regulatory approval,Rubraca (rucaparib) [package insert]. FDA.,"Clovis Oncology, Inc. Rubraca (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Clovis Oncology, Inc.",Rubraca,rucaparib,,2024-10-30,2022-12-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209115s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115,209115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,402,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],136,,,Drug,Rucaparib,ncit:C137800,C137800,Rucaparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C137800'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
473,Statement,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.trodelvy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trodelvy (sacituzumab govitecan) [package insert]. FDA.', 'citation': 'Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Gilead Sciences, Inc.', 'drug_name_brand': 'Trodelvy', 'drug_name_generic': 'sacituzumab govitecan', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115', 'application_number': 761115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trodelvy:0,"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.",2021-04-07,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s005s013lbl.pdf,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.",triple-negative breast cancer,unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC),Trodelvy (sacituzumab govitecan),,,,,,,,doc:fda.trodelvy,Document,Regulatory approval,Trodelvy (sacituzumab govitecan) [package insert]. FDA.,"Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.","Gilead Sciences, Inc.",Trodelvy,sacituzumab govitecan,,2024-10-30,2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115,761115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,403,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 44, 'name': 'PR negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 43, 'name': 'ER negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],94,,,Drug,Sacituzumab govitecan,ncit:C102783,C102783,Sacituzumab Govitecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783'],[],"[{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
474,Statement,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.trodelvy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trodelvy (sacituzumab govitecan) [package insert]. FDA.', 'citation': 'Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Gilead Sciences, Inc.', 'drug_name_brand': 'Trodelvy', 'drug_name_generic': 'sacituzumab govitecan', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115', 'application_number': 761115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trodelvy:1,"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","HR-positive, HER2-negative (HC 0, IHC 1+, or IHC 2+/ISH-)",locally advanced or metastatic ... breast cancer,Trodelvy (sacituzumab govitecan),,,,,,,,doc:fda.trodelvy,Document,Regulatory approval,Trodelvy (sacituzumab govitecan) [package insert]. FDA.,"Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.","Gilead Sciences, Inc.",Trodelvy,sacituzumab govitecan,,2024-10-30,2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115,761115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,404,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],94,,,Drug,Sacituzumab govitecan,ncit:C102783,C102783,Sacituzumab Govitecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783'],[],"[{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
475,Statement,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.trodelvy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trodelvy (sacituzumab govitecan) [package insert]. FDA.', 'citation': 'Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Gilead Sciences, Inc.', 'drug_name_brand': 'Trodelvy', 'drug_name_generic': 'sacituzumab govitecan', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115', 'application_number': 761115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trodelvy:1,"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","HR-positive, HER2-negative (HC 0, IHC 1+, or IHC 2+/ISH-)",locally advanced or metastatic ... breast cancer,Trodelvy (sacituzumab govitecan),,,,,,,,doc:fda.trodelvy,Document,Regulatory approval,Trodelvy (sacituzumab govitecan) [package insert]. FDA.,"Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.","Gilead Sciences, Inc.",Trodelvy,sacituzumab govitecan,,2024-10-30,2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115,761115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,405,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],94,,,Drug,Sacituzumab govitecan,ncit:C102783,C102783,Sacituzumab Govitecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783'],[],"[{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
476,Statement,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.trodelvy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trodelvy (sacituzumab govitecan) [package insert]. FDA.', 'citation': 'Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'Gilead Sciences, Inc.', 'drug_name_brand': 'Trodelvy', 'drug_name_generic': 'sacituzumab govitecan', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-02-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115', 'application_number': 761115, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trodelvy:1,"TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.",2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,"The U.S. Food and Drug Administration granted approval to sacituzumab govitecan for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.","HR-positive, HER2-negative (HC 0, IHC 1+, or IHC 2+/ISH-)",locally advanced or metastatic ... breast cancer,Trodelvy (sacituzumab govitecan),,,,,,,,doc:fda.trodelvy,Document,Regulatory approval,Trodelvy (sacituzumab govitecan) [package insert]. FDA.,"Gilead Sciences, Inc. Trodelvy (sacituzumab govitecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf. Revised February 2023. Accessed October 30, 2024.","Gilead Sciences, Inc.",Trodelvy,sacituzumab govitecan,,2024-10-30,2023-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761115,761115.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,406,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],94,,,Drug,Sacituzumab govitecan,ncit:C102783,C102783,Sacituzumab Govitecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102783'],[],"[{'name': 'therapy_strategy', 'value': ['Topoisomerase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
477,Statement,"The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [package insert]. FDA.', 'citation': 'Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Eli Lilly and Company.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2020-05-08', 'access_date': '2024-10-30', 'publication_date': '2024-09-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246', 'application_number': 213246, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.retevmo:0,"RETEVMO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.",2020-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test.",RET fusion,locally advanced or metastatic non-small cell lung cancer,Retevmo (selpercatinib),,,,,,,2020-05-08,doc:fda.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [package insert]. FDA.,"Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Eli Lilly and Company.,Retevmo,selpercatinib,2020-05-08,2024-10-30,2024-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246,213246.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,407,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
478,Statement,"The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [package insert]. FDA.', 'citation': 'Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Eli Lilly and Company.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2020-05-08', 'access_date': '2024-10-30', 'publication_date': '2024-09-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246', 'application_number': 213246, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.retevmo:1,"RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.",2024-05-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf,"The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.",RET mutation,advanced or metastatic medullary thyroid cancer,Retevmo (selpercatinib),,,,,,2024-09-27,2024-05-29,doc:fda.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [package insert]. FDA.,"Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Eli Lilly and Company.,Retevmo,selpercatinib,2020-05-08,2024-10-30,2024-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246,213246.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,408,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 152, 'name': 'RET oncogenic variants', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '10'}, {'name': 'requires_oncogenic', 'value': True}]}]",38,Disease,Medullary Thyroid Cancer,oncotree:THME,THME,Medullary Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THME'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
479,Statement,"The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [package insert]. FDA.', 'citation': 'Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Eli Lilly and Company.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2020-05-08', 'access_date': '2024-10-30', 'publication_date': '2024-09-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246', 'application_number': 213246, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.retevmo:2,"RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",2024-05-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s012lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).",RET gene fusion,advanced or metastatic thyroid cancer,Retevmo (selpercatinib),,,,,,2024-06-12,2024-05-29,doc:fda.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [package insert]. FDA.,"Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Eli Lilly and Company.,Retevmo,selpercatinib,2020-05-08,2024-10-30,2024-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246,213246.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,409,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",4,Disease,Anaplastic Thyroid Cancer,oncotree:THAP,THAP,Anaplastic Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
480,Statement,"The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.retevmo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Retevmo (selpercatinib) [package insert]. FDA.', 'citation': 'Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Eli Lilly and Company.', 'drug_name_brand': 'Retevmo', 'drug_name_generic': 'selpercatinib', 'first_published': '2020-05-08', 'access_date': '2024-10-30', 'publication_date': '2024-09-27', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246', 'application_number': 213246, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.retevmo:3,"RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",2022-09-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s007lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",RET gene fusion,locally advanced or metastatic solid tumors,Retevmo (selpercatinib),,,,,,,2022-09-21,doc:fda.retevmo,Document,Regulatory approval,Retevmo (selpercatinib) [package insert]. FDA.,"Eli Lilly and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Eli Lilly and Company.,Retevmo,selpercatinib,2020-05-08,2024-10-30,2024-09-27,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213246s011s013lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213246,213246.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,410,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 18, 'name': 'v::RET', 'genes': [{'id': 49, 'name': 'RET', 'primaryCoding': {'id': 'hgnc:9967', 'code': 'HGNC:9967', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9967']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_020975.6', 'code': 'NM_020975.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_020975.6']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000165731', 'code': 'ENSG00000165731', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165731']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5979', 'code': '5979', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5979']}}], 'extensions': [{'name': 'location', 'value': '10q11.21'}, {'name': 'location_sortable', 'value': '10q11.21'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],78,,,Drug,Selpercatinib,ncit:C134987,C134987,Selpercatinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C134987'],[],"[{'name': 'therapy_strategy', 'value': ['RET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
481,Statement,"The U.S. Food and Drug Administration granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. The product label states that this indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lumakras', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lumakras (sotorasib) [package insert]. FDA.', 'citation': 'Amgen, Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf. Revised April 2023. Accessed October 30, 2024.', 'company': 'Amgen, Inc.', 'drug_name_brand': 'Lumakras', 'drug_name_generic': 'sotorasib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-04-23', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214665', 'application_number': 214665, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lumakras:0,"LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2021-05-28,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. The product label states that this indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",KRAS G12C,locally advanced or metastatic non-small cell lung cancer,Lumakras (sotorasib),,,,,,,,doc:fda.lumakras,Document,Regulatory approval,Lumakras (sotorasib) [package insert]. FDA.,"Amgen, Inc. Lumakras (sotorasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf. Revised April 2023. Accessed October 30, 2024.","Amgen, Inc.",Lumakras,sotorasib,,2024-10-30,2023-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214665s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214665,214665.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,411,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 45, 'name': 'KRAS p.G12C', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '2'}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],57,,,Drug,Sotorasib,ncit:C154287,C154287,Sotorasib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C154287'],[],"[{'name': 'therapy_strategy', 'value': ['RAS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
482,Statement,The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:0,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.,2018-10-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.,"deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",locally advanced or metastatic breast cancer,Talzenna (talazoparib),,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,412,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],87,,,Drug,Talazoparib,ncit:C95733,C95733,Talazoparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
483,Statement,The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:0,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.,2018-10-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for Talazoparib.,"deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative",locally advanced or metastatic breast cancer,Talzenna (talazoparib),,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,413,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],87,,,Drug,Talazoparib,ncit:C95733,C95733,Talazoparib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733'],[],"[{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
484,Statement,The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tepmetko', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tepmetko (tepotinib) [package insert]. FDA.', 'citation': 'EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'EMD Serono, Inc.', 'drug_name_brand': 'Tepmetko', 'drug_name_generic': 'tepotinib', 'first_published': '2021-02-03', 'access_date': '2024-10-30', 'publication_date': '2024-02-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214096', 'application_number': 214096, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tepmetko:0,TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,2021-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf,The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,MET exon 14 skipping alterations,non-small cell lung cancer,Tepmetko (tepotinib),,,,,,2024-02-15,2021-02-03,doc:fda.tepmetko,Document,Regulatory approval,Tepmetko (tepotinib) [package insert]. FDA.,"EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2023. Accessed October 30, 2024.","EMD Serono, Inc.",Tepmetko,tepotinib,2021-02-03,2024-10-30,2024-02-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214096,214096.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,414,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 67, 'name': 'MET Exon 14 (Splice Site)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Splice Site'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],90,,,Drug,Tepotinib,ncit:C88314,C88314,Tepotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88314'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
485,Statement,The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tepmetko', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tepmetko (tepotinib) [package insert]. FDA.', 'citation': 'EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2023. Accessed October 30, 2024.', 'company': 'EMD Serono, Inc.', 'drug_name_brand': 'Tepmetko', 'drug_name_generic': 'tepotinib', 'first_published': '2021-02-03', 'access_date': '2024-10-30', 'publication_date': '2024-02-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214096', 'application_number': 214096, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tepmetko:0,TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,2021-02-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf,The U.S. Food and Drug Administration granted approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.,MET exon 14 skipping alterations,non-small cell lung cancer,Tepmetko (tepotinib),,,,,,2024-02-15,2021-02-03,doc:fda.tepmetko,Document,Regulatory approval,Tepmetko (tepotinib) [package insert]. FDA.,"EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2023. Accessed October 30, 2024.","EMD Serono, Inc.",Tepmetko,tepotinib,2021-02-03,2024-10-30,2024-02-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214096,214096.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,415,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 68, 'name': 'MET Exon 14 (Deletion)', 'genes': [{'id': 32, 'name': 'MET', 'primaryCoding': {'id': 'hgnc:7029', 'code': 'HGNC:7029', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7029']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000105976', 'code': 'ENSG00000105976', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000105976']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4233', 'code': '4233', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4233']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000245.4', 'code': 'NM_000245.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000245.4']}}], 'extensions': [{'name': 'location', 'value': '7q31.2'}, {'name': 'location_sortable', 'value': '07q31.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '14'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],90,,,Drug,Tepotinib,ncit:C88314,C88314,Tepotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C88314'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
486,Statement,"The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:0,MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",BRAF V600E or V600K,unresectable or metastatic melanoma,Mekinist (trametinib),,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,416,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],66,,,Drug,Trametinib,ncit:C77908,C77908,Trametinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908'],[],"[{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
487,Statement,"The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:0,MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.,,,"The U.S. Food and Drug Administration granted approval to trametinib for the treatment of BRAF-inhibitor treatment-naive patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",BRAF V600E or V600K,unresectable or metastatic melanoma,Mekinist (trametinib),,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,417,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],66,,,Drug,Trametinib,ncit:C77908,C77908,Trametinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908'],[],"[{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
488,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:1,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",BRAF V600E or V600K,unresectable or metastatic melanoma,Mekinist (trametinib) in combination with dabrafenib,,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,89,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
489,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:1,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.",BRAF V600E or V600K,unresectable or metastatic melanoma,Mekinist (trametinib) in combination with dabrafenib,,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,90,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
490,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:3,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",,,"The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation, as detected by an FDA-approved test.",BRAF V600E,metastatic non-small cell lung cancer,Mekinist (trametinib) in combination with dabrafenib,,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,91,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
491,Statement,"The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:4,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.",,,The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.,BRAF V600E,locally advanced or metastatic anaplastic thyroid cancer,Mekinist (trametinib) in combination with dabrafenib,,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,92,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",4,Disease,Anaplastic Thyroid Cancer,oncotree:THAP,THAP,Anaplastic Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
492,Statement,The U.S. Food and Drug Administration granted accelerated approval to dabrafenib in combination with trametinib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:5,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Limitations of Use: MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.",,,"The U.S. Food and Drug Administration granted accelerated approval to trametinib in combination with dabrafenib for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. The product label specifies that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, the product label states a Limitation of Use: trametinib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.",BRAF V600E,unresectable or metastatic solid tumors,Mekinist (trametinib) in combination with dabrafenib,,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,93,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
493,Statement,The U.S. Food and Drug Administration granted approval to dabrafenib in combination with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.mekinist', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Mekinist (trametinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Mekinist', 'drug_name_generic': 'trametinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-03-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513', 'application_number': 217513, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.mekinist:6,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.",,,The U.S. Food and Drug Administration granted approval to trametinib in combination with dabrafenib for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.,BRAF V600E,low-grade glioma (LGG),Mekinist (trametinib) i combination with dabrafenib,,,,,,,,doc:fda.mekinist,Document,Regulatory approval,Mekinist (trametinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf. Revised March 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Mekinist,trametinib,,2024-10-30,2024-03-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217513s003lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217513,217513.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,94,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],18,AND,"[{'id': 67, 'conceptType': 'Drug', 'name': 'Dabrafenib', 'primaryCoding': {'id': 'ncit:C82386', 'code': 'C82386', 'name': 'Dabrafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C82386']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 66, 'conceptType': 'Drug', 'name': 'Trametinib', 'primaryCoding': {'id': 'ncit:C77908', 'code': 'C77908', 'name': 'Trametinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77908']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
494,Statement,The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer. The product label specifies to select  patients for therapy based on an FDA-approved companion diagnostic for herceptin.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-06-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792', 'application_number': 103792, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.herceptin:0,Herceptin is a HER2/neu receptor antagonist indicated for the treatment of HER2 -overexpressing breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.,2008-01-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103792s5175lbl.pdf,The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of patients with HER2-overexpressing breast cancer. The product label specifies to select  patients for therapy based on an FDA-approved companion diagnostic for herceptin.,HER2-overexpressing,breast cancer,Herceptin (trastuzumab),,,,,,,,doc:fda.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [package insert]. FDA.,"Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf. Revised June 2024. Accessed October 30, 2024.","Genentech, Inc.",Herceptin,trastuzumab,,2024-10-30,2024-06-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792,103792.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,418,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],25,,,Drug,Trastuzumab,ncit:C1647,C1647,Trastuzumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
495,Statement,The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.herceptin', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Herceptin (trastuzumab) [package insert]. FDA.', 'citation': 'Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf. Revised June 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Herceptin', 'drug_name_generic': 'trastuzumab', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-06-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792', 'application_number': 103792, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.herceptin:1,Herceptin is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin.,2010-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf,The U.S. Food and Drug Administration granted approval to trastuzumab for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for trastuzumab.,HER2-overexpressing,metastatic gastric or gastroesophageal junction adenocarcinoma,Herceptin (trastuzumab),,,,,,,,doc:fda.herceptin,Document,Regulatory approval,Herceptin (trastuzumab) [package insert]. FDA.,"Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf. Revised June 2024. Accessed October 30, 2024.","Genentech, Inc.",Herceptin,trastuzumab,,2024-10-30,2024-06-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103792s5354lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103792,103792.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,419,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",22,Disease,Gastrointestinal Stromal Tumor,oncotree:GIST,GIST,Gastrointestinal Stromal Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GIST'],[],25,,,Drug,Trastuzumab,ncit:C1647,C1647,Trastuzumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
496,Statement,"The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [package insert]. FDA.', 'citation': 'Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Daiichi Sankyo, Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2019-12-20', 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139', 'application_number': 761139, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.enhertu:0,"ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.",2022-05-04,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s017s020lbl.pdf,"The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either (i) in the metastatic setting, or (ii) in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy.",HER2-positive (IHC 3+ or ISH positive),unresectable or metastatic breast cancer,Enhertu (trastuzumab deruxtecan),,,,,,2022-05-04,2019-12-20,doc:fda.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [package insert]. FDA.,"Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Daiichi Sankyo, Inc.",Enhertu,trastuzumab deruxtecan,2019-12-20,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139,761139.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,420,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
497,Statement,"The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [package insert]. FDA.', 'citation': 'Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Daiichi Sankyo, Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2019-12-20', 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139', 'application_number': 761139, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.enhertu:1,"ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",2022-08-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s022lbl.pdf,"The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.",HER2-low (IHC 1+ or IHC2+/ISH-),unresectable or metastatic ... breast cancer,Enhertu (trastuzumab deruxtecan),,,,,,,,doc:fda.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [package insert]. FDA.,"Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Daiichi Sankyo, Inc.",Enhertu,trastuzumab deruxtecan,2019-12-20,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139,761139.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,421,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 22, 'name': 'HER2-low', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Low'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
498,Statement,"The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The product label states that these indications are approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [package insert]. FDA.', 'citation': 'Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Daiichi Sankyo, Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2019-12-20', 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139', 'application_number': 761139, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.enhertu:2,"ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",2022-08-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s021lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The product label states that these indications are approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",HER2 (ERBB2) mutations,unresectable or metastatic non-small cell lung cancer,Enhertu (trastuzumab deruxtecan),,,,,,,2022-08-11,doc:fda.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [package insert]. FDA.,"Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Daiichi Sankyo, Inc.",Enhertu,trastuzumab deruxtecan,2019-12-20,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139,761139.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,422,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 23, 'name': 'ERBB2 oncogenic variants', 'genes': [{'id': 18, 'name': 'ERBB2', 'primaryCoding': {'id': 'hgnc:3430', 'code': 'HGNC:3430', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3430']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000141736', 'code': 'ENSG00000141736', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000141736']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2064', 'code': '2064', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2064']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004448.4', 'code': 'NM_004448.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004448.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
499,Statement,The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [package insert]. FDA.', 'citation': 'Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Daiichi Sankyo, Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2019-12-20', 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139', 'application_number': 761139, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.enhertu:3,ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.,2021-01-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf,The U.S. Food and Drug Administration granted approval to trastuzumab deruxtecan for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.,HER2-positive (IHC 3+ or IHC 2+/ISH positive),locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma,Enhertu (trastuzumab deruxtecan),,,,,,,,doc:fda.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [package insert]. FDA.,"Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Daiichi Sankyo, Inc.",Enhertu,trastuzumab deruxtecan,2019-12-20,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139,761139.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,423,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
500,Statement,The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.enhertu', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Enhertu (trastuzumab deruxtecan) [package insert]. FDA.', 'citation': 'Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Daiichi Sankyo, Inc.', 'drug_name_brand': 'Enhertu', 'drug_name_generic': 'trastuzumab deruxtecan', 'first_published': '2019-12-20', 'access_date': '2024-10-30', 'publication_date': '2024-04-05', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139', 'application_number': 761139, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.enhertu:4,ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf,The U.S. Food and Drug Administration granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. The product label states that this indication is approved under accelerated approval based on objective response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.,HER2-positive (IHC 3+),unresectable or metastatic solid tumors,Enhertu (trastuzumab deruxtecan),,,,,,,2022-08-11,doc:fda.enhertu,Document,Regulatory approval,Enhertu (trastuzumab deruxtecan) [package insert]. FDA.,"Daiichi Sankyo, Inc. Enhertu (trastuzumab deruxtecan) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Daiichi Sankyo, Inc.",Enhertu,trastuzumab deruxtecan,2019-12-20,2024-10-30,2024-04-05,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761139s028lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761139,761139.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,424,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",5,Disease,Any solid tumor,ncit:C132146,C132146,Malignant Solid Neoplasm,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132146'],[],26,,,Drug,Trastuzumab deruxtecan,ncit:C128799,C128799,Trastuzumab Deruxtecan,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C128799'],[],"[{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
501,Statement,"The U.S. Food and Drug Administration granted approval to tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tukysa', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tukysa (tucatinib) [package insert]. FDA.', 'citation': 'Seagen Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed October 30, 2024.', 'company': 'Seagen Inc.', 'drug_name_brand': 'Tukysa', 'drug_name_generic': 'tucatinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-01-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213411', 'application_number': 213411, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tukysa:0,"TUKYSA is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",2020-04-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",HER2-positive,advanced unresectable or metastatic breast cancer,Tukysa (tucatinib) in combination with trastuzumab or capecitabine,,,,,,,,doc:fda.tukysa,Document,Regulatory approval,Tukysa (tucatinib) [package insert]. FDA.,"Seagen Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed October 30, 2024.",Seagen Inc.,Tukysa,tucatinib,,2024-10-30,2023-01-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213411,213411.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,425,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],84,AND,"[{'id': 95, 'conceptType': 'Drug', 'name': 'Tucatinib', 'primaryCoding': {'id': 'ncit:C77896', 'code': 'C77896', 'name': 'Tucatinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C77896']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 25, 'conceptType': 'Drug', 'name': 'Trastuzumab', 'primaryCoding': {'id': 'ncit:C1647', 'code': 'C1647', 'name': 'Trastuzumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1647']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['HER2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
502,Statement,"The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zelboraf', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zelboraf (vemurafenib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Zelboraf', 'drug_name_generic': 'vemurafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-05-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429', 'application_number': 202429, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zelboraf:0,ZELBORAF is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.,2011-08-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation, as detected by an FDA-approved test.",BRAF V600E,unresectable or metastatic melanoma,Zelboraf (vemurafenib),,,,,,,,doc:fda.zelboraf,Document,Regulatory approval,Zelboraf (vemurafenib) [package insert]. FDA.,"Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.","Genentech, Inc.",Zelboraf,vemurafenib,,2024-10-30,2020-05-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429,202429.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,426,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",40,Disease,Melanoma,oncotree:MEL,MEL,Melanoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=MEL'],[],22,,,Drug,Vemurafenib,ncit:C64768,C64768,Vemurafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
503,Statement,The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zelboraf', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zelboraf (vemurafenib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Zelboraf', 'drug_name_generic': 'vemurafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-05-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429', 'application_number': 202429, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zelboraf:1,ZELBORAF is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.,2017-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf,The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.,BRAF V600,Erdheim-Chester Disease,Zelboraf (vemurafenib),,,,,,,,doc:fda.zelboraf,Document,Regulatory approval,Zelboraf (vemurafenib) [package insert]. FDA.,"Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.","Genentech, Inc.",Zelboraf,vemurafenib,,2024-10-30,2020-05-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429,202429.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,427,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",46,Disease,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,oncotree:ECD,ECD,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ECD'],[],22,,,Drug,Vemurafenib,ncit:C64768,C64768,Vemurafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
504,Statement,The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.zelboraf', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Zelboraf (vemurafenib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Zelboraf', 'drug_name_generic': 'vemurafenib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-05-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429', 'application_number': 202429, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.zelboraf:1,ZELBORAF is indicated for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.,2017-11-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s016lbl.pdf,The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.,BRAF V600,Erdheim-Chester Disease,Zelboraf (vemurafenib),,,,,,,,doc:fda.zelboraf,Document,Regulatory approval,Zelboraf (vemurafenib) [package insert]. FDA.,"Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed October 30, 2024.","Genentech, Inc.",Zelboraf,vemurafenib,,2024-10-30,2020-05-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202429,202429.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,428,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",46,Disease,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,oncotree:ECD,ECD,Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ECD'],[],22,,,Drug,Vemurafenib,ncit:C64768,C64768,Vemurafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C64768'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
505,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,429,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 145, 'name': 'EZH2 p.Y646N', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148508728}, {'name': 'end_position', 'value': 148508728}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1936T>A'}, {'name': 'protein_change', 'value': 'p.Y646N'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '16/20'}, {'name': 'rsid', 'value': 'rs267601395'}, {'name': 'hgvsg', 'value': '7:g.148508728A>T'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
506,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,430,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 146, 'name': 'EZH2 p.Y646F', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148508727}, {'name': 'end_position', 'value': 148508727}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.1937A>T'}, {'name': 'protein_change', 'value': 'p.Y646F'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '16/20'}, {'name': 'rsid', 'value': 'rs267601394'}, {'name': 'hgvsg', 'value': '7:g.148508727T>A'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
507,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,431,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 147, 'name': 'EZH2 p.Y646H', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148508728}, {'name': 'end_position', 'value': 148508728}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.1936T>C'}, {'name': 'protein_change', 'value': 'p.Y646H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '16/20'}, {'name': 'rsid', 'value': 'rs267601395'}, {'name': 'hgvsg', 'value': '7:g.148508728A>G'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
508,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,432,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 148, 'name': 'EZH2 p.Y646S', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148508727}, {'name': 'end_position', 'value': 148508727}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.1937A>C'}, {'name': 'protein_change', 'value': 'p.Y646S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '16/20'}, {'name': 'rsid', 'value': 'rs267601394'}, {'name': 'hgvsg', 'value': '7:g.148508727T>G'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
509,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,433,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 149, 'name': 'EZH2 p.Y646C', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148508727}, {'name': 'end_position', 'value': 148508727}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.1937A>G'}, {'name': 'protein_change', 'value': 'p.Y646C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '16/20'}, {'name': 'rsid', 'value': 'rs267601394'}, {'name': 'hgvsg', 'value': '7:g.148508727T>C'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
510,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,434,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 150, 'name': 'EZH2 p.A862G', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148506467}, {'name': 'end_position', 'value': 148506467}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.2045C>G'}, {'name': 'protein_change', 'value': 'p.A682G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '18/20'}, {'name': 'rsid', 'value': 'rs1057519833'}, {'name': 'hgvsg', 'value': '7:g.148506467G>C'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
511,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tazverik', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tazverik (tazemetostat) [package insert]. FDA.', 'citation': 'Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.', 'company': 'Epizyme, Inc.', 'drug_name_brand': 'Tazverik', 'drug_name_generic': 'tazemetostat', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-11-16', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723', 'application_number': 211723, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tazverik:0,TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tazemetostat for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least 2 prior systemic therapies. The product label states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",EZH2 mutation positive,follicular lymphoma,Tazverik (tazemetostat),,,,,,,,doc:fda.tazverik,Document,Regulatory approval,Tazverik (tazemetostat) [package insert]. FDA.,"Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf. Revised November 2023. Accessed October 30, 2024.","Epizyme, Inc.",Tazverik,tazemetostat,,2024-10-30,2023-11-16,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211723s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211723,211723.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,435,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 151, 'name': 'EZH2 p.A692V', 'genes': [{'id': 20, 'name': 'EZH2', 'primaryCoding': {'id': 'hgnc:3527', 'code': 'HGNC:3527', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3527']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000106462', 'code': 'ENSG00000106462', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000106462']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2146', 'code': '2146', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2146']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004456.5', 'code': 'NM_004456.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004456.5']}}], 'extensions': [{'name': 'location', 'value': '7q36.1'}, {'name': 'location_sortable', 'value': '07q36.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 148506437}, {'name': 'end_position', 'value': 148506437}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.2075C>T'}, {'name': 'protein_change', 'value': 'p.A692V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '18/20'}, {'name': 'rsid', 'value': 'rs2129467667'}, {'name': 'hgvsg', 'value': '7:g.148506437G>A'}]}]",20,Disease,Follicular Lymphoma,oncotree:FL,FL,Follicular Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=FL'],[],137,,,Drug,Tazemetostat,ncit:C107506,C107506,Tazemetostat,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C107506'],[],"[{'name': 'therapy_strategy', 'value': ['EZH2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
512,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,436,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 48, 'name': 'BRCA1 pathogenic variants', 'genes': [{'id': 9, 'name': 'BRCA1', 'primaryCoding': {'id': 'hgnc:1100', 'code': 'HGNC:1100', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007294.4', 'code': 'NM_007294.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000012048', 'code': 'ENSG00000012048', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000012048']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:672', 'code': '672', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/672']}}], 'extensions': [{'name': 'location', 'value': '17q21.31'}, {'name': 'location_sortable', 'value': '17q21.31'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
513,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,437,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 49, 'name': 'BRCA2 oncogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
514,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,438,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 50, 'name': 'BRCA2 pathogenic variants', 'genes': [{'id': 10, 'name': 'BRCA2', 'primaryCoding': {'id': 'hgnc:1101', 'code': 'HGNC:1101', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1101']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000139618', 'code': 'ENSG00000139618', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000139618']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:675', 'code': '675', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/675']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000059.4', 'code': 'NM_000059.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000059.4']}}], 'extensions': [{'name': 'location', 'value': '13q13.1'}, {'name': 'location_sortable', 'value': '13q13.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '13'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
515,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,439,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 104, 'name': 'ATM pathogenic variants', 'genes': [{'id': 3, 'name': 'ATM', 'primaryCoding': {'id': 'hgnc:795', 'code': 'HGNC:795', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000051.4', 'code': 'NM_000051.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149311', 'code': 'ENSG00000149311', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149311']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:472', 'code': '472', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/472']}}], 'extensions': [{'name': 'location', 'value': '11q22.3'}, {'name': 'location_sortable', 'value': '11q22.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
516,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,440,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 105, 'name': 'ATM oncogenic variants', 'genes': [{'id': 3, 'name': 'ATM', 'primaryCoding': {'id': 'hgnc:795', 'code': 'HGNC:795', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:795']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_000051.4', 'code': 'NM_000051.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_000051.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000149311', 'code': 'ENSG00000149311', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000149311']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:472', 'code': '472', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/472']}}], 'extensions': [{'name': 'location', 'value': '11q22.3'}, {'name': 'location_sortable', 'value': '11q22.3'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
517,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,441,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 160, 'name': 'ATR oncogenic variants', 'genes': [{'id': 56, 'name': 'ATR', 'primaryCoding': {'id': 'hgnc:882', 'code': 'HGNC:882', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:882']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ncbi:545', 'code': '545', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/545']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000175054', 'code': 'ENSG00000175054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000175054']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '3'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
518,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,442,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 125, 'name': 'CDK12 oncogenic variants', 'genes': [{'id': 14, 'name': 'CDK12', 'primaryCoding': {'id': 'hgnc:24224', 'code': 'HGNC:24224', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000167258', 'code': 'ENSG00000167258', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000167258']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:51755', 'code': '51755', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/51755']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_016507.4', 'code': 'NM_016507.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
519,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,443,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 161, 'name': 'ATR pathogenic variants', 'genes': [{'id': 56, 'name': 'ATR', 'primaryCoding': {'id': 'hgnc:882', 'code': 'HGNC:882', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:882']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ncbi:545', 'code': '545', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/545']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000175054', 'code': 'ENSG00000175054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000175054']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '3'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
520,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,444,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 162, 'name': 'FANCA oncogenic variants', 'genes': [{'id': 57, 'name': 'FANCA', 'primaryCoding': {'id': 'hgnc:3582', 'code': 'HGNC:3582', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3582']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000187741', 'code': 'ENSG00000187741', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000187741']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2175', 'code': '2175', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2175']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
521,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,445,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 128, 'name': 'CHEK2 pathogenic variants', 'genes': [{'id': 16, 'name': 'CHEK2', 'primaryCoding': {'id': 'hgnc:16627', 'code': 'HGNC:16627', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000183765', 'code': 'ENSG00000183765', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000183765']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:11200', 'code': '11200', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/11200']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007194.4', 'code': 'NM_007194.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007194.4']}}], 'extensions': [{'name': 'location', 'value': '22q12.1'}, {'name': 'location_sortable', 'value': '22q12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '22'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
522,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,446,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 129, 'name': 'CHEK2 oncogenic variants', 'genes': [{'id': 16, 'name': 'CHEK2', 'primaryCoding': {'id': 'hgnc:16627', 'code': 'HGNC:16627', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:16627']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000183765', 'code': 'ENSG00000183765', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000183765']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:11200', 'code': '11200', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/11200']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_007194.4', 'code': 'NM_007194.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_007194.4']}}], 'extensions': [{'name': 'location', 'value': '22q12.1'}, {'name': 'location_sortable', 'value': '22q12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '22'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
523,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,447,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 163, 'name': 'FANCA pathogenic variants', 'genes': [{'id': 57, 'name': 'FANCA', 'primaryCoding': {'id': 'hgnc:3582', 'code': 'HGNC:3582', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3582']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000187741', 'code': 'ENSG00000187741', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000187741']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:2175', 'code': '2175', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/2175']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
524,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,448,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 164, 'name': 'MLH1 oncogenic variants', 'genes': [{'id': 58, 'name': 'MLH1', 'primaryCoding': {'id': 'hgnc:7127', 'code': 'HGNC:7127', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7127']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000076242', 'code': 'ENSG00000076242', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000076242']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4292', 'code': '4292', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4292']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '3'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
525,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,449,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 132, 'name': 'PALB2 pathogenic variants', 'genes': [{'id': 38, 'name': 'PALB2', 'primaryCoding': {'id': 'hgnc:26144', 'code': 'HGNC:26144', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26144']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000083093', 'code': 'ENSG00000083093', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000083093']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:79728', 'code': '79728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/79728']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_024675.4', 'code': 'NM_024675.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_024675.4']}}], 'extensions': [{'name': 'location', 'value': '16p12.2'}, {'name': 'location_sortable', 'value': '16p12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
526,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,450,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 133, 'name': 'PALB2 oncogenic variants', 'genes': [{'id': 38, 'name': 'PALB2', 'primaryCoding': {'id': 'hgnc:26144', 'code': 'HGNC:26144', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26144']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000083093', 'code': 'ENSG00000083093', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000083093']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:79728', 'code': '79728', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/79728']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_024675.4', 'code': 'NM_024675.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_024675.4']}}], 'extensions': [{'name': 'location', 'value': '16p12.2'}, {'name': 'location_sortable', 'value': '16p12.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
527,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,451,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 165, 'name': 'MLH1 pathogenic variants', 'genes': [{'id': 58, 'name': 'MLH1', 'primaryCoding': {'id': 'hgnc:7127', 'code': 'HGNC:7127', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7127']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000076242', 'code': 'ENSG00000076242', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000076242']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4292', 'code': '4292', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4292']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '3'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
528,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,452,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 166, 'name': 'MRE11 oncogenic variants', 'genes': [{'id': 59, 'name': 'MRE11', 'primaryCoding': {'id': 'hgnc:7230', 'code': 'HGNC:7230', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7230']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000020922', 'code': 'ENSG00000020922', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000020922']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4361', 'code': '4361', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4361']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
529,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,453,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 136, 'name': 'RAD51C pathogenic variants', 'genes': [{'id': 45, 'name': 'RAD51C', 'primaryCoding': {'id': 'hgnc:9820', 'code': 'HGNC:9820', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9820']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_058216.3', 'code': 'NM_058216.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_058216.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000108384', 'code': 'ENSG00000108384', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000108384']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5889', 'code': '5889', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5889']}}], 'extensions': [{'name': 'location', 'value': '17q22'}, {'name': 'location_sortable', 'value': '17q22'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
530,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,454,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 137, 'name': 'RAD51C oncogenic variants', 'genes': [{'id': 45, 'name': 'RAD51C', 'primaryCoding': {'id': 'hgnc:9820', 'code': 'HGNC:9820', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9820']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_058216.3', 'code': 'NM_058216.3', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_058216.3']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000108384', 'code': 'ENSG00000108384', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000108384']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5889', 'code': '5889', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5889']}}], 'extensions': [{'name': 'location', 'value': '17q22'}, {'name': 'location_sortable', 'value': '17q22'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
531,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,455,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 167, 'name': 'MRE11 pathogenic variants', 'genes': [{'id': 59, 'name': 'MRE11', 'primaryCoding': {'id': 'hgnc:7230', 'code': 'HGNC:7230', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7230']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000020922', 'code': 'ENSG00000020922', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000020922']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4361', 'code': '4361', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4361']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '11'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
532,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,456,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 168, 'name': 'NBN oncogenic variants', 'genes': [{'id': 60, 'name': 'NBN', 'primaryCoding': {'id': 'hgnc:7652', 'code': 'HGNC:7652', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7652']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000104320', 'code': 'ENSG00000104320', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000104320']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4683', 'code': '4683', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4683']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '8'}, {'name': 'requires_oncogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
533,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,457,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 169, 'name': 'NBN pathogenic variants', 'genes': [{'id': 60, 'name': 'NBN', 'primaryCoding': {'id': 'hgnc:7652', 'code': 'HGNC:7652', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7652']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000104320', 'code': 'ENSG00000104320', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000104320']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4683', 'code': '4683', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4683']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '8'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
534,Statement,"The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:1,"AFINITOR is a kinase inhibitor indicated for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",2012-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s017lbl.pdf,"The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",TSC1/2,renal angiomyolipoma,everolimus,,,,,,2016-02-16,2012-04-26,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,458,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 158, 'name': 'TSC1 oncogenic variants', 'genes': [{'id': 54, 'name': 'TSC1', 'primaryCoding': {'id': 'hgnc:12362', 'code': 'HGNC:12362', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12362']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000165699', 'code': 'ENSG00000165699', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165699']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:7248', 'code': '7248', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/7248']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'requires_oncogenic', 'value': True}]}]",88,Disease,Renal Angiomyolipoma,oncotree:RAML,RAML,Renal Angiomyolipoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=RAML'],[],4,,,Drug,Everolimus,ncit:C48387,C48387,Everolimus,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387'],[],"[{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
535,Statement,"The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:1,"AFINITOR is a kinase inhibitor indicated for the treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",2012-04-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s017lbl.pdf,"The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.",TSC1/2,renal angiomyolipoma,everolimus,,,,,,2016-02-16,2012-04-26,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,459,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 159, 'name': 'TSC2 oncogenic variants', 'genes': [{'id': 55, 'name': 'TSC2', 'primaryCoding': {'id': 'hgnc:12363', 'code': 'HGNC:12363', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12363']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000103197', 'code': 'ENSG00000103197', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000103197']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:7249', 'code': '7249', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/7249']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_oncogenic', 'value': True}]}]",88,Disease,Renal Angiomyolipoma,oncotree:RAML,RAML,Renal Angiomyolipoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=RAML'],[],4,,,Drug,Everolimus,ncit:C48387,C48387,Everolimus,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387'],[],"[{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
536,Statement,The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:2,AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.,2010-10-29,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022334s032,203985s010lbl.pdf",The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.,TSC1/2,subependymal giant cell astrocytoma,everolimus,,,,,,2016-01-29,2010-10-29,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,460,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 158, 'name': 'TSC1 oncogenic variants', 'genes': [{'id': 54, 'name': 'TSC1', 'primaryCoding': {'id': 'hgnc:12362', 'code': 'HGNC:12362', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12362']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000165699', 'code': 'ENSG00000165699', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000165699']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:7248', 'code': '7248', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/7248']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '9'}, {'name': 'requires_oncogenic', 'value': True}]}]",4,Disease,Anaplastic Thyroid Cancer,oncotree:THAP,THAP,Anaplastic Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP'],[],4,,,Drug,Everolimus,ncit:C48387,C48387,Everolimus,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387'],[],"[{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
537,Statement,The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.afinitor', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Afinitor (everolimus) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Afinitor', 'drug_name_generic': 'everolimus', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-02-01', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334', 'application_number': 22334, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.afinitor:2,AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.,2010-10-29,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022334s032,203985s010lbl.pdf",The U.S. Food and Drug Administration granted approval to everolimus for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.,TSC1/2,subependymal giant cell astrocytoma,everolimus,,,,,,2016-01-29,2010-10-29,doc:fda.afinitor,Document,Regulatory approval,Afinitor (everolimus) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf. Revised February 2022. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Afinitor,everolimus,,2024-10-30,2022-02-01,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334,22334.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,461,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 159, 'name': 'TSC2 oncogenic variants', 'genes': [{'id': 55, 'name': 'TSC2', 'primaryCoding': {'id': 'hgnc:12363', 'code': 'HGNC:12363', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12363']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ENSG00000103197', 'code': 'ENSG00000103197', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000103197']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:7249', 'code': '7249', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/7249']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '16'}, {'name': 'requires_oncogenic', 'value': True}]}]",4,Disease,Anaplastic Thyroid Cancer,oncotree:THAP,THAP,Anaplastic Thyroid Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=THAP'],[],4,,,Drug,Everolimus,ncit:C48387,C48387,Everolimus,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48387'],[],"[{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
538,Statement,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.talzenna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Talzenna (talazoparib) [package insert]. FDA.', 'citation': 'Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Pfizer, Inc.', 'drug_name_brand': 'Talzenna', 'drug_name_generic': 'talazoparib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651', 'application_number': 211651, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.talzenna:1,TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,2023-06-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf,The U.S. Food and Drug Administration granted approval to talazoparib in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).,HRR gene-mutated,metastatic castration-resistant prostate cancer,Talzenna (talazoparib) in combination with enzalutamide,,,,,,,,doc:fda.talzenna,Document,Regulatory approval,Talzenna (talazoparib) [package insert]. FDA.,"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf. Revised February 2024. Accessed October 30, 2024.","Pfizer, Inc.",Talzenna,talazoparib,,2024-10-30,2024-02-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211651s012lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211651,211651.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,462,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 7, 'name': 'CDK12 pathogenic variants', 'genes': [{'id': 14, 'name': 'CDK12', 'primaryCoding': {'id': 'hgnc:24224', 'code': 'HGNC:24224', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:24224']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000167258', 'code': 'ENSG00000167258', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000167258']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:51755', 'code': '51755', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/51755']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_016507.4', 'code': 'NM_016507.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_016507.4']}}], 'extensions': [{'name': 'location', 'value': '17q12'}, {'name': 'location_sortable', 'value': '17q12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Germline Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '17'}, {'name': 'requires_pathogenic', 'value': True}]}]",55,Disease,Prostate Adenocarcinoma,oncotree:PRAD,PRAD,Prostate Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PRAD'],[],44,AND,"[{'id': 87, 'conceptType': 'Drug', 'name': 'Talazoparib', 'primaryCoding': {'id': 'ncit:C95733', 'code': 'C95733', 'name': 'Talazoparib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95733']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PARP inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 138, 'conceptType': 'Drug', 'name': 'Enzalutamide', 'primaryCoding': {'id': 'ncit:C71744', 'code': 'C71744', 'name': 'Enzalutamide', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71744']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antiandrogen'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
539,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:4,"TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R,non-small cell lung cancer,osimertinib,,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,304,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
540,Statement,"The U.S. Food and Drug Administration granted approval to osimertinib for the adjuvant treatment after tumor resection of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.tagrisso', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tagrisso (osimertinib) [package insert]. FDA.', 'citation': 'AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca Pharmaceuticals, LP.', 'drug_name_brand': 'Tagrisso', 'drug_name_generic': 'osimertinib', 'first_published': '2015-11-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-25', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065', 'application_number': 208065, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tagrisso:4,"TAGRISSO is a kinase inhibitor indicated for the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s143lbl.pdf,"The U.S. Food and Drug Administration granted approval to osimertinib for the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R,non-small cell lung cancer,osimertinib,,,,,,,,doc:fda.tagrisso,Document,Regulatory approval,Tagrisso (osimertinib) [package insert]. FDA.,"AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf. Revised September 2024. Accessed October 30, 2024.","AstraZeneca Pharmaceuticals, LP.",Tagrisso,osimertinib,2015-11-13,2024-10-30,2024-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208065,208065.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,305,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,,,Drug,Osimertinib,ncit:C116377,C116377,Osimertinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C116377'],[],"[{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
541,Statement,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2021-05-21', 'access_date': '2024-10-30', 'publication_date': '2024-09-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210', 'application_number': 761210, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rybrevant:2,"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",2024-08-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R,locally advanced or metastatic non-small cell lung cancer,Rybrevant (amivantamab-vmjw) in combination with lazertinib,,,,,,,,doc:fda.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [package insert]. FDA.,"Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Rybrevant,amivantamab-vmjw,2021-05-21,2024-10-30,2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210,761210.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,463,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,AND,"[{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primaryCoding': {'id': 'ncit:C148147', 'code': 'C148147', 'name': 'Lazertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C148147']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
542,Statement,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2021-05-21', 'access_date': '2024-10-30', 'publication_date': '2024-09-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210', 'application_number': 761210, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rybrevant:2,"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",2024-08-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R,locally advanced or metastatic non-small cell lung cancer,Rybrevant (amivantamab-vmjw) in combination with lazertinib,,,,,,,,doc:fda.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [package insert]. FDA.,"Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Rybrevant,amivantamab-vmjw,2021-05-21,2024-10-30,2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210,761210.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,464,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,AND,"[{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primaryCoding': {'id': 'ncit:C148147', 'code': 'C148147', 'name': 'Lazertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C148147']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
543,Statement,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Lazcluze (lazertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2024-08-19', 'access_date': '2024-10-30', 'publication_date': '2024-08-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219008', 'application_number': 219008, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lazcluze:0,"LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",2024-08-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf,"The U.S. Food and Drug Administration granted approval to lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R,non-small cell lung cancer,lazertinib in combination with amivantamab,,,,,,,,doc:fda.lazcluze,Document,Regulatory approval,Lazcluze (lazertinib) [package insert]. FDA.,"Janssen Biotech, Inc. Lazcluze (lazertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf. Revised August 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Lazcluze,lazertinib,2024-08-19,2024-10-30,2024-08-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219008,219008.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,463,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,AND,"[{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primaryCoding': {'id': 'ncit:C148147', 'code': 'C148147', 'name': 'Lazertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C148147']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
544,Statement,"The U.S. Food and Drug Administration granted approval to amivantamab-vmjw in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.lazcluze', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Lazcluze (lazertinib) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Lazcluze (lazertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Lazcluze', 'drug_name_generic': 'lazertinib', 'first_published': '2024-08-19', 'access_date': '2024-10-30', 'publication_date': '2024-08-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219008', 'application_number': 219008, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.lazcluze:0,"LAZCLUZE is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",2024-08-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf,"The U.S. Food and Drug Administration granted approval to lazertinib in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",EGFR exon 19 deletions or exon 21 L858R,non-small cell lung cancer,lazertinib in combination with amivantamab,,,,,,,,doc:fda.lazcluze,Document,Regulatory approval,Lazcluze (lazertinib) [package insert]. FDA.,"Janssen Biotech, Inc. Lazcluze (lazertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf. Revised August 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Lazcluze,lazertinib,2024-08-19,2024-10-30,2024-08-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219008s000lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219008,219008.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,464,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],85,AND,"[{'id': 139, 'conceptType': 'Drug', 'name': 'Lazertinib', 'primaryCoding': {'id': 'ncit:C148147', 'code': 'C148147', 'name': 'Lazertinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C148147']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
545,Statement,"The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2021-05-21', 'access_date': '2024-10-30', 'publication_date': '2024-09-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210', 'application_number': 761210, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rybrevant:3,"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,"The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",EGFR exon 19 deletions or exon 21 L858R,non-small cell lung cancer,amivantamab in combination with carboplatin and pemetrexed,,,,,,,,doc:fda.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [package insert]. FDA.,"Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Rybrevant,amivantamab-vmjw,2021-05-21,2024-10-30,2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210,761210.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,465,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 10, 'name': 'EGFR Exon 19 (Deletion)', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'variant_annotation', 'value': 'Deletion'}, {'name': 'exon', 'value': '19'}, {'name': 'requires_oncogenic', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,AND,"[{'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
546,Statement,"The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.rybrevant', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Rybrevant (amivantamab-vmjw) [package insert]. FDA.', 'citation': 'Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Janssen Biotech, Inc.', 'drug_name_brand': 'Rybrevant', 'drug_name_generic': 'amivantamab-vmjw', 'first_published': '2021-05-21', 'access_date': '2024-10-30', 'publication_date': '2024-09-19', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210', 'application_number': 761210, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.rybrevant:3,"RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,"The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.",EGFR exon 19 deletions or exon 21 L858R,non-small cell lung cancer,amivantamab in combination with carboplatin and pemetrexed,,,,,,,,doc:fda.rybrevant,Document,Regulatory approval,Rybrevant (amivantamab-vmjw) [package insert]. FDA.,"Janssen Biotech, Inc. Rybrevant (amivantamab-vmjw) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf. Revised September 2024. Accessed October 30, 2024.","Janssen Biotech, Inc.",Rybrevant,amivantamab-vmjw,2021-05-21,2024-10-30,2024-09-19,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761210,761210.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,466,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 9, 'name': 'EGFR p.L858R', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 55259515}, {'name': 'end_position', 'value': 55259515}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.2573T>G'}, {'name': 'protein_change', 'value': 'p.L858R'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '21'}, {'name': 'rsid', 'value': 'rs121434568'}, {'name': 'hgvsg', 'value': '7:g.55259515T>G'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],86,AND,"[{'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 108, 'conceptType': 'Drug', 'name': 'Amivantamab', 'primaryCoding': {'id': 'ncit:C124993', 'code': 'C124993', 'name': 'Amivantamab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C124993']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
547,Statement,"The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.elahere', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.', 'citation': 'ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'ImmunoGen, Inc.', 'drug_name_brand': 'Elahere', 'drug_name_generic': 'mirvetuximab soravtansine-gynx', 'first_published': '2022-11-14', 'access_date': '2024-10-30', 'publication_date': '2024-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310', 'application_number': 761310, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.elahere:0,"ELAHERE is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.",2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf,"The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",folate receptor-alpha tumor expression,"epithelial ovarian, fallopian tube, or primary peritoneal",mirvetuximab soravtansine-gynx,,,,,,,,doc:fda.elahere,Document,Regulatory approval,Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.,"ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.","ImmunoGen, Inc.",Elahere,mirvetuximab soravtansine-gynx,2022-11-14,2024-10-30,2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310,761310.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,467,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 153, 'name': 'FOLR1 positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'FOLR1'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",51,Disease,Ovarian Epithelial Tumor,oncotree:OVT,OVT,Ovarian Epithelial Tumor,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=OVT'],[],140,,,Drug,Mirvetuximab soravtansine,ncit:C102566,C102566,Mirvetuximab Soravtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102566'],[],"[{'name': 'therapy_strategy', 'value': ['Folate receptor-alpha inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
548,Statement,"The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.elahere', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.', 'citation': 'ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'ImmunoGen, Inc.', 'drug_name_brand': 'Elahere', 'drug_name_generic': 'mirvetuximab soravtansine-gynx', 'first_published': '2022-11-14', 'access_date': '2024-10-30', 'publication_date': '2024-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310', 'application_number': 761310, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.elahere:0,"ELAHERE is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.",2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf,"The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",folate receptor-alpha tumor expression,"epithelial ovarian, fallopian tube, or primary peritoneal",mirvetuximab soravtansine-gynx,,,,,,,,doc:fda.elahere,Document,Regulatory approval,Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.,"ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.","ImmunoGen, Inc.",Elahere,mirvetuximab soravtansine-gynx,2022-11-14,2024-10-30,2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310,761310.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,468,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 153, 'name': 'FOLR1 positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'FOLR1'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",27,Disease,High-Grade Serous Fallopian Tube Cancer,oncotree:HGSFT,HGSFT,High-Grade Serous Fallopian Tube Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=HGSFT'],[],140,,,Drug,Mirvetuximab soravtansine,ncit:C102566,C102566,Mirvetuximab Soravtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102566'],[],"[{'name': 'therapy_strategy', 'value': ['Folate receptor-alpha inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
549,Statement,"The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.elahere', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.', 'citation': 'ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.', 'company': 'ImmunoGen, Inc.', 'drug_name_brand': 'Elahere', 'drug_name_generic': 'mirvetuximab soravtansine-gynx', 'first_published': '2022-11-14', 'access_date': '2024-10-30', 'publication_date': '2024-03-22', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310', 'application_number': 761310, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.elahere:0,"ELAHERE is a folate receptor alpha (FR)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FR-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.",2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf,"The U.S. Food and Drug Administration granted approval to mirvetuximab soravtansine-gynx for the treatment of adult patients with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. The package insert states to select patients for therapy based on an FDA-approved test and, furthermore, that folate receptor-alpha tumor positive is defined as the presence of folate receptor-alpha tumor expression.",folate receptor-alpha tumor expression,"epithelial ovarian, fallopian tube, or primary peritoneal",mirvetuximab soravtansine-gynx,,,,,,,,doc:fda.elahere,Document,Regulatory approval,Elahere (mirvetuximab soravtansine-gynx) [package insert]. FDA.,"ImmunoGen, Inc. Elahere (mirvetuximab soravtansine-gynx) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf. Revised March 2024. Accessed October 30, 2024.","ImmunoGen, Inc.",Elahere,mirvetuximab soravtansine-gynx,2022-11-14,2024-10-30,2024-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761310Origs005lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761310,761310.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,469,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 153, 'name': 'FOLR1 positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'FOLR1'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",54,Disease,Peritoneal Serous Carcinoma,oncotree:PSEC,PSEC,Peritoneal Serous Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PSEC'],[],140,,,Drug,Mirvetuximab soravtansine,ncit:C102566,C102566,Mirvetuximab Soravtansine,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102566'],[],"[{'name': 'therapy_strategy', 'value': ['Folate receptor-alpha inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
550,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ojemda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ojemda (tovorafenib) [package insert]. FDA.', 'citation': 'Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Day One Biopharmaceuticals, Inc.', 'drug_name_brand': 'Ojemda', 'drug_name_generic': 'tovorafenib', 'first_published': '2024-04-23', 'access_date': '2024-10-30', 'publication_date': '2024-04-23', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700', 'application_number': 217700, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ojemda:0,"OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","BRAF fusion or rearrangement, or BRAF V600 mutation",low-grade glioma (LGG),tovorafenib,,,,,,,2024-04-23,doc:fda.ojemda,Document,Regulatory approval,Ojemda (tovorafenib) [package insert]. FDA.,"Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Day One Biopharmaceuticals, Inc.",Ojemda,tovorafenib,2024-04-23,2024-10-30,2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700,217700.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,470,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 155, 'name': 'BRAF rearrangements', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],141,,,Drug,Tovorafenib,ncit:C106254,C106254,Tovorafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106254'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
551,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ojemda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ojemda (tovorafenib) [package insert]. FDA.', 'citation': 'Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Day One Biopharmaceuticals, Inc.', 'drug_name_brand': 'Ojemda', 'drug_name_generic': 'tovorafenib', 'first_published': '2024-04-23', 'access_date': '2024-10-30', 'publication_date': '2024-04-23', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700', 'application_number': 217700, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ojemda:0,"OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","BRAF fusion or rearrangement, or BRAF V600 mutation",low-grade glioma (LGG),tovorafenib,,,,,,,2024-04-23,doc:fda.ojemda,Document,Regulatory approval,Ojemda (tovorafenib) [package insert]. FDA.,"Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Day One Biopharmaceuticals, Inc.",Ojemda,tovorafenib,2024-04-23,2024-10-30,2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700,217700.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,471,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 154, 'name': 'v::BRAF', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],141,,,Drug,Tovorafenib,ncit:C106254,C106254,Tovorafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106254'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
552,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ojemda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ojemda (tovorafenib) [package insert]. FDA.', 'citation': 'Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Day One Biopharmaceuticals, Inc.', 'drug_name_brand': 'Ojemda', 'drug_name_generic': 'tovorafenib', 'first_published': '2024-04-23', 'access_date': '2024-10-30', 'publication_date': '2024-04-23', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700', 'application_number': 217700, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ojemda:0,"OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","BRAF fusion or rearrangement, or BRAF V600 mutation",low-grade glioma (LGG),tovorafenib,,,,,,,2024-04-23,doc:fda.ojemda,Document,Regulatory approval,Ojemda (tovorafenib) [package insert]. FDA.,"Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Day One Biopharmaceuticals, Inc.",Ojemda,tovorafenib,2024-04-23,2024-10-30,2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700,217700.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,472,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],141,,,Drug,Tovorafenib,ncit:C106254,C106254,Tovorafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106254'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
553,Statement,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.ojemda', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ojemda (tovorafenib) [package insert]. FDA.', 'citation': 'Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.', 'company': 'Day One Biopharmaceuticals, Inc.', 'drug_name_brand': 'Ojemda', 'drug_name_generic': 'tovorafenib', 'first_published': '2024-04-23', 'access_date': '2024-10-30', 'publication_date': '2024-04-23', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700', 'application_number': 217700, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ojemda:0,"OJEMDA is a kinase inhibitor indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","BRAF fusion or rearrangement, or BRAF V600 mutation",low-grade glioma (LGG),tovorafenib,,,,,,,2024-04-23,doc:fda.ojemda,Document,Regulatory approval,Ojemda (tovorafenib) [package insert]. FDA.,"Day One Biopharmaceuticals, Inc. Ojemda (tovorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf. Revised April 2024. Accessed October 30, 2024.","Day One Biopharmaceuticals, Inc.",Ojemda,tovorafenib,2024-04-23,2024-10-30,2024-04-23,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217700s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217700,217700.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,473,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 17, 'name': 'BRAF p.V600K', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453137}, {'name': 'reference_allele', 'value': 'AC'}, {'name': 'alternate_allele', 'value': 'TT'}, {'name': 'cdna_change', 'value': 'c.1798_1799GT>AA'}, {'name': 'protein_change', 'value': 'p.V600K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs121913227'}, {'name': 'hgvsg', 'value': '7:g.140453136_140453137delinsTT'}]}]",35,Disease,"Low-Grade Glioma, NOS",oncotree:LGGNOS,LGGNOS,"Low-Grade Glioma, NOS",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=LGGNOS'],[],141,,,Drug,Tovorafenib,ncit:C106254,C106254,Tovorafenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C106254'],[],"[{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
554,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN
(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:2,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.,non-small cell lung cancer,durvalumab in combination with platinum-containing chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,474,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],25,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
555,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN
(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:2,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.,non-small cell lung cancer,durvalumab in combination with platinum-containing chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,475,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],87,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
556,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN
(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:2,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.,non-small cell lung cancer,durvalumab in combination with platinum-containing chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,476,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],88,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
557,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN
(NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imfinzi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imfinzi (durvalumab) [package insert]. FDA.', 'citation': 'AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'AstraZeneca UK Limited.', 'drug_name_brand': 'Imfinzi', 'drug_name_generic': 'durvalumab', 'first_published': '2017-05-01', 'access_date': '2025-01-17', 'publication_date': '2024-08-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069', 'application_number': 761069, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imfinzi:2,"IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.",2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to durvalumab in combination with platinum-containing chemotherapy for the neoadjuvant treatment, followed by durvalumab as a single agent as adjuvant treatment after surgery, of adult patients with resectable (tumors  4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. This indication is based on AEGEAN (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial where the choice of platinum-containing chemotherapy was dependent on tumor histology. Specifically, patients with squamous tumor histology received either carboplatin with paclitaxel or cisplatin with gemcitabine, and patients with non-squamous tumor histology received either pemetrexed with carboplatin or pemetrexed with cisplatin.",no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.,non-small cell lung cancer,durvalumab in combination with platinum-containing chemotherapy,,,,,,,,doc:fda.imfinzi,Document,Regulatory approval,Imfinzi (durvalumab) [package insert]. FDA.,"AstraZeneca UK Limited. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf. Revised August 2024. Accessed October 30, 2024.",AstraZeneca UK Limited.,Imfinzi,durvalumab,2017-05-01,2025-01-17,2024-08-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761069s043lbledt.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069,761069.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,477,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],89,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
558,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) and that continued approval for this indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.krazati', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Krazati (adagrasib) [package insert]. FDA.', 'citation': 'Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised December 2022. Accessed October 30, 2024.', 'company': 'Mirati Therapeutics, Inc.', 'drug_name_brand': 'Krazati', 'drug_name_generic': 'adagrasib', 'first_published': '2022-12-12', 'access_date': '2024-10-30', 'publication_date': '2022-12-12', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340', 'application_number': 216340, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.krazati:1,"KRAZATI is an inhibitor of the RAS GTPase family indicated in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.",2024-06-21,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216340s005lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to adagrasib in combination with cetuximab for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. The product label notes that this indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR) and that continued approval for this indications may be contingent upon verification and description of a clinical benefit in confirmatory trials.",KRAS G12C,colorectal cancer,Krazati (adagrasib) in combination with cetuximab,,,,,,,2024-06-21,doc:fda.krazati,Document,Regulatory approval,Krazati (adagrasib) [package insert]. FDA.,"Mirati Therapeutics, Inc. Krazati (adagrasib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf. Revised December 2022. Accessed October 30, 2024.","Mirati Therapeutics, Inc.",Krazati,adagrasib,2022-12-12,2024-10-30,2022-12-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340Orig1s000Corrected_lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=216340,216340.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,478,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 45, 'name': 'KRAS p.G12C', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '2'}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],90,AND,"[{'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 54, 'conceptType': 'Drug', 'name': 'Adagrasib', 'primaryCoding': {'id': 'ncit:C157493', 'code': 'C157493', 'name': 'Adagrasib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C157493']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['RAS inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
559,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,479,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
560,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,480,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
561,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,481,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
562,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,482,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
563,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,483,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
564,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,484,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 111, 'name': 'IDH2 p.R172K', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.515G>A'}, {'name': 'protein_change', 'value': 'p.R172K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>T'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
565,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,485,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 112, 'name': 'IDH2 p.R172M', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.515G>T'}, {'name': 'protein_change', 'value': 'p.R172M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
566,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,486,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 113, 'name': 'IDH2 p.R172G', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.514A>G'}, {'name': 'protein_change', 'value': 'p.R172G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>C'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
567,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,487,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 114, 'name': 'IDH2 p.R172S', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631837}, {'name': 'end_position', 'value': 90631837}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.516G>C'}, {'name': 'protein_change', 'value': 'p.R172S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519736'}, {'name': 'hgvsg', 'value': '15:g.90631837C>G'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
568,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,488,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 115, 'name': 'IDH2 p.R172W', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.514A>T'}, {'name': 'protein_change', 'value': 'p.R172W'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>A'}]}]",6,Disease,Astrocytoma,oncotree:ASTR,ASTR,Astrocytoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
569,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,489,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 74, 'name': 'IDH1 p.R132C', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.394C>T'}, {'name': 'protein_change', 'value': 'p.R132C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
570,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,490,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 75, 'name': 'IDH1 p.R132G', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.394C>G'}, {'name': 'protein_change', 'value': 'p.R132G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>C'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
571,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,491,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 76, 'name': 'IDH1 p.R132H', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.395G>A'}, {'name': 'protein_change', 'value': 'p.R132H'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>T'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
572,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,492,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 77, 'name': 'IDH1 p.R132L', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113112}, {'name': 'end_position', 'value': 209113112}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.385G>T'}, {'name': 'protein_change', 'value': 'p.R132L'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913500'}, {'name': 'hgvsg', 'value': '2:g.209113112C>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
573,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,493,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 78, 'name': 'IDH1 p.R132S', 'genes': [{'id': 28, 'name': 'IDH1', 'primaryCoding': {'id': 'hgnc:5382', 'code': 'HGNC:5382', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5382']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000138413', 'code': 'ENSG00000138413', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000138413']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3417', 'code': '3417', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3417']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005896.4', 'code': 'NM_005896.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005896.4']}}], 'extensions': [{'name': 'location', 'value': '2q34'}, {'name': 'location_sortable', 'value': '02q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '2'}, {'name': 'start_position', 'value': 209113113}, {'name': 'end_position', 'value': 209113113}, {'name': 'reference_allele', 'value': 'G'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.394C>A'}, {'name': 'protein_change', 'value': 'p.R132S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913499'}, {'name': 'hgvsg', 'value': '2:g.209113113G>T'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
574,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,494,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 111, 'name': 'IDH2 p.R172K', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.515G>A'}, {'name': 'protein_change', 'value': 'p.R172K'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>T'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
575,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,495,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 112, 'name': 'IDH2 p.R172M', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631838}, {'name': 'end_position', 'value': 90631838}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.515G>T'}, {'name': 'protein_change', 'value': 'p.R172M'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs121913503'}, {'name': 'hgvsg', 'value': '15:g.90631838C>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
576,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,496,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 113, 'name': 'IDH2 p.R172G', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'C'}, {'name': 'cdna_change', 'value': 'c.514A>G'}, {'name': 'protein_change', 'value': 'p.R172G'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>C'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
577,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,497,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 114, 'name': 'IDH2 p.R172S', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631837}, {'name': 'end_position', 'value': 90631837}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'G'}, {'name': 'cdna_change', 'value': 'c.516G>C'}, {'name': 'protein_change', 'value': 'p.R172S'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519736'}, {'name': 'hgvsg', 'value': '15:g.90631837C>G'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
578,Statement,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.voranigo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Voranigo (vorasidenib) [package insert]. FDA.', 'citation': 'Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.', 'company': 'Servier Pharmaceuticals LLC.', 'drug_name_brand': 'Voranigo', 'drug_name_generic': 'vorasidenib', 'first_published': '2024-08-06', 'access_date': '2024-10-30', 'publication_date': '2024-08-06', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784', 'application_number': 218784, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.voranigo:0,"VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",IDH1 or IDH2 mutations,astrocytoma or oligodendroglioma,vorasidenib,,,,,,,,doc:fda.voranigo,Document,Regulatory approval,Voranigo (vorasidenib) [package insert]. FDA.,"Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",Servier Pharmaceuticals LLC.,Voranigo,vorasidenib,2024-08-06,2024-10-30,2024-08-06,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784,218784.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,498,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 115, 'name': 'IDH2 p.R172W', 'genes': [{'id': 29, 'name': 'IDH2', 'primaryCoding': {'id': 'hgnc:5383', 'code': 'HGNC:5383', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_002168.4', 'code': 'NM_002168.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000182054', 'code': 'ENSG00000182054', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000182054']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3418', 'code': '3418', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3418']}}], 'extensions': [{'name': 'location', 'value': '15q26.1'}, {'name': 'location_sortable', 'value': '15q26.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '15'}, {'name': 'start_position', 'value': 90631839}, {'name': 'end_position', 'value': 90631839}, {'name': 'reference_allele', 'value': 'T'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.514A>T'}, {'name': 'protein_change', 'value': 'p.R172W'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '4'}, {'name': 'rsid', 'value': 'rs1057519906'}, {'name': 'hgvsg', 'value': '15:g.90631839T>A'}]}]",48,Disease,Oligodendroglioma,oncotree:ODG,ODG,Oligodendroglioma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ODG'],[],142,,,Drug,Vorasidenib,ncit:C152914,C152914,Vorasidenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914'],[],"[{'name': 'therapy_strategy', 'value': ['IDH1/2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
579,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:2,"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",early breast cancer,ribociclib in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,499,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],91,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 143, 'conceptType': 'Drug', 'name': 'Goserelin', 'primaryCoding': {'id': 'ncit:C1374', 'code': 'C1374', 'name': 'Goserelin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1374']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Gonadotropin-releasing hormone (GnRH) agonist'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
580,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:2,"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",early breast cancer,ribociclib in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,500,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],91,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 143, 'conceptType': 'Drug', 'name': 'Goserelin', 'primaryCoding': {'id': 'ncit:C1374', 'code': 'C1374', 'name': 'Goserelin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1374']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Gonadotropin-releasing hormone (GnRH) agonist'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
581,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:2,"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",early breast cancer,ribociclib in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,501,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],91,AND,"[{'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 143, 'conceptType': 'Drug', 'name': 'Goserelin', 'primaryCoding': {'id': 'ncit:C1374', 'code': 'C1374', 'name': 'Goserelin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1374']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Gonadotropin-releasing hormone (GnRH) agonist'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
582,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:2,"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",early breast cancer,ribociclib in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,502,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],92,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 143, 'conceptType': 'Drug', 'name': 'Goserelin', 'primaryCoding': {'id': 'ncit:C1374', 'code': 'C1374', 'name': 'Goserelin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1374']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Gonadotropin-releasing hormone (GnRH) agonist'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
583,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:2,"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",early breast cancer,ribociclib in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,503,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],92,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 143, 'conceptType': 'Drug', 'name': 'Goserelin', 'primaryCoding': {'id': 'ncit:C1374', 'code': 'C1374', 'name': 'Goserelin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1374']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Gonadotropin-releasing hormone (GnRH) agonist'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
584,Statement,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.kisqali', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Kisqali (ribociclib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Kisqali', 'drug_name_generic': 'ribociclib', 'first_published': '2017-03-13', 'access_date': '2024-10-30', 'publication_date': '2024-09-17', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092', 'application_number': 209092, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.kisqali:2,"KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.",2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,"The U.S. Food and Drug Administration granted approval to ribociclib in combination with an aromatase inhibitor for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. This indication is based on NATALEE (NCT03701334) was a randomized (1:1), open-label, multicenter study, where participants received goserelin and either letrozole or anastrozole, in addition to ribociclib.","hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",early breast cancer,ribociclib in combination with an aromatase inhibitor,,,,,,,,doc:fda.kisqali,Document,Regulatory approval,Kisqali (ribociclib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Kisqali (ribociclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf. Revised September 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Kisqali,ribociclib,2017-03-13,2024-10-30,2024-09-17,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092Orig1s018lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209092,209092.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,504,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],92,AND,"[{'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 53, 'conceptType': 'Drug', 'name': 'Ribociclib', 'primaryCoding': {'id': 'ncit:C95701', 'code': 'C95701', 'name': 'Ribociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C95701']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 143, 'conceptType': 'Drug', 'name': 'Goserelin', 'primaryCoding': {'id': 'ncit:C1374', 'code': 'C1374', 'name': 'Goserelin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1374']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Gonadotropin-releasing hormone (GnRH) agonist'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
585,Statement,"The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:0,"OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.",2024-10-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s127lbl.pdf,"The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",no known EGFR mutations or ALK rearrangement,non-small cell lung cancer,Opdivo (nivolumab) in combination with platinum-doublet chemotherapy,,,,,,2024-10-03,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,505,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],93,AND,"[{'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
586,Statement,"The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:0,"OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with resectable (tumors >=4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery.",2024-10-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s127lbl.pdf,"The U.S. Food and Drug Administration granted approval to nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment, followed by single-agent nivolumab as adjuvant treatment after surgery, of adult patients with resectable (tumors >= 4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements. This indication is based on CHECKMATE-816 (NCT02998528), a randomized, open label trial where patients received either: carboplatin with paclitaxel for either histology, cisplatin with pemetrexed for non-squamous histology, or cisplatin with gemcitabine for squamous histology.",no known EGFR mutations or ALK rearrangement,non-small cell lung cancer,Opdivo (nivolumab) in combination with platinum-doublet chemotherapy,,,,,,2024-10-03,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,506,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],94,AND,"[{'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
587,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:2,"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.",2020-05-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s082lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",no EGFR or ALK genomic tumor aberrations,non-small cell lung cancer,nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy,,,,,,2025-05-26,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,172,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],30,AND,"[{'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
588,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:2,"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.",2020-05-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s082lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",no EGFR or ALK genomic tumor aberrations,non-small cell lung cancer,nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy,,,,,,2025-05-26,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,173,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],31,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
589,Statement,"The U.S. Food and Drug Administration granted approval to ipilimumab in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:2,"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy.",2020-05-26,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125554s082lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. This indication is based on CHECKMATE-9LA (NCT03215706), a phase 3, randomized, and open-label study in which the platinum-based chemotherapy was either carboplatin and pemetrexed or cisplatin and pemetrexed for non-squamous NSCLC, or carboplatin and paclitaxel for squamous NSCLC.",no EGFR or ALK genomic tumor aberrations,non-small cell lung cancer,nivolumab in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy,,,,,,2025-05-26,,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,174,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],32,AND,"[{'id': 35, 'conceptType': 'Drug', 'name': 'Paclitaxel', 'primaryCoding': {'id': 'ncit:C1411', 'code': 'C1411', 'name': 'Paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1411']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
591,Statement,The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.,"[{'id': 4, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.', 'date': '2025-04-30'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:4,OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.,2018-07-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.,microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),colorectal cancer,nivolumab in combination with ipilimumab,,,,,,2025-04-08,2018-07-10,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,507,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
592,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.","[{'id': 4, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.', 'date': '2025-04-30'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:3,"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",2018-07-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),colorectal cancer,nivolumab as a single agent,,,,,,2024-04-08,2018-07-10,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,508,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],72,,,Drug,Nivolumab,ncit:C68814,C68814,Nivolumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
593,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.","[{'id': 4, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.', 'date': '2025-04-30'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:3,"OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",2018-07-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),colorectal cancer,nivolumab as a single agent,,,,,,2024-04-08,2018-07-10,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,509,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 36, 'name': 'dMMR', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Mismatch Repair'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Deficient'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],72,,,Drug,Nivolumab,ncit:C68814,C68814,Nivolumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814'],[],"[{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
594,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2024-10-10', 'access_date': '2024-10-30', 'publication_date': '2024-10-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249', 'application_number': 219249, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.itovebi:0,"ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",2024-10-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",metastatic breast cancer,inavolisib in combination with palbociclib and fulvestrant,,,,,,,,doc:fda.itovebi,Document,Regulatory approval,Itovebi (inavolisib) [package insert]. FDA.,"Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.","Genentech, Inc.",Itovebi,inavolisib,2024-10-10,2024-10-30,2024-10-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249,219249.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,510,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],95,AND,"[{'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primaryCoding': {'id': 'ncit:C132166', 'code': 'C132166', 'name': 'Inavolisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132166']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
595,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2024-10-10', 'access_date': '2024-10-30', 'publication_date': '2024-10-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249', 'application_number': 219249, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.itovebi:0,"ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",2024-10-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",metastatic breast cancer,inavolisib in combination with palbociclib and fulvestrant,,,,,,,,doc:fda.itovebi,Document,Regulatory approval,Itovebi (inavolisib) [package insert]. FDA.,"Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.","Genentech, Inc.",Itovebi,inavolisib,2024-10-10,2024-10-30,2024-10-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249,219249.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,511,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],95,AND,"[{'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primaryCoding': {'id': 'ncit:C132166', 'code': 'C132166', 'name': 'Inavolisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132166']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
596,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.itovebi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Itovebi (inavolisib) [package insert]. FDA.', 'citation': 'Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.', 'company': 'Genentech, Inc.', 'drug_name_brand': 'Itovebi', 'drug_name_generic': 'inavolisib', 'first_published': '2024-10-10', 'access_date': '2024-10-30', 'publication_date': '2024-10-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249', 'application_number': 219249, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.itovebi:0,"ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",2024-10-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to inavolisib in combination with palbociclib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.","PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative",metastatic breast cancer,inavolisib in combination with palbociclib and fulvestrant,,,,,,,,doc:fda.itovebi,Document,Regulatory approval,Itovebi (inavolisib) [package insert]. FDA.,"Genentech, Inc. Itovebi (inavolisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.","Genentech, Inc.",Itovebi,inavolisib,2024-10-10,2024-10-30,2024-10-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219249,219249.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,512,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 59, 'name': 'PIK3CA somatic variants', 'genes': [{'id': 41, 'name': 'PIK3CA', 'primaryCoding': {'id': 'hgnc:8975', 'code': 'HGNC:8975', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8975']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_006218.4', 'code': 'NM_006218.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_006218.4']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000121879', 'code': 'ENSG00000121879', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000121879']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:5290', 'code': '5290', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/5290']}}], 'extensions': [{'name': 'location', 'value': '3q26.32'}, {'name': 'location_sortable', 'value': '03q26.32'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],95,AND,"[{'id': 31, 'conceptType': 'Drug', 'name': 'Palbociclib', 'primaryCoding': {'id': 'ncit:C49176', 'code': 'C49176', 'name': 'Palbociclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49176']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 144, 'conceptType': 'Drug', 'name': 'Inavolisib', 'primaryCoding': {'id': 'ncit:C132166', 'code': 'C132166', 'name': 'Inavolisib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C132166']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PI3K/AKT/mTOR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 30, 'conceptType': 'Drug', 'name': 'Fulvestrant', 'primaryCoding': {'id': 'ncit:C1379', 'code': 'C1379', 'name': 'Fulvestrant', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1379']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Estrogen receptor inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
597,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.vyloy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vyloy (zolbetuximab) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Vyloy (zolbetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Vyloy', 'drug_name_generic': 'zolbetuximab', 'first_published': '2024-10-18', 'access_date': '2024-10-30', 'publication_date': '2024-10-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365', 'application_number': 761365, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vyloy:0,VYLOY is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.,2024-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",human epidermal growth factor receptor 2 (HER2)-negative .. claudin (CLDN) 18.2 positive,gastric or gastroesophageal junction adenocarcinoma,zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy,,,,,,,,doc:fda.vyloy,Document,Regulatory approval,Vyloy (zolbetuximab) [package insert]. FDA.,"Astellas Pharma US, Inc. Vyloy (zolbetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Vyloy,zolbetuximab,2024-10-18,2024-10-30,2024-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365,761365.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,513,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 103, 'name': 'CLDN18.2 >= 75%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CLDN18.2'}, {'name': 'unit', 'value': 'Percentage of tumor cells'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.75'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],96,AND,"[{'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 111, 'conceptType': 'Drug', 'name': 'Zolbetuximab', 'primaryCoding': {'id': 'ncit:C85475', 'code': 'C85475', 'name': 'Zolbetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C85475']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CLDN18.2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
598,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).","[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.vyloy', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Vyloy (zolbetuximab) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Vyloy (zolbetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Vyloy', 'drug_name_generic': 'zolbetuximab', 'first_published': '2024-10-18', 'access_date': '2024-10-30', 'publication_date': '2024-10-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365', 'application_number': 761365, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.vyloy:0,VYLOY is a claudin 18.2-directed cytolytic antibody and is indicated in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.,2024-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive, as determined by an FDA-approved test. The package insert states that that eligible patients should have CLDN18.2 positive tumors, defined as >= 75% of tumor cells demonstrating moderate to strong membranous CLDN18 immunohistochemical staining. The package insert further states that this indication is based on Spotlight (8951-CL-0301) and Glow (8951-CL-0302), both phase 3, double-blind, randomized, multicenter studies that enrolled 1072 patients where the choice of either mFOLFOX6 (oxaliplatin, folinic acid, and fluorouracil) or CAPOX (oxaliplatin and capecitabine).",human epidermal growth factor receptor 2 (HER2)-negative .. claudin (CLDN) 18.2 positive,gastric or gastroesophageal junction adenocarcinoma,zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy,,,,,,,,doc:fda.vyloy,Document,Regulatory approval,Vyloy (zolbetuximab) [package insert]. FDA.,"Astellas Pharma US, Inc. Vyloy (zolbetuximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf. Revised October 2024. Accessed October 30, 2024.","Astellas Pharma US, Inc.",Vyloy,zolbetuximab,2024-10-18,2024-10-30,2024-10-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761365s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761365,761365.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,514,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 103, 'name': 'CLDN18.2 >= 75%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'CLDN18.2'}, {'name': 'unit', 'value': 'Percentage of tumor cells'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.75'}]}]",2,Disease,Adenocarcinoma of the Gastroesophageal Junction,oncotree:GEJ,GEJ,Adenocarcinoma of the Gastroesophageal Junction,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=GEJ'],[],97,AND,"[{'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 38, 'conceptType': 'Drug', 'name': 'Capecitabine', 'primaryCoding': {'id': 'ncit:C1794', 'code': 'C1794', 'name': 'Capecitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1794']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 111, 'conceptType': 'Drug', 'name': 'Zolbetuximab', 'primaryCoding': {'id': 'ncit:C85475', 'code': 'C85475', 'name': 'Zolbetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C85475']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CLDN18.2 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
599,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.ziihera', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ziihera (zanidatamab-hrii) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Ziihera', 'drug_name_generic': 'zanidatamab-hrii', 'first_published': '2024-11-20', 'access_date': '2025-01-10', 'publication_date': '2024-11-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416', 'application_number': 761416, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ziihera:0,"ZIHERA is a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2024-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",HER2-positive (IHC 3+),biliary tract cancer (BTC),zanidatamab,,,,,,,2024-11-20,doc:fda.ziihera,Document,Regulatory approval,Ziihera (zanidatamab-hrii) [package insert]. FDA.,"Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Astellas Pharma US, Inc.",Ziihera,zanidatamab-hrii,2024-11-20,2025-01-10,2024-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416,761416.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,515,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",85,Disease,Intraductal Papillary Neoplasm of the Bile Duct,oncotree:IPN,IPN,Intraductal Papillary Neoplasm of the Bile Duct,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=IPN'],[],145,,,Drug,Zanidatamab,ncit:C130010,C130010,Zanidatamab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C130010'],[],"[{'name': 'therapy_strategy', 'value': ['ER signaling inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
600,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.ziihera', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ziihera (zanidatamab-hrii) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Ziihera', 'drug_name_generic': 'zanidatamab-hrii', 'first_published': '2024-11-20', 'access_date': '2025-01-10', 'publication_date': '2024-11-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416', 'application_number': 761416, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ziihera:0,"ZIHERA is a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2024-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",HER2-positive (IHC 3+),biliary tract cancer (BTC),zanidatamab,,,,,,,2024-11-20,doc:fda.ziihera,Document,Regulatory approval,Ziihera (zanidatamab-hrii) [package insert]. FDA.,"Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Astellas Pharma US, Inc.",Ziihera,zanidatamab-hrii,2024-11-20,2025-01-10,2024-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416,761416.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,516,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",86,Disease,Intracholecystic Papillary Neoplasm,oncotree:ICPN,ICPN,Intracholecystic Papillary Neoplasm,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ICPN'],[],145,,,Drug,Zanidatamab,ncit:C130010,C130010,Zanidatamab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C130010'],[],"[{'name': 'therapy_strategy', 'value': ['ER signaling inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
601,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.ziihera', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ziihera (zanidatamab-hrii) [package insert]. FDA.', 'citation': 'Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Astellas Pharma US, Inc.', 'drug_name_brand': 'Ziihera', 'drug_name_generic': 'zanidatamab-hrii', 'first_published': '2024-11-20', 'access_date': '2025-01-10', 'publication_date': '2024-11-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416', 'application_number': 761416, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ziihera:0,"ZIHERA is a bispecific HER2-directed antibody indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2024-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zanitdatamab for the treatment of adult patients with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",HER2-positive (IHC 3+),biliary tract cancer (BTC),zanidatamab,,,,,,,2024-11-20,doc:fda.ziihera,Document,Regulatory approval,Ziihera (zanidatamab-hrii) [package insert]. FDA.,"Astellas Pharma US, Inc. Ziihera (zanidatamab-hrii) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Astellas Pharma US, Inc.",Ziihera,zanidatamab-hrii,2024-11-20,2025-01-10,2024-11-20,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761416Orig1s000Lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761416,761416.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,517,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 20, 'name': 'HER2-positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",11,Disease,Cholangiocarcinoma,oncotree:CHOL,CHOL,Cholangiocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CHOL'],[],145,,,Drug,Zanidatamab,ncit:C130010,C130010,Zanidatamab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C130010'],[],"[{'name': 'therapy_strategy', 'value': ['ER signaling inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
602,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.bizengri', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bizengri (zenocutuzumab-zbco) [package insert]. FDA.', 'citation': 'Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Merus N.V.', 'drug_name_brand': 'Bizengri', 'drug_name_generic': 'zenocutuzumab-zbco', 'first_published': '2024-12-04', 'access_date': '2025-01-10', 'publication_date': '2024-12-04', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761352', 'application_number': 761352, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.bizengri:0,"BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2024-12-04,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",NGR1 gene fusion,non-small cell lung cancer,zenocutuzumab-zbco,,,,,,,2024-12-04,doc:fda.bizengri,Document,Regulatory approval,Bizengri (zenocutuzumab-zbco) [package insert]. FDA.,"Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed January 10, 2025.",Merus N.V.,Bizengri,zenocutuzumab-zbco,2024-12-04,2025-01-10,2024-12-04,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761352,761352.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,518,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 156, 'name': 'v::NRG1', 'genes': [{'id': 34, 'name': 'NRG1', 'primaryCoding': {'id': 'hgnc:7997', 'code': 'HGNC:7997', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7997']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157168', 'code': 'ENSG00000157168', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157168']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3084', 'code': '3084', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3084']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_013964.5', 'code': 'NM_013964.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_013964.5']}}], 'extensions': [{'name': 'location', 'value': '8p12'}, {'name': 'location_sortable', 'value': '08p12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],146,,,Drug,Zenocutuzumab,ncit:C152948,C152948,Zenocutuzumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152948'],[],"[{'name': 'therapy_strategy', 'value': ['NRG1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
603,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.bizengri', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Bizengri (zenocutuzumab-zbco) [package insert]. FDA.', 'citation': 'Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Merus N.V.', 'drug_name_brand': 'Bizengri', 'drug_name_generic': 'zenocutuzumab-zbco', 'first_published': '2024-12-04', 'access_date': '2025-01-10', 'publication_date': '2024-12-04', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761352', 'application_number': 761352, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.bizengri:1,"BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",2024-12-04,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on overall response rate and duration of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",NRG1 gene fusion,pancreatic adenocarcinoma,zenocutuzumab-zbco,,,,,,,2024-12-04,doc:fda.bizengri,Document,Regulatory approval,Bizengri (zenocutuzumab-zbco) [package insert]. FDA.,"Merus N.V. Bizengri (zenocutuzumab-zbco) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf. Revised December 2024. Accessed January 10, 2025.",Merus N.V.,Bizengri,zenocutuzumab-zbco,2024-12-04,2025-01-10,2024-12-04,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761352s001lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761352,761352.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,519,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 156, 'name': 'v::NRG1', 'genes': [{'id': 34, 'name': 'NRG1', 'primaryCoding': {'id': 'hgnc:7997', 'code': 'HGNC:7997', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7997']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157168', 'code': 'ENSG00000157168', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157168']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3084', 'code': '3084', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3084']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_013964.5', 'code': 'NM_013964.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_013964.5']}}], 'extensions': [{'name': 'location', 'value': '8p12'}, {'name': 'location_sortable', 'value': '08p12'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",52,Disease,Pancreatic Adenocarcinoma,oncotree:PAAD,PAAD,Pancreatic Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=PAAD'],[],146,,,Drug,Zenocutuzumab,ncit:C152948,C152948,Zenocutuzumab,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152948'],[],"[{'name': 'therapy_strategy', 'value': ['NRG1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
604,Statement,The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.ensacove', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ensacove (ensartinib) [package insert]. FDA.', 'citation': 'Xcovery Holdings, Inc. Ensacove (ensartinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Xcovery Holdings, Inc.', 'drug_name_brand': 'Ensacove', 'drug_name_generic': 'ensartinib', 'first_published': '2024-12-18', 'access_date': '2025-01-10', 'publication_date': '2024-12-18', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218171', 'application_number': 218171, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ensacove:0,ENSACOVE is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.,2024-12-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to ensartinib for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.,ALK-positive,non-small cell lung cancer,ensartinib,,,,,,,,doc:fda.ensacove,Document,Regulatory approval,Ensacove (ensartinib) [package insert]. FDA.,"Xcovery Holdings, Inc. Ensacove (ensartinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf. Revised December 2024. Accessed January 10, 2025.","Xcovery Holdings, Inc.",Ensacove,ensartinib,2024-12-18,2025-01-10,2024-12-18,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218171s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218171,218171.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,520,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 8, 'name': 'v::ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],147,,,Drug,Ensartinib,ncit:C102754,C102754,Ensartinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C102754'],[],"[{'name': 'therapy_strategy', 'value': ['ALK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
605,Statement,"The U.S. Food and Drug Administration granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, it states that encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.braftovi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Braftovi (encorafenib) [package insert]. FDA.', 'citation': 'Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.', 'company': 'Array BioPharma, Inc.', 'drug_name_brand': 'Braftovi', 'drug_name_generic': 'encorafenib', 'first_published': '2018-06-27', 'access_date': '2025-01-10', 'publication_date': '2024-12-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496', 'application_number': 210496, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.braftovi:3,"BRAFTOVI is a kinase inhibitor indicated in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.",2024-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf,"The U.S. Food and Drug Administration granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. The package insert states that this indication is approved under accelerated approval based on response rate and durability of response and that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). Furthermore, it states that encorafenib's package insert further states that it is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF colorectal cancer, or wild-type BRAF non-small cell lung cancer.",BRAF V600E,metastatic colorectal cancer,Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6,,,,,,,,doc:fda.braftovi,Document,Regulatory approval,Braftovi (encorafenib) [package insert]. FDA.,"Array BioPharma, Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf. Revised December 2024. Accessed January 10, 2025.","Array BioPharma, Inc.",Braftovi,encorafenib,2018-06-27,2025-01-10,2024-12-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210496s017lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210496,210496.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,521,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 16, 'name': 'BRAF p.V600E', 'genes': [{'id': 8, 'name': 'BRAF', 'primaryCoding': {'id': 'hgnc:1097', 'code': 'HGNC:1097', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000157764', 'code': 'ENSG00000157764', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000157764']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:673', 'code': '673', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/673']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004333.6', 'code': 'NM_004333.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004333.6']}}], 'extensions': [{'name': 'location', 'value': '7q34'}, {'name': 'location_sortable', 'value': '07q34'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '7'}, {'name': 'start_position', 'value': 140453136}, {'name': 'end_position', 'value': 140453136}, {'name': 'reference_allele', 'value': 'A'}, {'name': 'alternate_allele', 'value': 'T'}, {'name': 'cdna_change', 'value': 'c.1799T>A'}, {'name': 'protein_change', 'value': 'p.V600E'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '15'}, {'name': 'rsid', 'value': 'rs113488022'}, {'name': 'hgvsg', 'value': '7:g.140453136A>T'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],98,AND,"[{'id': 28, 'conceptType': 'Drug', 'name': 'Oxaliplatin', 'primaryCoding': {'id': 'ncit:C1181', 'code': 'C1181', 'name': 'Oxaliplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1181']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 18, 'conceptType': 'Drug', 'name': 'Encorafenib', 'primaryCoding': {'id': 'ncit:C98283', 'code': 'C98283', 'name': 'Encorafenib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C98283']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['B-RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 19, 'conceptType': 'Drug', 'name': 'Cetuximab', 'primaryCoding': {'id': 'ncit:C1723', 'code': 'C1723', 'name': 'Cetuximab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1723']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['EGFR inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 29, 'conceptType': 'Drug', 'name': 'Fluorouracil', 'primaryCoding': {'id': 'ncit:C505', 'code': 'C505', 'name': 'Fluorouracil', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C505']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Thymidylate synthase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
606,Statement,The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).,"[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.scemblix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Scemblix (asciminib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Scemblix', 'drug_name_generic': 'asciminib', 'first_published': None, 'access_date': '2025-01-10', 'publication_date': '2024-10-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358', 'application_number': 215358, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.scemblix:0,SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).,2022-10-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215358s001lbl.pdf,The U.S. Food and Drug Administration granted approval to asciminib for the treatment of adult patients with previously treated philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),Scemblix (asciminib),,,,,,,,doc:fda.scemblix,Document,Regulatory approval,Scemblix (asciminib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.",Novartis Pharmaceuticals Corporation.,Scemblix,asciminib,,2025-01-10,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358,215358.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,522,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],83,,,Drug,Asciminib,ncit:C114494,C114494,Asciminib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114494'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
607,Statement,The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.scemblix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Scemblix (asciminib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Scemblix', 'drug_name_generic': 'asciminib', 'first_published': None, 'access_date': '2025-01-10', 'publication_date': '2024-10-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358', 'application_number': 215358, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.scemblix:2,SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),Scemblix (asciminib),,,,,,,,doc:fda.scemblix,Document,Regulatory approval,Scemblix (asciminib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.",Novartis Pharmaceuticals Corporation.,Scemblix,asciminib,,2025-01-10,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358,215358.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,522,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],83,,,Drug,Asciminib,ncit:C114494,C114494,Asciminib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114494'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
608,Statement,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imjudo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imjudo (tremelimumab-actl) [package insert]. FDA.', 'citation': 'AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.', 'company': 'AstraZeneca AB.', 'drug_name_brand': 'Imjudo', 'drug_name_generic': 'tremelimumab-actl', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-11-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270', 'application_number': 761270, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imjudo:0,IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutation or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy,,,,,,,,doc:fda.imjudo,Document,Regulatory approval,Imjudo (tremelimumab-actl) [package insert]. FDA.,"AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",AstraZeneca AB.,Imjudo,tremelimumab-actl,,2024-10-30,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270,761270.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,523,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],99,AND,"[{'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
609,Statement,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imjudo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imjudo (tremelimumab-actl) [package insert]. FDA.', 'citation': 'AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.', 'company': 'AstraZeneca AB.', 'drug_name_brand': 'Imjudo', 'drug_name_generic': 'tremelimumab-actl', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-11-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270', 'application_number': 761270, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imjudo:0,IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutation or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy,,,,,,,,doc:fda.imjudo,Document,Regulatory approval,Imjudo (tremelimumab-actl) [package insert]. FDA.,"AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",AstraZeneca AB.,Imjudo,tremelimumab-actl,,2024-10-30,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270,761270.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,524,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],100,AND,"[{'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 49, 'conceptType': 'Drug', 'name': 'Pemetrexed', 'primaryCoding': {'id': 'ncit:C61614', 'code': 'C61614', 'name': 'Pemetrexed', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C61614']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antifolate'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
610,Statement,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imjudo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imjudo (tremelimumab-actl) [package insert]. FDA.', 'citation': 'AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.', 'company': 'AstraZeneca AB.', 'drug_name_brand': 'Imjudo', 'drug_name_generic': 'tremelimumab-actl', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-11-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270', 'application_number': 761270, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imjudo:0,IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutation or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy,,,,,,,,doc:fda.imjudo,Document,Regulatory approval,Imjudo (tremelimumab-actl) [package insert]. FDA.,"AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",AstraZeneca AB.,Imjudo,tremelimumab-actl,,2024-10-30,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270,761270.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,525,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],101,AND,"[{'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
611,Statement,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imjudo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imjudo (tremelimumab-actl) [package insert]. FDA.', 'citation': 'AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.', 'company': 'AstraZeneca AB.', 'drug_name_brand': 'Imjudo', 'drug_name_generic': 'tremelimumab-actl', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-11-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270', 'application_number': 761270, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imjudo:0,IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutation or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy,,,,,,,,doc:fda.imjudo,Document,Regulatory approval,Imjudo (tremelimumab-actl) [package insert]. FDA.,"AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",AstraZeneca AB.,Imjudo,tremelimumab-actl,,2024-10-30,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270,761270.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,526,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],102,AND,"[{'id': 39, 'conceptType': 'Drug', 'name': 'Cisplatin', 'primaryCoding': {'id': 'ncit:C376', 'code': 'C376', 'name': 'Cisplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C376']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 50, 'conceptType': 'Drug', 'name': 'Gemcitabine', 'primaryCoding': {'id': 'ncit:C66876', 'code': 'C66876', 'name': 'Gemcitabine', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C66876']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Antimetabolite'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
612,Statement,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.","[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.imjudo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Imjudo (tremelimumab-actl) [package insert]. FDA.', 'citation': 'AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.', 'company': 'AstraZeneca AB.', 'drug_name_brand': 'Imjudo', 'drug_name_generic': 'tremelimumab-actl', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2022-11-10', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270', 'application_number': 761270, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.imjudo:0,IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,"The U.S. Food and Drug Administration granted approval to tremelimumab-actl in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. This indication is based on POSEIDON (NCT03164616), a randomized, open-label, multicenter, active-controlled trial where patients received one of the following chemotherapy regimens: Pemetrexed in combination with carboplatin or cisplatin for patients with non-squamous NSCLC, gemcitabine with cisplatin or carboplatin for patients with squamous NSCLC, and nab-paclitaxel with carboplatin for either non-squamous or squamous NSCLC.",no sensitizing EGFR mutation or ALK genomic tumor aberrations,metastatic non-small cell lung cancer,Imjudo (tremelimumab-actl) in combination with durvalumab and platinum-based chemotherapy,,,,,,,,doc:fda.imjudo,Document,Regulatory approval,Imjudo (tremelimumab-actl) [package insert]. FDA.,"AstraZeneca AB. Imjudo (tremelimumab-actl) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Revised November 2022. Accessed October 30, 2024.",AstraZeneca AB.,Imjudo,tremelimumab-actl,,2024-10-30,2022-11-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761270,761270.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,527,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 34, 'name': 'Wild type ALK', 'genes': [{'id': 2, 'name': 'ALK', 'primaryCoding': {'id': 'hgnc:427', 'code': 'HGNC:427', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:427']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000171094', 'code': 'ENSG00000171094', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000171094']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:238', 'code': '238', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/238']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004304.5', 'code': 'NM_004304.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004304.5']}}], 'extensions': [{'name': 'location', 'value': '2p23.2-p23.1'}, {'name': 'location_sortable', 'value': '02p23.2-p23.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}, {'id': 35, 'name': 'Wild type EGFR', 'genes': [{'id': 17, 'name': 'EGFR', 'primaryCoding': {'id': 'hgnc:3236', 'code': 'HGNC:3236', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3236']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005228.5', 'code': 'NM_005228.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005228.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000146648', 'code': 'ENSG00000146648', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000146648']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:1956', 'code': '1956', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/1956']}}], 'extensions': [{'name': 'location', 'value': '7p11.2'}, {'name': 'location_sortable', 'value': '07p11.2'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Wild type'}, {'name': 'present', 'value': True}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],103,AND,"[{'id': 45, 'conceptType': 'Drug', 'name': 'Tremelimumab', 'primaryCoding': {'id': 'ncit:C49085', 'code': 'C49085', 'name': 'Tremelimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C49085']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 51, 'conceptType': 'Drug', 'name': 'Nab-paclitaxel', 'primaryCoding': {'id': 'ncit:C2688', 'code': 'C2688', 'name': 'Nab-paclitaxel', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2688']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Taxane-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 37, 'conceptType': 'Drug', 'name': 'Carboplatin', 'primaryCoding': {'id': 'ncit:C1282', 'code': 'C1282', 'name': 'Carboplatin', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1282']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Platinum-based chemotherapy'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Chemotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 44, 'conceptType': 'Drug', 'name': 'Durvalumab', 'primaryCoding': {'id': 'ncit:C103194', 'code': 'C103194', 'name': 'Durvalumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C103194']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
613,Statement,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.revuforj', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revuforj (revumenib) [package insert]. FDA.', 'citation': 'Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Syndax Pharmaceuticals, Inc.', 'drug_name_brand': 'Revuforj', 'drug_name_generic': 'revumenib', 'first_published': '2024-11-15', 'access_date': '2025-01-10', 'publication_date': '2024-11-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944', 'application_number': 218944, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.revuforj:0,REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,KMT2A translocation,acute leukemia,Revuforj (revumenib),,,,,,,,doc:fda.revuforj,Document,Regulatory approval,Revuforj (revumenib) [package insert]. FDA.,"Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Syndax Pharmaceuticals, Inc.",Revuforj,revumenib,2024-11-15,2025-01-10,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944,218944.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,528,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 157, 'name': 't(KMT2A;v)', 'genes': [{'id': 53, 'name': 'KMT2A', 'primaryCoding': {'id': 'hgnc:7131', 'code': 'HGNC:7131', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7131']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000118058', 'code': 'ENSG00000118058', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000118058']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4297', 'code': '4297', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4297']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Translocation'}]}]",0,Disease,Acute Lymphoid Leukemia,oncotree:ALL,ALL,Acute Lymphoid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],148,,,Drug,Revumenib,ncit:C165776,C165776,Revumenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C165776'],[],"[{'name': 'therapy_strategy', 'value': ['Menin inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
614,Statement,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.revuforj', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revuforj (revumenib) [package insert]. FDA.', 'citation': 'Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Syndax Pharmaceuticals, Inc.', 'drug_name_brand': 'Revuforj', 'drug_name_generic': 'revumenib', 'first_published': '2024-11-15', 'access_date': '2025-01-10', 'publication_date': '2024-11-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944', 'application_number': 218944, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.revuforj:0,REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,KMT2A translocation,acute leukemia,Revuforj (revumenib),,,,,,,,doc:fda.revuforj,Document,Regulatory approval,Revuforj (revumenib) [package insert]. FDA.,"Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Syndax Pharmaceuticals, Inc.",Revuforj,revumenib,2024-11-15,2025-01-10,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944,218944.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,529,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 157, 'name': 't(KMT2A;v)', 'genes': [{'id': 53, 'name': 'KMT2A', 'primaryCoding': {'id': 'hgnc:7131', 'code': 'HGNC:7131', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7131']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000118058', 'code': 'ENSG00000118058', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000118058']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4297', 'code': '4297', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4297']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Translocation'}]}]",1,Disease,Acute Myeloid Leukemia,oncotree:AML,AML,Acute Myeloid Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=AML'],[],148,,,Drug,Revumenib,ncit:C165776,C165776,Revumenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C165776'],[],"[{'name': 'therapy_strategy', 'value': ['Menin inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
615,Statement,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.revuforj', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revuforj (revumenib) [package insert]. FDA.', 'citation': 'Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Syndax Pharmaceuticals, Inc.', 'drug_name_brand': 'Revuforj', 'drug_name_generic': 'revumenib', 'first_published': '2024-11-15', 'access_date': '2025-01-10', 'publication_date': '2024-11-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944', 'application_number': 218944, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.revuforj:0,REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,KMT2A translocation,acute leukemia,Revuforj (revumenib),,,,,,,,doc:fda.revuforj,Document,Regulatory approval,Revuforj (revumenib) [package insert]. FDA.,"Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Syndax Pharmaceuticals, Inc.",Revuforj,revumenib,2024-11-15,2025-01-10,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944,218944.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,530,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 157, 'name': 't(KMT2A;v)', 'genes': [{'id': 53, 'name': 'KMT2A', 'primaryCoding': {'id': 'hgnc:7131', 'code': 'HGNC:7131', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7131']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000118058', 'code': 'ENSG00000118058', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000118058']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4297', 'code': '4297', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4297']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Translocation'}]}]",78,Disease,Burkitt Lymphoma,oncotree:BL,BL,Burkitt Lymphoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BL'],[],148,,,Drug,Revumenib,ncit:C165776,C165776,Revumenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C165776'],[],"[{'name': 'therapy_strategy', 'value': ['Menin inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
616,Statement,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,"[{'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.revuforj', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Revuforj (revumenib) [package insert]. FDA.', 'citation': 'Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.', 'company': 'Syndax Pharmaceuticals, Inc.', 'drug_name_brand': 'Revuforj', 'drug_name_generic': 'revumenib', 'first_published': '2024-11-15', 'access_date': '2025-01-10', 'publication_date': '2024-11-15', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944', 'application_number': 218944, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.revuforj:0,REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.,KMT2A translocation,acute leukemia,Revuforj (revumenib),,,,,,,,doc:fda.revuforj,Document,Regulatory approval,Revuforj (revumenib) [package insert]. FDA.,"Syndax Pharmaceuticals, Inc. Revuforj (revumenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf. Revised November 2024. Accessed January 10, 2025.","Syndax Pharmaceuticals, Inc.",Revuforj,revumenib,2024-11-15,2025-01-10,2024-11-15,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218944s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218944,218944.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,531,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 157, 'name': 't(KMT2A;v)', 'genes': [{'id': 53, 'name': 'KMT2A', 'primaryCoding': {'id': 'hgnc:7131', 'code': 'HGNC:7131', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7131']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000118058', 'code': 'ENSG00000118058', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000118058']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:4297', 'code': '4297', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/4297']}}], 'extensions': [{'name': 'location', 'value': None}, {'name': 'location_sortable', 'value': None}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Translocation'}]}]",87,Disease,Acute Leukemias of Ambiguous Lineage,oncotree:ALAL,ALAL,Acute Leukemias of Ambiguous Lineage,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALAL'],[],148,,,Drug,Revumenib,ncit:C165776,C165776,Revumenib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C165776'],[],"[{'name': 'therapy_strategy', 'value': ['Menin inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
617,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,703,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],143,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 40, 'conceptType': 'Drug', 'name': 'Letrozole', 'primaryCoding': {'id': 'ncit:C1527', 'code': 'C1527', 'name': 'Letrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1527']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
618,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,701,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],142,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
619,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,699,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],142,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
620,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,700,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],142,AND,"[{'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 36, 'conceptType': 'Drug', 'name': 'Anastrozole', 'primaryCoding': {'id': 'ncit:C1607', 'code': 'C1607', 'name': 'Anastrozole', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1607']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
621,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,792,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}, {'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],165,AND,"[{'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
622,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,793,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 1, 'name': 'ER positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Estrogen receptor (ER)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],165,AND,"[{'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
623,Statement,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","[{'id': 3, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Added propositions and statements for approval of abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for patients with HR+, HER2- breast cancer. Additional propositions are for combinations with letrozole, anastrozole, or exemestane per endocrine offerings within monarchE (NCT03155997).', 'date': '2025-04-10'}, {'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}]","[{'id': 'doc:fda.verzenio', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Verzenio (abemaciclib) [package insert]. FDA.', 'citation': 'Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.', 'company': 'Eli and Lily Company.', 'drug_name_brand': 'Verzenio', 'drug_name_generic': 'abemaciclib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2023-03-03', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716', 'application_number': 208716, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.verzenio:0,"Verzenio is a kinase inhibitor indicated in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence.",2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted approval to abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node positive, early breast cancer at high risk of recurrence. This indication is based on the monarchE (NCT03155997) clinical trial, which was a randomized (1:1), open-label, two cohort, multicenter study. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).","HR+, HER2-negative",early breast cancer,Verzenio (abemaciclib) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor),,,,,,,,doc:fda.verzenio,Document,Regulatory approval,Verzenio (abemaciclib) [package insert]. FDA.,"Eli and Lily Company. Verzenio (abemaciclib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf. Revised March 2023. Accessed October 30, 2024.",Eli and Lily Company.,Verzenio,abemaciclib,,2024-10-30,2023-03-03,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208716s010s011lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208716,208716.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,794,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 3, 'name': 'PR positive', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Progesterone receptor (PR)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Positive'}]}, {'id': 2, 'name': 'HER2-negative', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'Human epidermal growth factor receptor 2 (HER2)'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '='}, {'name': 'value', 'value': 'Negative'}]}]",9,Disease,Invasive Breast Carcinoma,oncotree:BRCA,BRCA,Invasive Breast Carcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=BRCA'],[],165,AND,"[{'id': 5, 'conceptType': 'Drug', 'name': 'Exemestane', 'primaryCoding': {'id': 'ncit:C1097', 'code': 'C1097', 'name': 'Exemestane', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1097']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['Aromatase inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Hormone therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 99, 'conceptType': 'Drug', 'name': 'Abemaciclib', 'primaryCoding': {'id': 'ncit:C97660', 'code': 'C97660', 'name': 'Abemaciclib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C97660']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CDK4/6 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
624,Statement,The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 4, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to nivolumab in combination with ipilimumab the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR), metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. However, they split the approval in two indications: as a single agent and still as a combination for patients who have progressed on the previously listed therapies. We added a new indication to cover the combination treatment and updated all statements and propositions accordingly.', 'date': '2025-04-30'}]","[{'id': 'doc:fda.opdivo', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Opdivo (nivolumab) [package insert]. FDA.', 'citation': 'Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.', 'company': 'Bristol-Myers Squibb Company.', 'drug_name_brand': 'Opdivo', 'drug_name_generic': 'nivolumab', 'first_published': '2014-12-22', 'access_date': '2025-04-30', 'publication_date': '2025-04-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554', 'application_number': 125554, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.opdivo:4,OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab.,2018-07-10,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s063lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to nivolumab in combination with ipilimumab for the treatment of adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.,microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR),colorectal cancer,nivolumab in combination with ipilimumab,,,,,,2025-04-08,2018-07-10,doc:fda.opdivo,Document,Regulatory approval,Opdivo (nivolumab) [package insert]. FDA.,"Bristol-Myers Squibb Company. Opdivo (nivolumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf. Revised April 2025. Accessed April 30, 2025.",Bristol-Myers Squibb Company.,Opdivo,nivolumab,2014-12-22,2025-04-30,2025-04-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s129lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554,125554.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,169,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 38, 'name': 'MSI-H', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Microsatellite Stability'}, {'name': 'present', 'value': True}, {'name': 'status', 'value': 'Microsatellite instability-high (MSI-H)'}]}]",15,Disease,Colorectal Adenocarcinoma,oncotree:COADREAD,COADREAD,Colorectal Adenocarcinoma,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=COADREAD'],[],29,AND,"[{'id': 71, 'conceptType': 'Drug', 'name': 'Ipilimumab', 'primaryCoding': {'id': 'ncit:C2654', 'code': 'C2654', 'name': 'Ipilimumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C2654']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['CTLA-4 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 72, 'conceptType': 'Drug', 'name': 'Nivolumab', 'primaryCoding': {'id': 'ncit:C68814', 'code': 'C68814', 'name': 'Nivolumab', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C68814']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['PD-1/PD-L1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Immunotherapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
625,Statement,The U.S. Food and Drug Administration (FDA) granted approval to taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The package insert instructs to select patients based on the presence of ROS1 rearrangements in tumor specimen(s).,"[{'id': 6, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to taletrectinib for the treatment of patients with ROS1 positive non-small cell lung cancer, accelerated approval to telisotuzumab vedotin-tllv for the treatment of patients with non-squamous non-small cell lung cancer with high c-Met expression, and avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer.', 'date': '2025-06-12'}]","[{'id': 'doc:fda.ibtrozi', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Ibtrozi (taletrectinib) [package insert]. FDA.', 'citation': 'Nuvation Bio Inc. Ibtrozi (taletrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf. Revised June 2025. Accessed June 12, 2025.', 'company': 'Nuvation Bio Inc', 'drug_name_brand': 'Ibtrozi', 'drug_name_generic': 'taletrectinib', 'first_published': '2025-06-11', 'access_date': '2025-06-12', 'publication_date': '2025-06-11', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219713', 'application_number': 219713, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.ibtrozi:0,IBTROZI is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,2015-06-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf,The U.S. Food and Drug Administration (FDA) granted approval to taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The package insert instructs to select patients based on the presence of ROS1 rearrangements in tumor specimen(s).,ROS1-positive,non-small cell lung cancer,taletrectinib,,,,,,2025-06-11,,doc:fda.ibtrozi,Document,Regulatory approval,Ibtrozi (taletrectinib) [package insert]. FDA.,"Nuvation Bio Inc. Ibtrozi (taletrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf. Revised June 2025. Accessed June 12, 2025.",Nuvation Bio Inc,Ibtrozi,taletrectinib,2025-06-11,2025-06-12,2025-06-11,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219713,219713.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,836,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 62, 'name': 'v::ROS1', 'genes': [{'id': 50, 'name': 'ROS1', 'primaryCoding': {'id': 'hgnc:10261', 'code': 'HGNC:10261', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10261']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000047936', 'code': 'ENSG00000047936', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000047936']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:6098', 'code': '6098', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/6098']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_001378902.1', 'code': 'NM_001378902.1', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_001378902.1']}}], 'extensions': [{'name': 'location', 'value': '6q22.1'}, {'name': 'location_sortable', 'value': '06q22.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",47,Disease,Non-Small Cell Lung Cancer,oncotree:NSCLC,NSCLC,Non-Small Cell Lung Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=NSCLC'],[],149,,,Drug,Taletrectinib,ncit:C118948,C118948,Taletrectinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C118948'],[],"[{'name': 'therapy_strategy', 'value': ['NTRK inhibition', 'ROS1 inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
626,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).","[{'id': 6, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to taletrectinib for the treatment of patients with ROS1 positive non-small cell lung cancer, accelerated approval to telisotuzumab vedotin-tllv for the treatment of patients with non-squamous non-small cell lung cancer with high c-Met expression, and avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer.', 'date': '2025-06-12'}]","[{'id': 'doc:fda.emrelis', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Emrelis (telisotuzumab vedotin-tllv) [package insert]. FDA.', 'citation': 'Abbvie Inc. Emrelis (telisotuzumab vedotin-tllv) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.', 'company': 'Abbvie Inc.', 'drug_name_brand': 'Emrelis', 'drug_name_generic': 'telisotuzumab vedotin', 'first_published': '2025-05-14', 'access_date': '2025-06-12', 'publication_date': '2025-05-14', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761384', 'application_number': 761384, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.emrelis:0,"EMRELIS is a c-Met-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.",2025-05-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin, a c-Met-directed antibody and microtubule inhibitor conjugate, for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",high c-Met protein overexpression [>=50% of tumor cells with strong (3+) staining],non-squamous non-small cell lung cancer,telisotuzumab vedotin,,,,,,,2025-05-14,doc:fda.emrelis,Document,Regulatory approval,Emrelis (telisotuzumab vedotin-tllv) [package insert]. FDA.,"Abbvie Inc. Emrelis (telisotuzumab vedotin-tllv) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.",Abbvie Inc.,Emrelis,telisotuzumab vedotin,2025-05-14,2025-06-12,2025-05-14,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761384,761384.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,837,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 170, 'name': 'c-Met >= 50%', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Protein expression'}, {'name': 'present', 'value': True}, {'name': 'marker', 'value': 'c-Met'}, {'name': 'unit', 'value': 'status'}, {'name': 'equality', 'value': '>='}, {'name': 'value', 'value': '0.50'}]}]",89,Disease,Lung Non-Squamous Non-Small Cell Carcinoma,ncit:C135017,C135017,Lung Non-Squamous Non-Small Cell Carcinoma,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C135017'],[],150,,,Drug,Telisotuzumab Vedotin,ncit:C118571,C118571,Telisotuzumab Vedotin,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C118571'],[],"[{'name': 'therapy_strategy', 'value': ['MET inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
627,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.","[{'id': 6, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to taletrectinib for the treatment of patients with ROS1 positive non-small cell lung cancer, accelerated approval to telisotuzumab vedotin-tllv for the treatment of patients with non-squamous non-small cell lung cancer with high c-Met expression, and avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer.', 'date': '2025-06-12'}]","[{'id': 'doc:fda.avmapki-fakzynja', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. FDA.', 'citation': 'Verastem Inc. Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.', 'company': 'Verastem Inc', 'drug_name_brand': 'Avmapki Fakzynja co-pack', 'drug_name_generic': 'avutometinib; defactinib', 'first_published': '2025-05-08', 'access_date': '2025-06-12', 'publication_date': '2025-05-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219616', 'application_number': 219616, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.avmapki-fakzynja:0,"AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.",2025-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.",KRAS-mutated,low-grade serous ovarian cancer (LGSOC),avutometinib; defactinib,,,,,,,2025-05-08,doc:fda.avmapki-fakzynja,Document,Regulatory approval,Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. FDA.,"Verastem Inc. Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.",Verastem Inc,Avmapki Fakzynja co-pack,avutometinib; defactinib,2025-05-08,2025-06-12,2025-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219616,219616.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,838,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 45, 'name': 'KRAS p.G12C', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398285}, {'name': 'end_position', 'value': 25398285}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.34G>T'}, {'name': 'protein_change', 'value': 'p.G12C'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '2'}, {'name': 'rsid', 'value': 'rs121913530'}, {'name': 'hgvsg', 'value': '12:g.25398285C>A'}]}]",90,Disease,Low-Grade Serous Ovarian Cancer,oncotree:LGSOC,LGSOC,Low-Grade Serous Ovarian Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],182,AND,"[{'id': 151, 'conceptType': 'Drug', 'name': 'Avutometinib', 'primaryCoding': {'id': 'ncit:C80060', 'code': 'C80060', 'name': 'Avutometinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80060']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition', 'RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 152, 'conceptType': 'Drug', 'name': 'Defactinib', 'primaryCoding': {'id': 'ncit:C79809', 'code': 'C79809', 'name': 'Defactinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C79809']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FAK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
628,Statement,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.","[{'id': 6, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'The FDA provided regular approval to taletrectinib for the treatment of patients with ROS1 positive non-small cell lung cancer, accelerated approval to telisotuzumab vedotin-tllv for the treatment of patients with non-squamous non-small cell lung cancer with high c-Met expression, and avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer.', 'date': '2025-06-12'}]","[{'id': 'doc:fda.avmapki-fakzynja', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. FDA.', 'citation': 'Verastem Inc. Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.', 'company': 'Verastem Inc', 'drug_name_brand': 'Avmapki Fakzynja co-pack', 'drug_name_generic': 'avutometinib; defactinib', 'first_published': '2025-05-08', 'access_date': '2025-06-12', 'publication_date': '2025-05-08', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219616', 'application_number': 219616, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.avmapki-fakzynja:0,"AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.",2025-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf,"The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib in combination with defactinib (Avmapki Fakzynja co-pack) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. The package insert notes that this indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This approval is based on RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC. The KRAS mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). 44% of patients responded (3.5% with complete response, 40% with partial response), and the package insert notes that the tumor KRAS mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.",KRAS-mutated,low-grade serous ovarian cancer (LGSOC),avutometinib; defactinib,,,,,,,2025-05-08,doc:fda.avmapki-fakzynja,Document,Regulatory approval,Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. FDA.,"Verastem Inc. Avmapki Fakzynja co-pack (avutometinib potassium; defactinib hydrochloride) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf. Revised May 2025. Accessed June 12, 2025.",Verastem Inc,Avmapki Fakzynja co-pack,avutometinib; defactinib,2025-05-08,2025-06-12,2025-05-08,https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219616s000lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219616,219616.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,839,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 171, 'name': 'KRAS p.G12V', 'genes': [{'id': 31, 'name': 'KRAS', 'primaryCoding': {'id': 'hgnc:6407', 'code': 'HGNC:6407', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6407']}, 'mappings': [{'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004985.5', 'code': 'NM_004985.5', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004985.5']}}, {'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000133703', 'code': 'ENSG00000133703', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000133703']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:3845', 'code': '3845', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/3845']}}], 'extensions': [{'name': 'location', 'value': '12p12.1'}, {'name': 'location_sortable', 'value': '12p12.1'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Somatic Variant'}, {'name': 'present', 'value': True}, {'name': 'chromosome', 'value': '12'}, {'name': 'start_position', 'value': 25398284}, {'name': 'end_position', 'value': 25398284}, {'name': 'reference_allele', 'value': 'C'}, {'name': 'alternate_allele', 'value': 'A'}, {'name': 'cdna_change', 'value': 'c.35G>T'}, {'name': 'protein_change', 'value': 'p.G12V'}, {'name': 'variant_annotation', 'value': 'Missense'}, {'name': 'exon', 'value': '2'}, {'name': 'rsid', 'value': 'rs121913529'}, {'name': 'hgvsg', 'value': '12:g.25398284C>A'}]}]",90,Disease,Low-Grade Serous Ovarian Cancer,oncotree:LGSOC,LGSOC,Low-Grade Serous Ovarian Cancer,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ALL'],[],182,AND,"[{'id': 151, 'conceptType': 'Drug', 'name': 'Avutometinib', 'primaryCoding': {'id': 'ncit:C80060', 'code': 'C80060', 'name': 'Avutometinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C80060']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['MEK inhibition', 'RAF inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}, {'id': 152, 'conceptType': 'Drug', 'name': 'Defactinib', 'primaryCoding': {'id': 'ncit:C79809', 'code': 'C79809', 'name': 'Defactinib', 'system': 'https://evsexplore.semantics.cancer.gov', 'systemVersion': '25.01d', 'iris': ['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C79809']}, 'mappings': [], 'extensions': [{'name': 'therapy_strategy', 'value': ['FAK inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]}]",,,,,,,,,,,fda
629,Statement,The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,"[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.trisenox', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trisenox (arsenic trioxide) [package insert]. FDA.', 'citation': 'Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.', 'company': 'Cephalon, Inc.', 'drug_name_brand': 'Trisenox', 'drug_name_generic': 'arsenic trioxide', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-10-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248', 'application_number': 21248, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trisenox:0,TRISENOX is an arsenical indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,2018-01-12,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021248s015lbledt.pdf,The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,t(15;17) translocation or PML/RAR-alpha gene expression,low-risk acute promyelocytic leukemia (APL),Trisenox (arsenic trioxide),,,,,,,,doc:fda.trisenox,Document,Regulatory approval,Trisenox (arsenic trioxide) [package insert]. FDA.,"Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.","Cephalon, Inc.",Trisenox,arsenic trioxide,,2024-10-30,2020-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248,21248.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,840,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 172, 'name': 't(15;17)', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Translocation'}]}]",10,Disease,APL with PML-RARA,oncotree:APLPMLRARA,APLPMLRARA,APL with PML-RARA,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=APLPMLRARA'],[],93,,,Drug,Arsenic trioxide,ncit:C1005,C1005,Arsenic Trioxide,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1005'],[],"[{'name': 'therapy_strategy', 'value': ['PML::RARA inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
630,Statement,The U.S. Food and Drug Administration granted approval to arsenic trioxide in combination with tretinoin for the treatment of adult patients with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,"[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.trisenox', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Trisenox (arsenic trioxide) [package insert]. FDA.', 'citation': 'Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.', 'company': 'Cephalon, Inc.', 'drug_name_brand': 'Trisenox', 'drug_name_generic': 'arsenic trioxide', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2020-10-20', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248', 'application_number': 21248, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.trisenox:1,"TRISENOX is an arsenical indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",2000-09-25,https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21248lbl.pdf,"The U.S. Food and Drug Administration granted approval to arsenic trioxide for the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.",t(15;17) translocation or PML/RAR-alpha gene expression,acute promyelocytic leukemia (APL),Trisenox (arsenic trioxide),,,,,,,,doc:fda.trisenox,Document,Regulatory approval,Trisenox (arsenic trioxide) [package insert]. FDA.,"Cephalon, Inc. Trisenox (arsenic trioxide) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf. Revised October 2020. Accessed October 30, 2024.","Cephalon, Inc.",Trisenox,arsenic trioxide,,2024-10-30,2020-10-20,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021248s019lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021248,21248.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,840,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 172, 'name': 't(15;17)', 'genes': [], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Translocation'}]}]",10,Disease,APL with PML-RARA,oncotree:APLPMLRARA,APLPMLRARA,APL with PML-RARA,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=APLPMLRARA'],[],93,,,Drug,Arsenic trioxide,ncit:C1005,C1005,Arsenic Trioxide,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C1005'],[],"[{'name': 'therapy_strategy', 'value': ['PML::RARA inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
631,Statement,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068', 'application_number': 22068, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tasigna:2,Tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.,2018-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.,philadelphia chromosome-positive,Ph+ CML-CP and CML-AP,Tasigna (nilotinib),,,,,,,,doc:fda.tasigna,Document,Regulatory approval,Tasigna (nilotinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tasigna,nilotinib,,2024-10-30,2024-02-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,22068.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,221,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],88,,,Drug,Nilotinib,ncit:C48375,C48375,Nilotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
632,Statement,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.,"[{'id': 0, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Initial access of FDA approvals', 'date': '2024-10-30'}, {'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}]","[{'id': 'doc:fda.tasigna', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Tasigna (nilotinib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Tasigna', 'drug_name_generic': 'nilotinib', 'first_published': None, 'access_date': '2024-10-30', 'publication_date': '2024-02-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068', 'application_number': 22068, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.tasigna:2,Tasigna is a kinase inhibitor indicated for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.,2018-03-22,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022068s027lbl.pdf,The U.S. Food and Drug Administration granted approval to nilotinib for the treatment of pediatric patients greater than or equal to 1 year of age with Ph+ CML-CP and CML-AP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.,philadelphia chromosome-positive,Ph+ CML-CP and CML-AP,Tasigna (nilotinib),,,,,,,,doc:fda.tasigna,Document,Regulatory approval,Tasigna (nilotinib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf. Revised February 2024. Accessed October 30, 2024.",Novartis Pharmaceuticals Corporation.,Tasigna,nilotinib,,2024-10-30,2024-02-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022068s041lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068,22068.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,222,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",71,Disease,"Chronic Myeloid Leukemia, BCR-ABL1+",oncotree:CMLBCRABL1,CMLBCRABL1,"Chronic Myeloid Leukemia, BCR-ABL1+",https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CMLBCRABL1'],[],88,,,Drug,Nilotinib,ncit:C48375,C48375,Nilotinib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C48375'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
634,Statement,The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).,"[{'id': 7, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Resolving statements mapped to incorrect propositions', 'date': '2025-06-26'}, {'id': 1, 'type': 'Contribution', 'agent': {'id': 0, 'type': 'Agent', 'subtype': 'organization', 'name': 'Van Allen lab', 'description': 'Van Allen lab, Dana-Farber Cancer Institute'}, 'description': 'Additional FDA approvals for initial version', 'date': '2025-01-10'}]","[{'id': 'doc:fda.scemblix', 'type': 'Document', 'subtype': 'Regulatory approval', 'name': 'Scemblix (asciminib) [package insert]. FDA.', 'citation': 'Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.', 'company': 'Novartis Pharmaceuticals Corporation.', 'drug_name_brand': 'Scemblix', 'drug_name_generic': 'asciminib', 'first_published': None, 'access_date': '2025-01-10', 'publication_date': '2024-10-29', 'url': 'https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf', 'url_drug': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358', 'application_number': 215358, 'organization': {'id': 'fda', 'name': 'Food and Drug Administration', 'description': 'Regulatory agency that approves drugs for use in the United States.', 'url': 'https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm', 'last_updated': '2025-04-03'}}]",supports,ind:fda.scemblix:2,SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,The U.S. Food and Drug Administration granted accelerated approval to asciminib for the treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). The package insert states that this indication is approved under accelerated approval based on major molecular response rate and that continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).,philadelphia chromosome-positive,philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML),Scemblix (asciminib),,,,,,,,doc:fda.scemblix,Document,Regulatory approval,Scemblix (asciminib) [package insert]. FDA.,"Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf. Revised October 2024. Accessed January 10, 2025.",Novartis Pharmaceuticals Corporation.,Scemblix,asciminib,,2025-01-10,2024-10-29,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215358Orig1s008lbl.pdf,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215358,215358.0,fda,Food and Drug Administration,Regulatory agency that approves drugs for use in the United States.,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm,2025-04-03,29,VariantTherapeuticResponseProposition,predictSensitivityTo,"[{'id': 12, 'name': 'BCR::ABL1', 'genes': [{'id': 0, 'name': 'ABL1', 'primaryCoding': {'id': 'hgnc:76', 'code': 'HGNC:76', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:76']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000097007', 'code': 'ENSG00000097007', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000097007']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:25', 'code': '25', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/25']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_005157.6', 'code': 'NM_005157.6', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_005157.6']}}], 'extensions': [{'name': 'location', 'value': '9q34.12'}, {'name': 'location_sortable', 'value': '09q34.12'}]}, {'id': 6, 'name': 'BCR', 'primaryCoding': {'id': 'hgnc:1014', 'code': 'HGNC:1014', 'name': None, 'system': 'https://genenames.org', 'systemVersion': None, 'iris': ['https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1014']}, 'mappings': [{'relation': 'exactMatch', 'coding': {'id': 'ensembl:ensg00000186716', 'code': 'ENSG00000186716', 'name': None, 'system': 'https://www.ensembl.org', 'systemVersion': None, 'iris': ['https://www.ensembl.org/id/ENSG00000186716']}}, {'relation': 'exactMatch', 'coding': {'id': 'ncbi:613', 'code': '613', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/gene', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/gene/613']}}, {'relation': 'relatedMatch', 'coding': {'id': 'refseq:NM_004327.4', 'code': 'NM_004327.4', 'name': None, 'system': 'https://www.ncbi.nlm.nih.gov/nuccore', 'systemVersion': None, 'iris': ['https://www.ncbi.nlm.nih.gov/nuccore/NM_004327.4']}}], 'extensions': [{'name': 'location', 'value': '22q11.23'}, {'name': 'location_sortable', 'value': '22q11.23'}]}], 'type': 'CategoricalVariant', 'extensions': [{'name': 'biomarker_type', 'value': 'Rearrangement'}, {'name': 'present', 'value': True}, {'name': 'rearrangement_type', 'value': 'Fusion'}]}]",13,Disease,Chronic Myelogenous Leukemia,oncotree:CML,CML,Chronic Myelogenous Leukemia,https://oncotree.mskcc.org,oncotree_2021_11_02,['https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=CML'],[],83,,,Drug,Asciminib,ncit:C114494,C114494,Asciminib,https://evsexplore.semantics.cancer.gov,25.01d,['https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C114494'],[],"[{'name': 'therapy_strategy', 'value': ['BCR-ABL inhibition'], 'description': 'Associated therapeutic strategy or mechanism of action of the therapy.'}, {'name': 'therapy_type', 'value': 'Targeted therapy', 'description': 'Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types'}]",fda
